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Abstract 
 
Macromolecule therapeutics, such as oligonucleotides, are playing an increasingly important 
role in the fight against diseases. Unfortunately, the majority of macromolecules are unable to 
cross the cell membrane barrier, which severely reduces the number of potential intracellular 
targets this class of therapeutic can act on. The AB5 complexes, cholera toxin and heat-labile 
enterotoxin have evolved the ability to enter mammalian cells effortlessly by using a retrograde 
transport mechanism. It has been previously reported that non-toxic analogues of these proteins 
can be used to transport macromolecular cargo into cells. However, the majority of these 
strategies utilise recombinant technologies and as a result are limited to protein based cargo.  
Sortase A (SrtA) is a class of transpeptidase enzyme that attaches virulence factors to the cell 
wall of gram Gram-positive bacteria. The enzyme recognises proteins carrying a C-terminal 
LPXTG motif and ligates them to peptidoglycans at the N-terminus of an oligoglycine 
sequence. Since its discovery, SrtA has been viewed as a potential new tool for protein 
modification. However, the enzyme-mediated ligation reaction is relatively inefficient in vitro. 
In this thesis, I will describe the development of depsipeptide substrates for SrtA that allow the 
quantitative N-terminal labelling of proteins/peptides. In addition, a simple and robust strategy 
to chemically-modified AB5 complexes that are able to enter mammalian cells will be reported. 
Finally, a novel approach to generate oligonucleotide-conjugated AB5 complexes using a 
combination of enzymatic and bioorthogonal reactions will also be outlined.  
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Chapter 1: Introduction part I 
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1.1 Biological therapeutics  
In 2012, seven of the top ten selling drugs were biological-based therapeutics with the top three 
being antibodies.
1
 This represents a significant paradigm shift in the way diseases are being 
treated as small molecules were always at the centre of drugs research. Traditionally, small 
molecule drugs were used to either inhibit or activate proteins, such as enzymes, that are 
associated with a particular disease. However, this approach has its limitations; it can be 
difficult to design a drug that specifically targets the protein of interest without producing 
unwanted side effects. Furthermore, some protein targets are simply “undruggable” using small 
molecules.
178 
Biopharmaceuticals are highly specific and have a low systemic toxicity compared to their small 
molecule counterparts. Previously incurable or life debilitating illnesses, such as paroxysmal 
nocturnal haemoglobinuria,
2
 are now being treated with new biological-based therapeutics. 
Although antibody-based drugs are currently leading worldwide drugs sales, there is also a 
significant amount of research being invested into the use of therapeutic oligonucleotides for 
genetic-based therapies.
3
 However, there are still significant challenges associated with each 
different class of biopharmaceutical. These can include high production costs, poor cellular 
uptake and reduced in vivo stability.
2-4
  
1.1.1 Oligonucleotides therapeutics 
Genetic disorders can cause the production of defective proteins that alter normal cellular 
function and trigger chronic disease. The RNA and pre-RNA sequences that govern faulty 
protein expression can be directly targeted by oligonucleotide therapeutics and are either 
removed or repaired to restore normal bioactivity. Diseases, such as Duchenne muscular 
dystrophy, that were previously untreatable with conventional medicines are now being fought 
with a new generation of oligonucleotide therapeutics.
5,6
 In principle, this strategy has the 
potential to treat any genetic disorder, but there are still serious challenges to overcome before 
oligonucleotides can be used ubiquitously in disease treatment.
3,7
 
1.1.1.1 Synthetic oligonucleotides  
Natural oligonucleotides are notoriously unstable in vivo due to the abundance of enzymes that 
will hydrolyse them. Consequentially, oligonucleotides therapeutics have to be chemically 
altered before they can be used as viable drugs (Figure 1.1).
3,7-9
 The most common modification 
is the incorporation of phosphorothioate linkages 1.3 into the backbone of an oligonucleotide. 
The phosphorothioate linkage reduces the rate of hydrolysis by nuclease enzymes and decreases 
3 
the efficiency of renal clearance; therefore, their stability in vivo is dramatically increased. RNA 
based therapeutics can be additionally modified to increase their enzymatic stability. Generally, 
the 2'-hydroxyl group on the ribose sugar is either alkylated 1.4, substituted with a fluoride 1.5 
or cyclised to form a locked nucleic acid (LNA) 1.6.
3,7-9
 The 2'-modifications also have the 
additional benefit of improving mRNA binding by forcing the oligonucleotides to adopt a more 
favourable conformation for base-base pairing. In their structure, oligonucleotide drugs 
commonly contain a mixture of both 2'-modifications and phosphorothioate linkages to ensure 
that maximum stability and potency are achieved.   
 
Interestingly, it possible to replace the entire backbone structure of oligonucleotides with a 
range of analogues molecules and still maintain effective base pairing.
3,7
 Prime examples are 
phosphorodiamidate morpholino oligomer (PMO) 1.7 and peptide nucleic acids (PNA) 1.8 
(Figure 1.2) .
3,7  
 
 
Figure 1.1: Structure of nucleic acids with different chemical modifications. Deoxyribonucleic 
acid (DNA) 1.1; ribonucleic acid (RNA) 1.2; nucleic acid with a phosphorothioate backbone 
1.3, R1= H, OH; 2'O-alkylated ribonucleic acid 1.4, R2 = methyl, methoxyethyl; 2'-fluorinated 
deoxyribonucleic acid 1.5; locked nucleic acid (LNA) 1.6 with the 2'O and 4' positions cyclised.  
. 
Figure 1.2: Structures of phosphorodiamidate morpholino oligomers (PMO) 1.7 and 
peptide nucleic acid (PNA) 1.8. 
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1.1.1.2 Biological mode of action   
There are several classes of oligonucleotide therapeutics that act on different biological targets 
to either inhibit or fix faulty protein production; four of the most widely studied include:     
Antisense oligonucleotide     
Antisense oligonucleotides are short, single stranded pieces of RNA that silence gene 
expression by removing mRNA before it can be translated. The antisense strand binds to target 
mRNA sequences forming a duplex structure that is recognised and subsequently degraded by 
ribonuclease H (RNase H) enzymes before protein expression can occur.
3,7,8
 
Modern antisense drugs are generally 20mers in length with a central ~10mer binding site.
3,7
 
The entire RNA backbone is usually modified with phosphorothioate linkages, whereas 2'-
modifications are restricted to flanking sequences on the peripheries of the oligonucleotide to 
ensure RNase H binding is not inhibited.
3,7,8
 
Interfering oligonucleotides   
Small interfering RNAs (siRNA) are short double stranded pieces of RNA that associate with 
the RNA-induced silencing complex (RISC) and catalytically silence gene expression.
3,7,8
 The 
RISC binds to the siRNA duplex causing it to dissociate into two separate oligonucleotide 
sequences; the antisense strand remains bound to the RISC while the sense strand is discarded. 
The complexed antisense sequence associates with complementary mRNA, which is then 
subsequently cleaved by the Argonaut-2 component of the RISC complex. This mechanism is 
repeated continuously allowing many copies of mRNA to be destroyed by a single antisense-
RISC enzyme    
Typical siRNA therapeutics are ~20 base pairs in length and carry only minimal chemical 
modifications to guarantee successful RISC binding.
3,7
 The guide strand that binds directly to 
the RISC can only be modified with phosphorothioate linkages and 2'-methyl alkylations at one 
or two nucleotide positions.
3
 However, the complementary sense strand that is discarded during 
complexation can tolerate a greater number of chemical modifications.  
Steric-blocking oligonucleotides  
Gene silencing can also be achieved without destroying mRNA if it is neutralised with a 
complementary binding partner. Heavily modified oligonucleotides, such as PMOs 1.7 (Figure 
1.2), bind to mRNA forming a duplex structure that is stable to degradation by RNase H due to 
5 
the abundance of chemical modification.
3,7
 However, the complexed synthetic oligonucleotide 
also sterically blocks the ribosome from binding and translating the mRNA into protein.  
Splice-switching oligonucleotides 
Remarkably, synthetic oligonucleotides are now being used in therapies that elegantly restore 
the function of defective proteins by reengineering the splicing mechanisms that produce the 
mRNA.
3,7
 The therapeutic oligonucleotides bind to the faulty splice sites or even mutated pre-
RNA sequences to form a stable duplex that is unable to be incorporated into the mature mRNA 
chain, thus restoring full or partial protein function.    
1.1.1.3 Delivery vehicles  
In most cases, therapeutic oligonucleotides are unable to cross the cell membrane barrier to 
reach their target as they are large and highly charged species. In addition, they show poor 
bioavailability in vivo and as a result, their efficacy is limited.
10
 The use of a delivery vehicle to 
transport the oligonucleotides directly to a target site is one strategy that could overcome these 
challenges. In the past, therapeutic nucleic acids were delivered using viral-based systems, but 
there are now several different classes of non-viral based delivery vehicles; these include 
liposomes, cell penetrating peptides (CPP) and polymeric carriers   
Viral vectors 
Viruses have evolved specific mechanisms that enable them to transfect and deliver their 
genetic material inside mammalian cells. Different types of viruses can gain entry into cells by 
either receptor-mediated endocytosis, macropinocytosis or phagocytosis.
11,12
 However, clathrin-
mediated endocytosis is the most common transfection mechanism. This process is triggered 
when viral particles and other substances bind to receptors on the surface of the cell in areas that 
are rich in clathrin.
11
 The protein is then internalised by the cell in a clathrin-coated vesicle 
before rapid endosomal formation takes place. Typically, substances internalised by clathrin-
mediated endocytosis are trafficked through early endosomes, late endosomes and finally 
lysosomes. However, viruses avoid the usual intracellular transportation mechanisms and escape 
into the cytosol.
11,12
 This is done in a number of different ways, but in general, it involves the 
disruption of an endosomal vesicle. For example, adenoviruses use a proton-pump mechanism 
to reduce the pH of the vesicle and trigger endosomal escape.
11
 Whereas, poliovirus is thought 
to undergo a structural change in the slightly acidic environment of the vesicle to expose a 
hydrophobic protein domain that disrupts the membrane and aids viral release into the cytosol.
12
 
The natural endosomal escape mechanisms of viruses make them an attractive vehicle to deliver 
therapeutic nucleic acids into cells. 
6 
The genomes of viral vectors are modified to remove any pathogenic genes and to introduce 
therapeutic nucleotide sequences.
11,13-15
 This delivery approach protects the nucleic acid cargo 
inside a viral capsid until it is released into the cytosolic interior of a cell.  There are currently 
five commonly used viral vectors based on the adenovirus, adeno-associated virus, herpes 
simplex virus, lentivirus and retrovirus. Each system has its own associated limitations, such as 
production difficulties, non-specific cell targeting, insertional mutagenesis and limited insert 
size.
11,13
 However, the major obstacle is safety. There is a possibility that the host will undergo a 
harsh immunogenic response to the viral vector. Furthermore, viral vectors based on 
retroviruses have been implicated in the onset of cancer in patients that have taken part in 
clinical trials.
11,16,17
  
Liposomes  
Liposomes are biocompatible artificial vesicles composed of a lipid bilayer structure 
surrounding an aqueous core (Figure 1.3) 
18,19
 Once absorbed onto the surface of a cell, 
liposomes are internalised by endocytosis or membrane fusion
20-22
 Drug molecules can be 
encapsulated inside the central core of the structure protecting them from degradation by extra-
liposomal reactions. Sequestrated therapeutics can exhibit a significantly altered 
pharmacokinetic profile to the free drug.
18,19
 For example, the anti cancer drug anthracyclines 
showed prolonged circulation, delayed adsorption and less bio-distribution when injected into 
mice with colon cancer.
23
 In addition, ligands (e.g., carbohydrates,
24
 antibodies,
25
 etc) can also 
be incorporated onto the surface of liposomes enabling them to target specific cells and 
therefore increase the specificity of the treatment.
19,26
 However, the successful targeting of 
receptors is heavily dependent on the vesicle being in circulation for long periods of time. 
Liposomal delivery vehicles are systemically removed by the mononuclear phagocytic system 
(MPS) reducing the effectiveness of the encapsulated therapeutic; a major limitation of the 
approach.
19,26,27
 Smaller unilamellar liposomes with a 50-250 nm diameter are commonly used 
as drug carriers as they are not readily recognised by the MPS and therefore have an increased 
circulation time.
18,28
 The surface charge of the liposome can be tailored to increase the 
incorporation of certain substances. However, a non-neutral net charge can significantly 
increase the rate of MPS clearance,
29
 so the final surface composition is usually a compromise 
between successful encapsulation and optimal liposomal circulation time.
18,19
 
Oligonucleotides are only efficiently encapsulated inside or associated to the surface of cationic 
liposomes.
18,28
 Unfortunately, the positively charged vesicles are inherently toxic and are readily 
cleared by the immune system. However, formulation with hydrophilic polymers, such as 
poly(ethyleneglycol) (PEG),
30
 can help mask them from the MPS, but cytotoxicity is still a 
considerable problem.
18,22,28
  
7 
Liposomes have the potential to be used as universal delivery vehicles for both small and 
macromolecules, but issues regarding MPS clearance and toxicity of cationic vesicles need to be 
addressed.   
 
 
Figure 1.3: Schematic representation of a unilamellar liposome and the structure of 
some lipids typically used in formulation   
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Cell penetrating peptides  
Cell penetrating peptides (CPP) are short positively charged peptides that can cross the cell 
membrane barrier.
31
 Their structure and sequence can vary substantially, but there is always an 
abundance of arginine or lysine residues giving them a net positive charge (Table 1.1).  The 
mechanism of internalisation is commonly believed to be endocytosis triggered by electrostatic 
interactions with negatively charged glycosaminoglycans on the surface of cells.
31
 In general, 
the concentrations of CPPs required for cell entry are low enough to induce a biological effect 
without causing cytotoxicity, or at the very least they are less toxic than comparable delivery 
vehicles.  
CPP name   Sequence  
 Tat RKKRRQRRR 
 Antp RQIKIWFQNRRMKWKK 
 Transportan 10 AGYLLGKINLKALAALAKKIL 
 Polyarginine  (R)n 
 
CPPs are powerful delivery vehicles that have been used to transport a range of 
macromolecules, including oligonucleotides and proteins, inside cells.
36-41
 Interestingly, both 
covalently and non-covalently linked oligonucleotides have been successfully transported using 
the same technique.
37-41
  However, there are still some major limitations associated with CPP 
mediated delivery. 
CPPs frequently become trapped in endosomal compartments after internalisation and this can 
limit the efficacy of the therapeutic cargo.
31
 Endosomal release can be assisted by the 
incorporation of membrane destabilising sequences, such as KALA
33
 or KLLKLLL,
32
 into the 
peptides structure. Additionally, CPPs can be co-administrated with lysosomotropic agents, but 
they are usually toxic and cannot be used over a prolonged period of time.  
The other main problem of CPP delivery vehicles is their poor stability, in vivo.
42
  The peptides 
are subject to degradation by proteases in blood, although chemical modifications to their 
structure have been shown to increase resistance.
31,43
  Furthermore, they are rapidly removed by 
the MPS of the body and show wide biodistribution indicating low specificity.
31,42
 Until these 
issues are addressed the wider application of CPP delivery systems are limited.   
Table 1.1: Name and sequence of CPPs peptides: Tat
32
, Antp,
33
 Transportan 10,
34
 and 
polyarginine
35
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Polymeric carriers   
There are several different classes of polymer-based delivery vehicles that can carry 
oligonucleotides; these include polyplexes, polymer micelle and nanoplexes (Figure 1.4).
44
 
Polyplexes consist of cationic polymers, such as polyethylenimine, that non-covalently associate 
with the negatively charged backbone of oligonucleotides forming a polyanionic complex.
44,45
 
Polymer micelles are produced by the spontaneous assembly of block copolymers, with cationic 
(e.g. polylysine) and hydrophilic (e.g. PEG) properties, around oligonucleotides.
44,46,47
 The 
resulting complex has a hydrophilic surface surrounding a cationic centre associated with 
nucleic acids. Nanoplexes are amphiphilic nanoparticles typically produced by the block 
copolymerisation of poly(alkylcyanoacrylate) with polysaccharides.
44,48
 The surface of the 
nanoparticle is additionally coated with chitosan or surfactants materials to create a positively 
charged surface that can complex with oligonucleotides to form the nanoplex.  
The aforementioned polymeric carriers can be prepared by several different methods, but many 
produce intrinsically toxic delivery vehicles.
44
 The toxicity is either attributed to the materials 
used in formulation or the high positive charge of the final polymeric carrier. It is often possible 
to replace the hazardous materials used in the synthesis of the polymeric carrier, but reducing 
the cation abundance is more problematic. The cationic charge is the basis of oligonucleotide 
association and has also been demonstrated to facilitate transfection by increasing endosomal 
escape. However, there is a relatively new class of polymer carrier termed nanocapsules that 
could be used a viable alternative.   
Lambert et al. developed a polymerisation technique in an organic solvent/aqueous emulsion 
that generated polymeric vesicles with an aqueous core surrounded by a polymer membrane, 
such as poly(iso-butylcyanoacrylate).
49
 Oligonucleotides can be encapsulated inside the aqueous 
interior protecting them from the external environment. Furthermore, oligonucleotide 
incorporation does not require the use of cationic polymers. However, the efficiency of 
incorporation is greatly improved when cationic polymers are coencapsulated.
44,50
 This class of 
carrier are considered non-toxic, but their formation typically requires the use of hazardous 
chlorinated solvents that need to be stringently removed before use in vivo.
44
 Further 
investigation is still required to assess the capability of nanocapsules based delivery vehicles  
10 
 
 
Figure 1.4: Schematic representation of polymer-based delivery vehicles and the structures of 
their typical polymeric components. 
44,51
 R= Butyl or isobutyl  
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1.2 Bacterial toxins  
Bacterial toxins, such as cholera and shiga toxins,
52
 have evolved specific and efficient 
mechanisms to breach the cell membrane barrier allowing them to enter mammalian cells 
effortlessly. If these mechanisms could be manipulated it could lead to the development of new 
range of cell penetrating biological tools.  
1.2.1 AB5 enterotoxins 
Cholera toxin (CT), secreted from Vibrio cholera, and the closely related heat-labile enterotoxin 
(LT), from Escherichia coli, share an almost identical protein sequence and structure (Figure 
1.5).
53-55
 The proteins are composed of a toxic A-subunit (CTA/LTA) surrounded by a pentamer 
of B-subunits (CTB) that are combined in a hexameric AB5 structure (Figure 1.6).
53,56
 The A-
subunit is snipped by a bacterial endoprotease splitting it into two distinct domains that are 
connected by a single disulfide bond, the A1 and A2-domain (CTA1/LTA1 and CTA2/LTA2). 
57 
 
 
Figure 1.5: Protein sequence of cholera toxin (CT) and heat-labile enterotoxin (LT) taken from 
the UniProt codes: P01555 (CTA), P01556 (CTB), P06717 (LTA) and P32890 (LTB). Green-
dashed line: A2-domain sequence; red: Differences between the CT and LT sequences.  
a) 
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The holotoxins infect their host using an identical retrograde trafficking mechanism.
53-55
 This 
process is initiated when the toxins bind to the plethora of GM1 ganglioside receptors located at 
the epithelial cell surface. The five binding sites located on the bottom face of the pentameric B-
subunit produce a strong multivalent interaction between the surface of the cell and the 
toxins.
53,58
 This powerful association causes the plasma membrane to engulf the proteins in an 
endocytic vesicle, which is subsequently trafficked inside the cell.
55,57,59
 The membrane phase 
separates to form regions that are rich in cholesterol and gangliosides and it has been found that 
these areas,
 
termed lipid rafts, are essential for the successful delivery of the AB5 toxins to their 
intracellular target.
55,57,59
 The vesicle containing the toxin is delivered to the endoplasmic 
reticulum (ER) via the trans-Golgi body; however, the mechanisms governing the intracellular 
transportation process are poorly understood (Figure 1.7).
55,57,59,60  
 
Figure 1.6: A) Overlaid crystal structures of cholera toxin generated from the PDB codes of atomic 
coordinates: 1S5E and 3CHB (UniProt codes: P01555 and: P01556).
178, 179
 A1-domain (blue); A2-
domain (green); CTB pentamer (red); GM1 pentasaccharide (black). B) Crystal structure of the 
GM1 pentasaccharide (black) bound to the bottom surface of the pentameric B-subunit (red) 
generated from the PDB codes of atomic coordinates: 3CHB C) Structure of the GM1 ganglioside 
13 
 
It has been proposed that when cholera toxin reaches the ER, a protein disulfide isomerise (PDI) 
enzyme reduces the disulfide bond between the A1 and A2 domains.
55,57,59,60
 The free A1-
fragment partially unfolds triggering the internal machinery of the ER to eject the protein into 
the cytosol for proteasomal degradation.
62,63
 However, ADP-ribosylation factor 6 binds to the 
A1-protein in the cytosol and protects it from degradation.
53,63
 This process allows the A1-
protein to reach its target G-protein and induce toxicity. The A1-protein has ADP-
ribosyltransferase activity that modifies the G-protein and inhibits the α-subunit from GTPase 
activity.
59
 This inhibition results in a constant stimulation of adenylate cyclase causing a sharp 
increase in the concentration of cyclic adenosine monophosphate (AMP) within the cell. As a 
consequence of this process, ions and fluid are continually lost from the cell triggering watery 
diarrhoea in the host. 
The retrograde trafficking mechanism of the toxins is not cytotoxic;
54
 therefore, the 
transportation process can be hijacked and used to deliver other macromolecules, such as 
oligonucleotides, into mammalian cells. Several studies have already made significant progress 
in developing enterotoxin-based delivery vehicles. For example, Tinker et al. fused a non-
cleavable green fluorescent protein (GFP) to the A2-domain of a truncated cholera toxin.
64
 The 
fluorescent protein was then successfully delivered to the ER of both Y1 adrenal and Vero cells. 
In a very recent study,
65
 Daniell and co-workers bioencapsulated CTB chimeras by expressing 
the proteins in the chloroplast of plant cells. When orally administered to mice, the 
bioencapsulated proteins were transported safely to the intestine before eventually crossing the 
blood brain barrier to produce a therapeutic effect. Impressively, the authors used CTB fused to 
myelin basic protein to reduce the number of amyloid fibrils in the neurons of genetically 
altered mice with Alzheimer’s disease. In an earlier study, Barrett et al. used a CTB-polylysine 
Figure 1.7: Diagram of CT/LT mode of action on mammalian cells.
61 
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conjugate to transport plasmid DNA inside neurons (rat PC12 pheochromocytoma) leading to 
the transgene expression of GFP within the cells.
66
 Furthermore, in vivo studies have shown 
CTB preferentially targets motor neurons when administered to mice and rats with 
intraperitoneal, intravenous and intramuscular injections.
67,68
 This research has established 
enterotoxins as viable delivery vehicles, but it has also highlighted their rare ability to target 
motor neurons and cross the blood-brain barrier. In principle, therapeutics linked to the proteins 
could be used to treat neurological disorders that are currently difficult to target with 
conventional drugs.  
1.2.2 Formation of novel AB5 complexes   
Investigation into the assembly of holotoxins has led to the development of novel AB5 
complexes both in vivo and in vitro. 
1.2.2.1 AB5 formation in vivo 
Research into the kinetics of cholera toxin assembly, in vivo and in vitro, was originally 
pioneered by Hirst and co-workers.
69
 The team discovered that CTA does not interact with a 
preformed pentameric CTB to generate complete cholera toxin, as previously thought.
64,69 
On 
the contrary, it was found that holotoxin assembly only occurred when CTA interacted with 
CTB monomers during the assembling process.
64
 Secondly, the rate of formation of pentameric 
CTB in E. coli cells increased three fold in the presence of CTA.
69
 These discoveries were 
surprising because it had been previously thought that CTA did not play an active role in the 
formation of pentameric CTB as its formation had been observed without the presence of any 
CTA.
69,70
  
Unsurprisingly, the mechanism of heat-labile enterotoxin assembly seems to be controlled by 
very similar processes to its closely related cousin, cholera toxin. In another study by Hirst and 
co-workers,
71
 it was found that the total observed yield of pentameric LTB expressed from E. 
coli cells was five-fold lower when it was expressed in the absence of LTA. Moreover, the yield 
of pentameric LTB even increased when LTA was expressed from a different plasmid within 
the same E. coli cell; this indicated the increase in yield was attributed to a posttranslational 
process.  
The specific interactions between LTA and LTB were explored by Hirst and co workers, using 
site directed mutagenesis to create LTA mutants with truncated C-terminal sequences (Table 
1.2).
71
 The mutants had their amino acid sequence reduced by four and fourteen residues. Stable 
holotoxin generation was not observed when LTB was coexpressed with the truncated LTA 
mutants. Interestingly, both mutants did enhance the yield of pentameric LTB assembly 
15 
compared to LTB being expressed on its own. Therefore, it was postulated that interactions 
distal to the C-terminal extremities of LTA are important for the facilitation of LTB expression 
and/or LTB pentamer assembly. Furthermore, interactions between LTB and the final four C-
terminal residues of LTA play a key role in anchoring the A-subunit in place after holotoxin 
generation.
71
 
LTA  C-terminal sequence 
 Wild type  YGSEVGIYNRIRDEL 
 Mutant 1 YGSEVGIYNRI 
 Mutant 2 Y 
 
Jobling et al. made fusions proteins of CTA2 with maltose binding protein (MBP), β-lactamase 
(BLA) and bacterial alkaline phosphatase (BAP).
72
 The protein fusions were coexpressed with 
CTB to successfully generate hybrid AB5 complexes for the first time. This research 
demonstrated the potential of using chimeric CTA2 proteins to create a range of different AB5 
complexes. Intriguingly, when the fusion proteins were expressed in V. cholera they were not 
transported through the secretory apparatus of the bacteria into the growth media. This is 
probably due to the large steric bulk of the new hybrid proteins blocking the secretory pathway.  
1.2.2.2 AB5 formation in vitro 
It is possible to reform viable AB5 complexes from their constituent subunits in vitro.
73-75
 The 
basic procedure involves fully denaturing the B-subunits into their monomeric states using acid, 
or a combination of acid and reducing agent. The acidic-protein solution is then neutralised and 
the A-subunit is immediately added to allow the AB5 complex to reform. The exact method used 
to assemble the holotoxin changes depending on whether CTB or LTB are being used. CTB and 
LTB share nearly 80% sequence identity, which gives them almost identical properties (Figure 
1.5).
76
 However, they have different stabilities under acidic conditions. When exposed to pH 1.5 
for 2.5 minutes, only 20% of LTB monomers will reassemble into pentamers.
77
 In contrast, CTB 
can remain in acidic condition at pH ≤ 1 for up to an hour before its ability to reassemble into 
pentamers is compromised.
78
 The discrepancy between the acid stability of the B-pentamers is 
probably due to a cis-trans isomerisation of a proline residue (Pro-93) shared by both CTB and 
LTB. The proline isomerisation alters the configuration of the B-monomer preventing vital 
interactions with other monomeric proteins and thus inhibiting pentamer assembly.
77,78
 
Therefore, it is reasonable to assume that CTB must be more resistant to this isomerisation 
change under acidic conditions compared to LTB. 
 Table 1.2 Amino acid sequence of the truncated LTA mutants. 
71
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Takeda et al. demonstrated that the A and B subunits of heat-labile enterotoxin and cholera 
toxin could be assembled inter-changeably in vitro.
73
 These hybrid holotoxins comprised of 
LTA/CTB and CTA/LTB proteins showed exactly the same activity as the parent holotoxins 
from which the A subunits were derived.  
It has also been shown that CTA2 fusion proteins can be assembled with CTB to form novel 
AB5 structures in vitro. Hatic et al. generated a fluorescent AB5 protein by combining CTB 
monomers with a CTA2-GFP fusion.
74
 However, less than 20% of the fluorescent AB5 protein 
was recovered. Interestingly, the efficiency of AB5 complex formation in other in vitro 
experiments has generally gone unreported, which suggests this approach is low yielding   
1.2.3 Formation of Novel LTB/CTB Proteins 
Modifications to the N- or C-termini of LTB and CTB have also been reported. 
1.2.3.1 N-terminal Modifications  
Dertzbaugh et al. successfully fused Glucosyltransferase B to the N-terminus of CTB via a short 
peptide linker.
79
 The monomeric CTB chimeras formed viable pentamers and also produced an 
immune response to Streptococcus mutans, the bacteria that express Glucosyltransferase B. 
However, there are limitations to this approach. In another study by Dertzbaugh et al.,
80
 it was 
found that the GM1 binding affinity of CTB fusions decreased with increasing N-terminal linker 
length. Interestingly, the ability of the chimeras to induce an immune response also decreased.  
Rose et al. used a chemical based approach to modify pentameric CTB.
81,82
 Peptide extensions 
were introduced by oxidising the N-terminal threonine residue 1.9 to aldehyde 1.10 before 
peptide 1.11 was coupled via an oximation reaction (Scheme 1.1). Peptide 1.11 contained 
multiple lysine residues covalently linked, though their amino side chains, to serine residues. 
The serine residues were subsequently oxidised and reacted with aminooxyacetylated 
immunogenic peptide 1.14 to generate modified CTB monomers 1.15.
81,82
 The N-terminal 
extensions did not appear to affect the GM1 binding ability of CTB and in one instance, the 
hybrid protein actually showed an increased binding affinity to GM1.   
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1.2.3.2 C-terminal Modifications 
A number of different research groups have also investigated the effects of C-terminal 
modifications to LTB and CTB. Sandkvist et al. extended the C-terminus of LTB with random 
peptide sequences (Table 1.3).
83
 The extensions affected the ability of some of the mutants to 
form stable pentamers and in one case, no LTB protein was detected after expression. 
Intriguingly, all the mutants were unable to complex with the A-subunit to generate AB5 
proteins.
83
 This study highlighted how sensitive the C-terminal structure of LTB is to 
alterations. However, the amino acid extensions were chosen randomly, so it is difficult to 
ascertain whether it was their length and/or sequence that affected LTB assembly. 
No. of amino acid in extension  C-terminal sequence  Assembly  
0 (Wild type) EN Holotoxin 
6 EKLGCFGG Monomeric  
16 EKLAWLFWRMRGDFQPDTD Monomeric  
6 EKLFQPDTD Pentameric 
6 EKLAPQKRW Pentameric 
12 ESLAVLADERRFSA Not detected  
Scheme 1.1: Chemical modification of CTB by the oxidation and subsequent oximation of 
the N-terminal threonine residue.
81 
Table 1.3: Amino acid sequence and assembly of LTB wild type and C-terminal mutants.
83
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A peptide epitope, designated Pk, was fused onto the C-terminus of LTB in a study by Green et 
al. (Table 1.4);
84
 the Pk epitope is recognised by the monoclonal antibody SV5-P-k3. The 
hybrid protein was expressed in Vibrio sp 60 cells and exported into the growth media. The 
expression yield of the hybrid protein was less than wild type LTB; the low yields were 
probably due to degradation of the peptide extensions by proteases native to Vibrio sp 60 cells. 
Interestingly, the protein fusion was still able to form stable pentamers and raise an immune 
response to both LTB and the peptide tag. In a separate study,
85
 Loregian et al. extended the C-
terminus of LTB with a DNA polymerase fragment (pol) from herpes simplex virus type 1 and 
observed very similar results concerning protein assembly to the findings reported by Green et 
al. (Table 1.4).  
Peptide tag No. of amino acids in extension C-terminal sequence  
Pk 14 GKPIPNPLLGLDST 
pol 27 LPTGEASPGAFSAFRGGPQTPYGFGFP 
The initial research into LTB-Pk fusions was further developed in a study by O’Dowd et al.86 
The group introduced a cysteine residue at different positions along the C-terminal peptide 
extension in a series of different LTB-Pk mutants. The expression yield of the fusion proteins 
decreased with the introduction of cysteine. However, the addition of EDTA to the growth 
media helped increase the yield by inhibiting native proteases. A Michael addition was used to 
couple Horseradish peroxidase (HRP) 1.17, functionalised with a maleimide group, to the 
cysteine residue in LTB-Pk 1.16 (Scheme 1.2). The LTB-Pk-HRP protein 1.18 was able to bind 
to GM1 at the surface of Vero cells and induce a mucosal immune response to HRP in mice. 
This research indicated that chemically-modified LTB could be used as an adjuvant and may be 
useful in the development of vaccines.   
 
Table 1.4: Amino acid sequence of C-terminal LTB fusion tags.
 68,69
 
Scheme 1.2: The coupling of CTB to HRP via a Michael addition.
86
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It is clear that extensions to the C-terminus of LTB are possible without reducing its ability to 
form stable pentamers. However, it is less clear what sequence and length of peptide extension 
will defiantly not interfere with pentamer assembly. Furthermore, no AB5 complex formation 
has been observed with C-terminal mutants  
1.3 Protein modification  
There are many bioorthogonal reactions that can be used to modify proteins, such as strain-
promoted cycloadditions and Staudinger ligation.
87,88
 However, these methods often necessitate 
the incorporation of non-natural amino acids into a target proteins.
89
 Native chemical ligation 
(NCL) is one of the earliest and most widely used protein modification techniques; it has been 
utilised many times in the synthesis of synthetic proteins. In contrast, sortase-mediated chemical 
ligation is a relevantly new technique that is fast becoming the tool of choice for protein 
modification. The substrates for both NCL and SrtA are more readily accessible compared to 
alternative protein labelling techniques.   
1.3.1 Native chemical ligation   
A landmark paper by Kent and co-workers established a completely new method to connect 
polypeptides together, which they termed NCL (Scheme 1.3).
90
 The authors discovered that 
substrates bearing an N-terminal cysteine residue 1.20 will form a new amide bond with 
peptides containing a C-terminal thioester 1.19. A reversible transthioesterification reaction 
between the -thiol of cysteine 1.20 and the C-terminal thioester 1.19 produces a thioester-
linked intermediate 1.21. Finally, in an irreversible intramolecular rearrangement, the 
intermediate 1.21 forms an amide-linked polypeptide 1.22.
90
 The reaction is usually performed 
on unprotected peptides under denaturing aqueous conditions with additional free thiol.
91,92
 
Catalysts, such as (4-carboxymethyl)thiophenol, can greatly increase the reaction speed.
93
 The 
ligation is highly chemospecific even in the presence of other non-terminal cysteine 
residues.
90,91,94
 Cysteine residues contained within the proteins structure are only able to form 
the transient thioester intermediate 1.21 as they lack the necessary nucleophilic amino group for 
the final transpeptidation reaction.
92
 Furthermore, NCL proceeds with less than 1% 
racemisation.
91
  
One of the main challanges of NCL is the preparation of the thioester peptides. Boc solid phase 
peptide synthesis (SPPS) coupled with thioester linkers is the most effective way to synthesis 
thioester peptides.
92,94,95
 However, this process routinely requires the use of harsh and toxic 
reagents, so it is not accessible in many laboratories.
92
 An alternative strategy, developed by 
20 
Dawson and co-workers, utilises a diaminobenzoyl linker attached to Rink amide resin to 
efficiently synthesise peptidyl thioesters using the more conventional Fmoc-SPPS approach.
96
  
 
 
 
 
 
 
The synthesis of larger peptidyl thioesters can be achieved recombinantly using an intein 
fusion.
91,97
 Intein chimeras 1.23 have a unique folded structure that distorts the cysteine residue 
at the junction between the fused polypeptides (Scheme 1.4).
91
 The N-terminal amide bond of 
the cysteine residue is twisted, so that the lone pair on the nitrogen is not fully conjugated into 
the system. The -thiol on the cysteine residue can attack the distorted amide bond and trigger a 
reversible intramolecular rearrangement forming a thioester 1.25.
91,97
 The thioester intermediate 
1.25 can be intercepted using a suitable thiol 1.24 to generate a peptidyl thioester 1.26. 
Exploiting this mechanism, Chong et al. developed a technique to purify proteins 1.23 that had 
been fused to an intein and a chitin-binding domain (CBD). The authors captured the protein 
chimera 1.23 on chitin resin and used thiols 1.24 to cleave the target protein from the 
immobilised intein-CBD fusion, forming peptidyl thioesters 1.26. Ingeniously Muir et al. 
combined this approach with NCL to generate ligated proteins 1.27 directly on solid support by 
intercepting the thioester intermediate 1.25 with an N-terminal cysteine peptide 1.26 instead of a 
thiol 1.24.
98
 
NCL is a powerful technique that has been used to make numerous synthetic proteins,
73
 such as 
crambin and human lysozyme.
99,100
 However, ligations are typically carried out under 
denaturing conditions, so there is no guarantee that every synthetic protein will fold into the 
correct higher level structure. Interestingly, other macromolecules, including oligosaccharides 
and oligonucleotides,
101,102
 can be attached onto peptide chains using this approach.  
 
Scheme 1.3: General mechanism for native chemical ligation.
90 
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1.3.2 Sortase-mediated chemical ligations  
Sortases are a class of transpeptidase enzyme that covalently sort and link proteins to the cell 
wall of gram-positive bacteria.
103-105
 The first sortase discovered and consequently most studied 
enzyme is the type II membrane bound protein, Sortase A (SrtA) expressed by Staphylococcus 
aureus
103,105
 The enzyme recognises proteins bearing a conserved LPXTG motif and ligates 
them to peptidoglycans substrates carrying an N-terminal oligoglycine sequence.
103,106,107
  
SrtANΔ59 is a truncated variant of SrtA that is catalytically active despite having 59 amino acid 
residues removed from its N-terminus. Zong et al. obtained a crystal structure of an inactive 
SrtANΔ59 mutant (Cys184Ala) bound to an LPETG peptide substrate (Figure 1.8).
108
 However, 
the substrate conformation in the active site appears to be slightly different to the description 
reported by the authors. For example, the lipophilic residues proline and leucine are supposed to 
be sat in a hydrophobic pocket that anchors the substrate in place, but the aliphatic side chain of 
leucine is not interacting with the surface of the protein at all. Furthermore, the glutamic acid 
was described as solvated; however, the carboxylate group is pointing towards the protein, 
which suggests an interaction is taking place. This is unusual as the glutamic acid in the 
substrate can be replaced with any amino acid; therefore, little or no interaction with the enzyme 
should be expected. The final threonine and glycine amino acids sit between the arginine 
(Arg197) and cysteine (Cys184Ala) active-site residues as reported. Although it is clear the 
Scheme 1.4: Intein catalysed formation of C-terminal thioesters on chitin solid support 
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crystal structure does show enzyme-substrate binding, it is unlikely that the substrate is in the 
active conformation.  
 
 
The SrtA/substrate complex is commonly thought to undergo a “reverse proton transfer 
reaction” (Scheme 1.5).106,109,110 SrtA is primed when the active site cysteine 1.30 and histidine 
1.29 residues exist in a thiolate–imidizolium ion pair; however, under physiological conditions, 
only o.o6% of the enzyme is in this activated state at any given time.
110,111
 The deprotonated 
form of cysteine attacks the theronine and glycine amide bond of the substrate 1.31.
106,109-112
 
This generates a transient oxyanion intermediate 1.32 that is stabilised by hydrogen bonding to 
the arginine residue 1.28 in the activate site. Subsequently, the intermediate collapses leading to 
loss of the C-terminal glycine amino acid and formation of thioester intermediate 1.34. The 
cationic imidizolium group on the histidine residue 1.29 catalyses the cleavage event by 
protonating the departing glycine amino acid. The incoming oligoglycine substrate 1.35 attacks 
the enzyme-intermediate thioester to form the ligated peptide 1.38. It has also been postulated 
that the imidazole group of the histidine residue 1.33 can act as a base and deprotonate the 
incoming oligoglycine-substrate 1.35.
112,113
  
 
Figure 1.8: Crystal structure of the SrtANΔ59 Cys184Ala mutant bound to an LPETG substrate. 
Active site residues: Blue = His 120; Green = Arg 197; Red = Ala 184. Peptide residues: 
Orange = Glycine; cyan =: Threonine; black = Glutamic acid; yellow = Proline; and purple = 
Leucine. Generated from PDB codes of atomic coordinates: 1T2W (UniProt code: Q9S446).
108
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Investigations into the LPXTG sequence has led to a better understating of the optimum 
recognition site needed for efficient ligations. Kruger et al. discovered that any amino acid 
residue can be incorporated at the X position of the substrate with minimal effect on effect on 
the total ligation yield;
114
 however, cysteine and tryptophan were not tested. A very detailed 
study into the transpeptidation reaction by Pritz et al.,
115
 highlighted the importance of amino 
Scheme 1.5: Proposed mechanism for the sortase mediated ligation reaction.
106,109,112
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acids residues neighbouring the conserved LPXTG motif. The authors varied the amino acid 
sequence at several key positions after the C-terminal LPXTG sequence and measured the 
ligation efficiency using a model N-terminal oligoglycine peptide, GGGWW. They found that a 
peptide with an optimised LPXTGGG[X]n motif at the C-terminus gave the maximum ligated 
product yield. Interestingly, a significant increase in yield was also obtained by introducing just 
one additional glycine residue after the LPXTG motif. Substituting the additional glycine 
residue with other amino acids led to a decrease in product formation; this change was most 
dramatic when proline was used. These results support the previous kinetic studies carried out 
by Huang et al.,
116
 which suggested the rate determining step of a sortase-transpeptidation 
reaction is the formation of the thioester intermediate and not attack of the glycine peptide 
substrate.     
 
1.3.2.1 Substrates for SrtA-mediated modifications of proteins   
There are various types of molecules that can react with the thioester enzyme intermediate. N-
terminal diglycine peptides/proteins are the optimal substrates, but substantial ligation has been 
observed with substrates carrying only a single N-terminal glycine residue.
103,116,117
 It has been 
reported that the thioester intermediate can interact with the -amine group of lysine residues; 
however, the ligation proceeds at an exceptionally reduced rate.
118
 Hydroxylamine, a powerful 
inorganic nucleophile, can also act as a compatible substrate for the SrtA-mediated 
ligation.
116,119
 The thioester intermediate will undergo hydrolysis, albeit very slowly, if no other 
suitable substrate is available for the transpeptidation reaction.
103,117
 Hydrolysis proceeds so 
slowly that the kinetics of the reaction are inverted; the rate determining step becomes the 
nucleophilic attack of water instead of the formation of the thioester intermediate.
116
 
There is now a huge catalogue of chemical probes that have been site-specifically incorporated 
into protein substrates using SrtA-mediated ligations.
111
 In general, C-terminal modification 
simply requires the introduction of a solvent exposed LPXTG motif into a protein 
structure.
103,107,111
 Protein labelling is then achieved by using peptide substrates carrying an N-
terminal oligoglycine sequence. This methodology has been used to attach an assortment of 
chemical probes onto proteins including biotin 1.39,
120
 folate 1.40, 
117
 cholesterol 1.41, 
121
 and 
glycosylphosphatidylinositol (GPI) anchor 1.42 
122
 (Figure 1.9). 
 The C-terminal labelling strategy can also be reversed. Peptide substrates carrying the LPXTG 
motif can be ligated onto proteins that present an accessible N-terminal glycine residue. Once 
again, this approach has allowed derivatisation of proteins with a wide range of functional 
groups, such as azides and fluorophores.
111,123
 In principle, any molecule that can be 
his 120 
cys 184 ala 
ala 197 
LPETG 
Substrate 
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incorporated into the structure of a peptide can feasibly be attached onto a protein using SrtA. 
However, to achieve high level of protein modification a large excess of the label is generally 
required, which could be problematic if the label is precious  
 
1.3.2.2 Duel SrtA-mediated modifications of both the N- and C-termini of 
proteins 
An ingenious strategy developed by Ploegh and co-workers enabled both the N- and C-termini 
of human UCHL3 protein to be labelled using SrtA-mediated ligations (Scheme 1.6).
124
 The 
success of the technique relied on the subtle difference in substrate recognition of SrtA derived 
from two different species of bacteria, Streptococcus pyogenes (SrtAstrep) and Staphylococcus 
aureus (SrtAstaph). The ligation mechanism of both enzymes is almost identical except StrAstrep 
can accept N-terminal glycine and alanine substrates. Therefore, the ligated products of StrAstrep 
can carry an LPXTA amino acid sequence, which is an extremely poor substrate for SrtAstaph. 
The team genetically incorporated a SrtA recognition site at the C-terminus, and a thrombin 
cleavage site at the N-terminus of UCHL3 1.43. SrtAstrep was used to ligate a rhodamine-
Figure 1.9: Structure of sortase substrates that contain: Biotin 1.39;  Folate 1.40; Cholesterol 
1.41 and a GPI anchor 1.42 
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conjugated peptide carrying an N-terminal alanine residue to the C-terminus of UCHL3 1.44. 
The modified protein 1.44 was treated with thrombin to expose an N-terminal glycine residue, 
which was then modified with a fluorescent peptide using SrtAstaph. This process generated a 
duel labelled UCHL3 protein 1.46 at over 90% purity. Furthermore, to demonstrate the 
versatility of their approach, the authors also labelled the N- and C- termini of an eGFP protein.  
 
1.3.2.3 SrtA-mediated modifications of cholera toxin  
In a series of elegant studies conducted by Ploegh and co-workers,
60,124
  SrtA ligations were 
used to modify both the A and B subunits of cholera toxin with a variety of chemical and 
biological probes.   
N-terminal modification of CTB  
Ploegh and co-workers developed a method to label the N-terminus of CTB using SrtA-
mediated ligations (Scheme 1.7).
124
 The authors introduced one, three or five glycine residues to 
the N-terminus of a series of CTB mutants and labelled the proteins using SrtA-mediated 
ligations. The mutants with three and five additional glycine residues were labelled successfully, 
but no modification was observed with the single glycine extension. This suggests the native N-
terminus of CTB is not accessible to SrtA without an appropriate peptide extension.  
Scheme 1.6: N- and C- terminal labelling strategy of proteins UCHL3 and eGFP using SrtA- 
developed by Ploegh
124
 F1 = fluorescein; F2= rhodamine.  
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Modification of AB5 proteins 
Ploegh and co-workers modified a fully functioning variant of cholera toxin using sortase-
mediated ligations.
60
 The authors genetically incorporated an extended peptide sequence 
including a SrtA recognition site at the C-terminus of the A1-domain directly before the final 
proline and serine residues (Scheme 1.8). The AB5 protein was primed for transpeptidation 
when the peptide sequence connecting the A1 and A2-domains was cleaved using trypsin. SrtA 
was then used to chemically modify the C-terminus of the A1-domain with a range of biological 
probes including a fluorescent and biotinylated peptide. Vero cells were transfected with the 
modified AB5 proteins and the intracellular fate of the A1-fragment was investigated. The 
biological probes provided direct evidence of the A1-protein reaching the ER supporting 
previous studies.
60,125
 Using the same approach, the group ligated the catalytic domain of 
diphtheria toxin onto the A1-protein.
60
 The essential genes required for cholera toxin 
transfection in human cells were screened using the AB5-fusion protein. However, the most 
interesting aspect of the study was the observation that the modified A1-protein was still able to 
escape the ER and deliver the diphtheria toxin fragment to the cytosol of the cell. Theoretically, 
this methodology could be used to transport an assortment of macromolecules into human cells; 
however, the cytotoxicity of the A1-fragment is an enormous obstacle in the wider application 
of this approach. A solution to this problem would be to create a non-toxic A1-protein, but 
doing so without affecting the ER escape mechanism may be challenging.    
Scheme 1.7: N-terminal labelling of CTB using SrtA-mediated ligations. n = 3 or 5. Probe = 
FITC and biotin   
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Scheme 1.8: Schematic representation of the engineered CTA variant and modification 
strategy developed by Ploegh.
60
 Blue: natural CTA1 sequence. Red: sortase recognition 
site. Orange: extended peptide sequence. Green: natural CTA2 sequence. 
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1.4 Project outline  
The project was an investigation into the formation of bacterial toxin based delivery vehicles 
that could be used to transport oligonucleotides and other macromolecules inside mammalian 
cells. Studies discussed in the previous section have already demonstrated the ability of bacterial 
toxins to deliver chemical probes, proteins and nucleic acids into a range of mammalian cells. 
However, a simple and robust strategy has not yet been developed to allow the efficient 
formation of an oligonucleotide-delivery vehicle. The progress towards realising this goal is 
documented within the work presented here.   
The primary objective was to use SrtA-mediated ligations to site-specifically modify a truncated 
cholera toxin variant at the N-terminus of the CTA2-peptide (Scheme 1.9). In general, SrtA 
ligations need a large excess of labelling regent and stoichiometric quantities of enzyme to 
achieve high levels of protein modification.
126,127
 Therefore, initial research was focused on 
optimising the efficiency of the SrtA-transpeptidation reaction for N-terminal labelling of 
proteins. To this end, the incorporation of non-natural amino acids and chemical modification of 
the peptide label was investigated.  
 
The second objective was to deliver a modified AB5 complex into mammalian cells and track its 
intracellular fate (Figure 1.10). Using a combination of immunostaining and fluorescence 
microscopy, the pathway of a fluorescently labelled AB5 complex was studied.  
Scheme 1.9: AB5 modification strategy using SrtA-mediated ligations   
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The final objective was to develop a method to attach oligonucleotides site-specifically onto the 
AB5 complex (Scheme 1.10). The incorporation of a bioorthogonal linker into peptide substrates 
for SrtA was investigated. This strategy would allow the site-specific labelling of the AB5 
complex with a functional handle that could be subsequently derivatised with an oligonucleotide 
macromolecule.           
 
  
Figure 1.10: Diagram of the predicted intracellular pathway of the modified AB5 complex  
Scheme 1.10: AB5 modification strategy using SrtA-mediated ligations and a bioorthogonal 
linker   
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Chapter 2: Efficient N-terminal labelling of proteins 
using Sortase 
 
Two papers based on the following section have been published: 
“Efficient N-Terminal Labeling of Proteins by Use of Sortase” Angewandte Chemie 
International Edition, 2012, volume 51, pages 9377-9380, D. J. Williamson, M. A. Fascione, M. 
E. Webb and W. B. Turnbull.  
“Depsipeptide substrates for sortase-mediated N-terminal protein ligation” D. J. Williamson, M. 
E. Webb, W. B. Turnbull, Nature protocols, 2014, volume 9, pages 253-262. 
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2.1 Introduction  
SrtA can be used to attach a wide variety of peptide labels 2.1, which carry an LPXTG 
recognition sequence, onto a protein 2.2 through a sterically accessible N-terminal glycine 
residue (Scheme 2.1).
111,127
 In principle, any molecule that can be coupled onto a peptide 
substrate can be attached to a protein. Furthermore, the conditions of the reaction are extremely 
mild typically being performed at pH 7.5 in the presence of a buffering agent, such as HEPES, 
TRIS etc.
111
 The elegant simplicity of the SrtA-transpeptidation reaction makes it a powerful 
protein-modification tool.    
 
The reaction is reversible, so many protein modification protocols recommend the use of a large 
excess of label and stoichiometric amounts of StrA to ensure high ligation yields.
111,124,127
  
However, if the label is precious, or available in finite quantities, this may not always be 
possible. In this chapter, the development of a method to increase the efficiency of the 
transpeptidation reaction using depsipeptide substrates for SrtA will be described.   
2.2 Investigation into the efficiency of the SrtA-mediated 
ligation reaction  
There is an abundance of literature that demonstrates the SrtA-mediated transpeptidation 
reaction as a versatile protein modification technique. Therefore, to allow a comparison to 
previous studies and gain an insight into the general efficiency of the ligation reaction, the 
activity of SrtA with model peptide substrates was investigated.    
2.2.1 SrtA-mediated ligation with model peptide substrates   
A pETMCS-III plasmid harbouring a SrtA gene with an N-terminal truncation, which removed 
the membrane-anchoring peptide sequence, was donated by Dr C. Neylon (University of 
Southampton). However, the plasmid construct encoded SrtA without a purification tag. To 
introduce a polyhistidine-tag (His-tag) to the N-terminus of the enzyme, the SrtA gene was 
Scheme  2.1: General N-terminal labelling of proteins using SrtA. X= any amino acid, R= 
amino acid or NH2 
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subcloned from pETMCS-III into pET28a using restriction enzymes EcoRI and NdeI (Figure 
2.1). Then E. coli BL21-Gold (DE3) cells were transformed using the subcloned pET28a 
plasmid to allow SrtA to be overexpressed and subsequently purified by nickel chelation and 
size-exclusion chromatographies. 
 
 
The reactivity of the SrtA mediated ligation reaction was probed with a simple assay; a range of 
acyl donors 2.4, 2.5 and 2.6 and a single acyl acceptor peptide 2.8 (Scheme 2.1) were 
synthesised using SPPS in quantitative, or near quantitative yields. The first acyl donor 2.4 was 
built as a positive control because its structure was based on a compound that had previously 
shown activity with SrtA.
128
 The other peptides 2.5 and 2.6 maintained the common YALPET 
sequence of the control substrate 2.4, but the C-terminus of both peptides were sequentially 
truncated to determine the minimum residue length required for SrtA activity. The ability of 
SrtA to ligate the acyl donor peptides 2.4, 2.5 and 2.6 to a simple acyl acceptor peptide 2.8, 
containing an N-terminal diglycine motif, was monitored by LCMS (Scheme 2.1). 
Figure 2.1: Schematic representation of the subcloning of the SrtA gene from pETMCS-III 
into a pET28a plasmid using restriction digests. 
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Control peptide 2.4 was successfully ligated onto peptide 2.8 after an overnight incubation with 
SrtA. LCMS analysis before and after incubation allowed the identification of a new m/z peak 
with a UV absorbance that corresponded to ligated product 2.9, thus confirming the reaction 
was a success. Under the same reaction conditions, peptide 2.5, which contained a diglycine 
sequence at its C-terminus, showed similar reactivity to control peptide 2.4. Interestingly, no 
ligation was observed when the assay was repeated with peptide 2.6, which had only the 
minimal LPETG sequence at its C-terminus. However, once the pKa and position of the C-
terminal carboxylic acid were considered, the result was not surprising. Under the conditions of 
the reaction, the C-terminal carboxylic acid will be deprotonated creating an anionic charge at 
the SrtA recognition site, which could potentially inhibit substrate-enzyme binding. We 
proposed that replacing the carboxylic acid with a primary amide would remove the anionic 
charge and allow SrtA to bind to the substrate. Therefore, a fifth peptide 2.7 containing a C-
terminal amide was synthesised and successfully attached to peptide 2.8 (Scheme 2.1). These 
observations support previous findings reported by Huang et al.
116
 The authors measured the 
rate of ligation between a SrtA-acyl intermediate and a series of acyl acceptors. When glycine 
was used as a substrate, no reaction was observed. If glycine cannot participate in the reversible 
SrtA transpeptidation reaction, it is reasonable to assume that corresponding peptides bearing a 
C-terminal glycine residue in the LPXTG motif will also be unsuitable substrates. In addition, 
the authors observed SrtA activity when glycine amide was used as the acyl acceptor instead of 
glycine, which vindicates our strategy of replacing the C-terminal carboxylic acid of acyl donor 
2.8 with an amide bond to restore SrtA reactivity.  
 
Scheme 2.1: Sortase mediated ligation of acyl-acceptor peptide 2.8 to acyl-donor peptides 2.4-
2.5 forming product 2.9 and by-products 2.10-2.12 
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2.2.2 HPLC time-course analysis of the SrtA-mediated ligation 
reaction with peptide substrates   
The initial experiments with peptides 2.4-2.7 had confirmed the general substrate selectivity and 
reactivity of SrtA that had already been widely reported in the literature. However, in each assay 
where ligation had been successful there was a significant amount of starting material identified 
in the UV chromatogram and it was impossible to determine if or when the reaction had reached 
completion. Therefore, an HPLC time-course experiment was used to establish the point at 
which there was no further reaction. The ligated product 2.9 was synthesised independently and 
analysed by HPLC to determine its retention time, so that there was no ambiguity about what 
was being formed in the reaction. Acyl donor 2.5 (500 M) was incubated with one, two and 
four equivalents of acyl acceptor 2.8 in three separate assays. The assays were carried out in 
parallel over an 8 hour period and the amount of product 2.9 formed was plotted as a function of 
time (Figure 2.2) 
 
 
Figure 2.2: Time-course of StrA-mediated ligation of peptides 2.5 (500 M) and 2.8 (0.5, 1 or 4 
mM) forming product 2.9. The ratio of peptides 2.8 and 2.5 was increased for each experiment, 
as indicated: Red: 1:1, Blue: 2:1 and Green 4:1 Error bars are present, but in some cases smaller 
than the data. point. 
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When peptides 2.5 and 2.8 were mixed in equal concentrations, the time-course showed the 
reaction reached completion in roughly four hours with ~50% product conversion (Figure 2.2). 
This is probably due to the reaction reaching equilibrium as it is well documented that the 
cleaved diglycine residue 2.12 can act as substrate and participate in the reverse reaction.
116
 
Predictably, increasing the concentration of acyl acceptor 2.8 pushes the equilibrium towards 
greater product formation, but even with four equivalents there was still some acyl donor 2.5 
left at the end of the assay. The time-course experiment was repeated for acyl acceptor 2.8 and 
acyl donor 2.7, which had a C-terminal amide group (Figure 2.3). The results of the second 
time-course experiment followed an almost identical pattern to the first experiment: when the 
substrates were mixed in a 1:1 ratio, the ligation reaction reached about 50% product conversion 
before levelling off, and increasing the concentration of acyl acceptor 2.8 maximised the 
product yield. These observations are consistent with the current literature precedent regarding 
SrtA-mediated ligations.
114,116,117,128
 The formation of a 100% ligated product is probably 
unachievable using SrtA-mediated ligations as the reverse reaction will still be operational even 
at much higher concentration of one of the substrates. 
 
 Figure 2.3:Time-course of StrA-mediated ligation of peptides 2.7 (500 M) and 2.8 (0.5, 1 
or 4 mM) forming product 2.9. The ratio of peptides 2.7 to 2.8 was increased for each 
experiment, as indicated: Red: 1:1, Blue: 2:1 and Green 4:1 
38 
2.3 Optimization of the SrtA mediated ligation reaction  
The previous time-course experiments had confirmed the major limitation of the SrtA ligation 
reaction. High yields can only be achieved when a large excess of one substrate is used, which 
may not always be possible if only a limited amount of compound is available. Furthermore, 
future purification steps could be problematic as the ligation reaction did not give complete 
product formation. An obvious solution to these problems is to try and prevent the reverse 
ligation reaction, which theoretically could maximise the product yield and obviate the need for 
excess reagents. Previous work by Ploegh and co workers had endeavoured to tackle the 
inefficiencies of the SrtA ligation reaction.
124
 The authors replaced the C-terminal glycine 
residue in the LPXTG motif with a methyl ester. SrtA continued to recognise the methyl ester 
2.13 as a substrate and ligated it to proteins 2.14 bearing an N-terminal oligoglycine sequence 
(Scheme 2.2). The reaction now generated methanol as a byproduct, which is not a substrate for 
SrtA, so the ligation effectively became irreversible. However, a large excess (in some cases 
approximately ten equivalents) of methyl ester 2.13 and stoichiometric amounts of StrA were 
still required for complete conversion to the modified protein. It is probable the authors were 
forced to use a large excess of reagents and stoichiometric amounts of enzyme to overcome the 
possible product inhibition of SrtA. The methyl ester 2.13 was probably a poor substrate for 
SrtA as it did not contain the full LPXTG recognition motif. Therefore, as more ligated product 
accumulated during the course of the reaction, it is reasonable to assume it would have bound 
preferentially to SrtA inhibiting the forward ligation reaction.   
 
We postulated that depsipeptide substrates 2.17, which had the scissile amide bond between the 
threonine and glycine residues replaced with an ester linkage, would also avoid the reverse 
ligation reaction (Scheme 2.3). If SrtA accepted depsipeptide 2.17 as a substrate then 
hydroxyacetyl byproduct 2.20 would be generated and, like methanol, it should not be 
Scheme 2.2: Sortase ligation of methyl ester 213 and generic protein 2.14 to form ligated 
product 2.15 and methanol 2.16 byproduct. X = any amino acid 
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recognised by the enzyme. In principle, this approach should avoid the reverse reaction without 
reducing the rate of the forward reaction as depsipeptide substrate 2.17 would only contain 
minimal alterations to the LPXTG recognition sequence. Therefore, only substoichiometric 
amounts of enzyme and equal concentrations of both substrates should be required for efficient 
protein modification.      
 
2.3.1 Initial Synthetic route to depsipeptide substrates  
Replacing the glycine residue in the LPXTG sequence with glycolic acid was thought to be the 
simplest way to create a depsipeptide using SPPS. However, the hydroxyl group of the glycolic 
acid had to be protected before it could be used as a SPPS building block. The choice of 
protecting group had to be carefully considered as conventional resins used in Fmoc-SPPS are 
acid sensitive; this ruled out traditional acid labile projecting groups. After consultation of past 
literature, a synthetic strategy was found that would lead to silyl-protected glycolic acid 2.23 in 
two steps (Scheme 2.4).
129
 The first step involved capping the hydroxyl group of butyl glycolate 
2.21 with TBDMS-Cl in the presence of imidazole to give silyl ether 2.22 in 90% yield. The 
silyl ether 2.22 was then hydrolysed to form the protected glycolic acid 2.23 as the predominant 
product (~70% by 
1
H NMR spectroscopy) in a mixture with starting material 2.22. The 
remaining silyl ether 2.22 was not expected to cause complications with the SPPS, so the 
reaction mixture was used without any further purification.  
 
 
Scheme 2.3: Sortase ligation of depsipeptide 2.17 and generic oligoglycine peptide 2.18 
forming ligated product 2.19 and hydroxyacetyl byproduct 2.20 
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The silyl-protected glycolic acid 2.23 was now able to be used in the synthesis of a 
depsipeptide. The previous HPLC-time course investigations into the SrtA-mediated ligation 
reaction had used acyl donor peptides 2.5 and 2.7, so it was necessary to synthesise the 
analogous depsipeptides 2.24 and 2.25 to allow a direct comparison of the two types of substrate 
(Figure 2.4).  
 
Using standard Fmoc-SPPS conditions, silyl-protected glycolic acid 2.23 was coupled to gly-2-
chlorotrityl resin. The resin was treated with TBAF in THF to remove the silyl protecting 
groups and allow elongation of the depsipeptide through the hydroxyl group of the glycolic 
acid. Cleavage of the peptide gave the correct product, but with two significant byproducts: an 
incomplete peptide that did not include the ester linkage, and a depsipeptide that contained the 
ester linkage, but had not been elongated correctly. These two truncated compounds were 
indicative of incomplete coupling steps: the initial loading of silyl-protected glycolic acid 2.23 
to the resin, and the coupling of the resin-linked glycolic acid to threonine. The SPPS was 
repeated and in an effort to avoid truncated peptide formation each of the challenging coupling 
steps were conducted twice to increase the loading efficiency. Regrettably, these extra steps 
proved ineffective as the reactions always led to a heterogeneous mixture of compounds. In 
addition, the silyl deprotection step had also been problematic; half of the TBAF treatments had 
not managed to remove the protecting group. After several failed attempts, it was decided to 
terminate this approach. 
There were two major issues with the direct SPPS of depsipeptide substrates: the deprotection of 
the silyl-protecting group and the formation of the ester linkage. An obvious solution to the first 
problem would be to replace the silyl groups with an alternative SPPS protecting group, such as 
Scheme 2.4: Synthetic route to silyl protected glycolic acid 2.23 
Figure 2.4: Structure of peptides 2. 5 and 2.7; and depsipeptide analogues 2.24 and 2.25 
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Fmoc. Seeberger and co-workers use sugars with Fmoc-protected hydroxyl groups in the solid-
phase synthesis of oligosaccharides.
130-132
 However, this strategy does not address the issue of 
inefficient ester formation as the solid-phase synthesis of oligosaccharides uses activated 
glycosyl donors to link the sugars and not the standard SPPS-coupling reagents. It may have 
been possible to optimise the coupling of the resin-linked glycolic acid to theronine, but it was 
decided it would be more efficient to connect the residues in solution prior to SPPS. Therefore, 
an alternative strategy was developed    
2.3.2 Improved synthetic route to depsipeptide substrates  
The solution-phase synthesis of an Fmoc-protected depsipeptide precursor would allow the 
synthesis of depsipeptide 2.24 and 2.25 on solid support using the standard 
deprotection/elongation steps of Fmoc-SPPS. Suich et al. had already reported a two step 
synthesis to a protected tyrosine-glycolic acid conjugate 2.26 (Scheme 2.5).
133
 Using a modified 
version of the authors’ strategy, depsipeptide precursor 2.30 was synthesised. This was achieved 
by alkylating Fmoc-threonine 2.27 with 2-bromobenzyl glycolate 2.28 in the presence of 
tetrabutylammonium iodide (TBAI) to form tri-protected ester 2.29 in 95% yield (Scheme 2.5). 
After a selective deprotection of the benzyl ester by hydrogenation, depsipeptide precursor 2.30 
was generated in 87% yield. This step, although relatively straightforward, had to be monitored 
carefully as the reaction conditions can remove the Fmoc-protecting group if left for long 
periods of time. It is also important to note that the crude product could be used without further 
purification if required.  
 
Scheme 2.5: Synthesis of depsipeptide precursor 2.30.  Adapted from the original synthesis of 
tyrosine-glycolic acid conjugate 2.26 by Suich et al.
133
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Depsipeptide precursor 2.30 was successfully used to build depsipeptides 2.24 and 2.25 using 
conventional SPPS (Scheme 2.6). Depsipeptide 2.24 was synthesised, in 87% yield, on 
preloaded gly-2-chlorotrityl resin 2.31 generating a C-terminal carboxylic acid. Depsipeptide 
2.25, which contained the C-terminal amide, was constructed on rink amide resin 2.32 with a 
slightly lower yield of 67%. 
 
2.3.3 Synthesis of methyl ester substrates for SrtA 
The reactivities of depsipeptides 2.24 and 2.25 could now be compared to their peptide 
analogues 2.5 and 2.7. However, it was also important to evaluate the reactivity of methyl ester 
variant 2.35, which was analogous to that reported by Ploegh,
124
 as it would allow a direct 
comparison of both alternative ester-linked substrates under the same reaction conditions 
(Scheme 2.7). The synthesis of methyl ester 2.35 was achieved by constructing a partially 
protected peptide 2.34 on Thr-2-chlorotrityl resin 2.33 before cleaving the peptide with the very 
mild acid, hexafluoroisopropanol (HFIP). The use of HFIP allows peptide cleavage from 2-
chlorotrityl resins, but without the loss of protecting groups from the amino acid side chains. 
The partially protected peptide 2.34 was then methylated with methyl iodide in the presence of 
DIPEA. The crude methyl ester intimidate was treated with a standard TFA cleavage cocktail to 
generate methyl ester 2.35 in a modest 25% yield.  
Scheme 2.6: Synthetic route to depsipeptide 2.24 and 2.25. Structure of gly-2-
chlorotrityl 2.31 and rink amide 2.32 used in their SPPS 
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2.3.4 Comparison of SrtA reactivity with peptide, depsipeptide and 
methyl ester substrates  
The SrtA mediated ligation of depsipeptide 2.24 to acyl acceptor peptide 2.8 was monitored by 
a HPLC time-course assay (Figure 2.5). When one equivalent of depsipeptide 2.24 was used, 
peptide 2.8 was almost completely transformed into ligated product 2.9 in approximately 4 
hours. This was a huge improvement on the amide-linked substrate 2.5, which only reached 
~50% product conversion in the same time period. In contrast, methyl ester 2.35 reacted 
significantly slower than both depsipeptide 2.24 and peptide 2.5 to give only ~30% of ligated 
product 2.9 during the entire assay.  
Depsipeptide 2.24 appeared to slowly hydrolyse under the conditions of the reaction, which 
probably prevented complete product formation. Furthermore, as the product would still be in 
equilibrium with the SrtA-linked thioester intermediate, the 2 mol% of enzyme would also 
reduce the maximum product yield. Therefore, the experiment was repeated with 1.5 
equivalents of depsipeptide 2.24; the small increase in the number of equivalents allowed the 
reaction to reach completion rapidly. However, some enzymatic hydrolysis of the product was 
observed if the ligation was left for long periods of time; e.g. overnight. This is expected as it is 
Scheme 2.7: Synthetic route of methyl ester 2.35 
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well documented that SrtA will catalyse the hydrolysis of acyl donor substrates if there is no 
acyl acceptor present.
103,116
 
 
We propose that depsipeptide 2.24 was a much more efficient substrate for the SrtA-mediated 
ligation reaction than methyl ester 2.35 because it was able to bind efficiently to the enzyme and 
rapidly form ligated product 2.9. In contrast, the truncated SrtA-recognition site in methyl ester 
2.35 was predicted to cause inefficient enzyme-substrate binding and as a consequence the rate 
of the ligation was significantly reduced. Therefore, even though both ester-linked substrates 
produce non-reactive alcohol byproducts that cannot participate in the reverse reaction, only 
depsipeptide 2.24 was turned over efficiently to produce a high level of ligated product 2.9. 
Furthermore, it is unlikely that methyl ester 2.35 would have been completely converted to 
ligated product 2.9 if the reaction had been left for a longer period of time. It was more likely, 
however, that the reaction would have started to slow down before eventually stopping as a 
result of product inhibition. This hypothesis seems plausible because ligated product 2.9 carried 
the full recognition sequence, so it would have presumably bound more tightly to SrtA than 
methyl ester 2.35 and as a result the forward reaction would be inhibited. This could explain 
Figure 2.5: Time-course of the SrtA-mediated ligation of peptide 2.5, depsipeptide 2.24 and 
methyl ester 2.35 to peptide 2.8 forming ligated product 2.9. The acyl donor substrates 2.5, 
2.24 and 2.36 (500 M) and acyl acceptor peptide 2.8 (500 M) were mixed in a 1:1 ratio 
and monitored over an 8 period. 
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why Ploegh had to use stoichiometric amounts of SrtA and a large excess of methyl ester to 
achieve complete protein modification.
124
   
The ligation reaction was repeated using amide-terminated depsipeptide 2.25, which was almost 
quantitatively converted to product 2.9 (Figure 2.6). Once again, the reaction could be pushed to 
completion with the addition of 1.5 equivalents of depsipeptide 2.25. Intriguingly, the formation 
of ligated product 2.9 appeared to be more rapid than the ligation with depsipeptide 2.24; ~95% 
yield was achieved in just over 2 hours compared to the 4 hours for depsipeptide 2.24. However, 
once the maximum yield had been obtained the amount of observed product declined to ~90% 
after 8 hours. The reasons for this are unclear, but SrtA mediated hydrolysis of the product is 
one possibility. 
 
2.4 Protein modification using optimised SrtA-mediated 
ligations   
The initial time-course investigations had proved conclusively that depsipeptide substrates can 
be used to transform a model acyl donor peptide into the corresponding ligated product in near 
Figure 2.6: Time-course of the SrtA-mediated ligation of peptide 2.7 (500 M) and 
depsipeptide 2.25 (500 M) to peptide 2.8 (500 M) forming ligated product 2.9. 
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quantitative yields. However, it was less clear how the new system would perform when a 
protein was used as the acyl acceptor rather than a model peptide. This was a more challenging 
task as proteins are larger molecules with less flexible N-termini that may not be freely 
accessible to SrtA. Furthermore, it was unlikely that protein substrates would be available in the 
same quantities as the model peptide substrates, so the transpeptidation reaction would have to 
be performed at much lower concentrations. Therefore, the rate of the reaction may be 
significantly reduced, which could allow the non-enzymatic hydrolysis of the depsipeptide 
substrate to start competing with the ligation step.     
Three proteins bearing an N-terminal glycine residue were identified as potential substrates. A 
construct for a variant of human mannose binding lectin (hMBL) was kindly provided by Prof. 
K. Drickamer (Imperial Collage London). Myoglobin, from equine heart, was purchased from 
Sigma. The puf domain of mouse pumilio-2 was donated by Dr. T.A. Edwards (University of 
Leeds). The pumilio protein had been treated with tobacco etch virus (TEV) protease to remove 
its purification tag and leave an N-terminal glycine residue. 
It is important to note that each of the three proteins selected for the ligation assays contained 
only a single N-terminal glycine residue. This is significant because it has been previously 
demonstrated that the rate of SrtA-mediated ligation is maximised when there are two or more 
glycine residues present.
116,117
 Therefore, the limits of the optimised ligation reaction were 
thoroughly tested with the choice of proteins. 
2.4.1 Human mannose binding lectin 
hMBL plays an important role in the innate immune system defence against bacterial 
pathogens.
134-136
 hMBL is found in blood serum where it binds to complementary glycoproteins 
on the surface of yeast or bacteria inducing an immune response. 
135,136
 The hMBL is a trimeric 
protein that has a triple helical coiled-coil central structure; the N-terminal amino acid residues 
are located at the apex of the coiled-coil (Figure 2.7). The construct provided by Prof. K. 
Drickamer encoded a variant of hMBL, which has an active site mutation that changes the 
binding selectivity of the protein from mannose to galactose. However, the parent structure of 
the protein is essentially the same as native hMBL apart from a short peptide extension, 
GDSSL, at the N-terminus. 
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The hMBL variant was isolated using the overexpression and purification methods described in 
the experimental chapter. The initial protein modification assays were performed using 
fluorescent depsipeptide 2.36, which was synthesised in an 89% yield (Figure 2.8). The C-
terminal glycine depsipeptide 2.24 was chosen as the template for dansyl-depsipeptide 2.36 
because product degradation had not been observed during the HLPC time course experiment 
(Figure 2.4).  
 
 
 
Figure 2.7: Crystal structure of human mannose binding lectin. Red, blue and yellow = 
monomeric protein. Green = N-terminus of protein. Generated from PDB code of atomic 
coordinates: 1HUP (UniProt code: P11226).
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Figure 2.8: Structure of dansyl-depsipeptide 2.36  
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The N-termini of hMBL are located in close proximity to each other (Figure 2.7) and even 
though the variant protein has an N-terminal peptide extension it was not clear if steric effects 
would reduce the efficiency of the SrtA-mediated ligation reaction. In addition, each monomeric 
protein only contained a single N-terminal glycine residue, which, as previously discussed, is 
not ideal for SrtA recognition. Therefore, the initial modification experiments screened hMBL 
at 60 M with increasing concentrations of dansyl-depsipeptide 2.36 to establish an optimum 
depsipeptide ratio for effective protein ligation. The total concentration of substrates used in the 
ligation reaction was significantly lower than that used in the previous model peptide studies 
and as a consequence the rate of the reaction was predicted to be slower. Thus, the concentration 
of SrtA was increased from 2 mol% to 10 mol% to maintain the relative reactivity of the 
transpeptidation reaction. After 4 hours incubation, SDS-PAGE was used to analyse the reaction 
mixtures. When the polyacrylamide gel was irradiated with ultraviolet light, the labelled hMBL 
could be seen as a discrete fluorescent band (Figure 2.9). The depsipeptide 2.36 starting material 
and more surprisingly the thioester-SrtA intermediate were also visible as separate fluorescent 
bands. The modified hMBL could also be seen as a slightly elevated band once the gel had been 
stained with Coomassie blue and the proteins visualised. The preliminary assays had identified 
1.5 equivalents of depsipeptide as the minimal substrate concentration for efficient protein 
ligation. However, the modified and unmodified hMBL bands ran very close to one another on 
the polyacrylamide gel, so it was difficult to determine the level of protein labelling. Therefore, 
the experiments were repeated and mass spectrometry was used to follow the progress of the 
reaction as the analytical technique is highly sensitive. Mass spectrometry identified modified 
protein and could not detect the presence of any unlabelled protein when 1.5, 3 and 5 
equivalents of dansyl-depsipeptide 2.36 were used the ligation reaction (Figure 2.9). These 
results suggest that a high level of protein modification was achieved with only a minimal 
excess of depsipeptide label. However, product hydrolysis was observed when the ligation 
reactions were left overnight. The level of protein hydrolysis was less apparent in the samples 
that had a greater concentration of depsipeptide label as it would have taken longer for SrtA to 
turn over the excess substrate.   
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The previous ligation experiments had used depsipeptide substrates that all contained a common 
YALPETG sequence; however, only the LPETG motif is essential for SrtA activity. Therefore, 
a second fluorescein-depsipeptide 2.37 (Figure 2.10) with a minimal LPETG sequence linked to 
a fluorescein molecule was synthesised; the compound was isolated in a modest 52% yield.  
Figure 2.9: SrtA-mediated ligation of dansyl-depsipeptide 2.36 (90 1.5 equivalents) to 
hMBL (60 M) after 4 hours incubation with SrtA (10 mol %) at 37ºC. a) Polyacrylamide 
gel (15%) of the reaction mixture: Lane 1: SrtA, lane 2: hMBL, lane 3: Reaction mixture, 
lane 4: UV irradiation of reaction mixture. b) Overlaid mass spectra of modified and 
unmodified hMBL. No starting material was detected by mass spectrum analysis after 4 
hours incubation. Calculated mass change after modification, 1036 Da - observed mass 
change, 1035 Da.    
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It had already been demonstrated that hMBL could be labelled in high yields using just 1.5 
equivalents of dansyl-depsipeptide 2.36, so the protein-modification procedure was repeated 
with truncated fluorescein-depsipeptide 2.38. Unfortunately, the same results could not be 
reproduced and only partial labelling of the protein was observed. Mass spectrometry analysis 
showed that fluorescein-depsipeptide 2.37 had hydrolysed to form peptide 2.38 before complete 
protein modification was detected. Although, depsipeptide hydrolysis had been observed in 
previous experiments it had not been this rapid. Consequently, the ligation assay was repeated 
with two equivalents of fluorescein-depsipeptide 2.37 to ensure there was enough available 
substrate to allow the transpeptidation reaction to proceed efficiently. However, after 4 hours 
incubation, fluorescein-depsipeptide 2.37 had hydrolysed again before hMBL had been 
sufficiently labelled, but extensive protein modification was observed when an extra equivalent 
of depsipeptide was added to the ligation mixture and the incubation time was extended by 1.5 
hours (Figure 2.11a). There were still a few small signals in the mass spectrum that 
corresponded to unmodified protein; therefore, SDS-PAGE analysis was performed to elucidate 
the extent of the protein labelling (Figure 2.11b). The modified hMBL could be seen as a 
discrete band that had shifted up the gel from the position of the unlabelled protein. There was 
also a small quantity of unlabelled protein (approx. <10%) in the reaction mixture, but it was 
quite clear that the majority of hMBL had been modified, which is in good agreement with the 
mass spectrometry analysis. 
Figure 2.10: Structure of fluorescein-depsipeptide 2.37 and hydrolysed peptide 2.38 
51 
 
The successful modification of hMBL using fluorophores 2.36 and 2.37 demonstrated the 
versatility of the depsipeptide substrate in SrtA-mediated ligation reaction. However, 
fluorescein-depsipeptide 2.37 appeared to be more susceptible to hydrolysis under the 
conditions of the reaction compared to the previous depsipeptide substrates. The reason for this 
is unclear, but it is unlikely that removal of the tyrosine and alanine residues from the 
depsipeptide structure would cause such a drastic change in stability. The more likely 
explanation is that the fluorescein molecule is catalysing the rate of background hydrolysis by 
some unknown mechanism.  
Figure 2.11: SrtA-mediated ligation of fluorescein-depsipeptide 2.37 (180 3 equivalents) 
to hMBL (60 M) after 5 hours incubation with SrtA (15 mol %) at 37ºC. a) Mass spectrum 
of reaction mixture, b) Polyacrylamide gel (15%) of reaction mixture. Lane 1: reaction 
mixture, lane 2: hMBL, lane 3: SrtA, lane 4: UV irradiation of reaction mixture. Calculated 
mass change after modification, 915 Da - observed mass change, 917 Da.    
52 
2.4.2 Mouse pumilio-2 puf domain  
Pumilio is a class of protein that controls eukaryotic gene expression by regulating mRNA 
transcription.
137
 For example, during the early embryonic development of Drosophila, pumilio 
proteins bind to maternal mRNA sequences, termed hunchback mRNA, and recruit other 
proteins to repress their transcription, which results in anterior/posterior patterning of the 
embryo.
137-140
 The mouse pumilio-2 homologue has not been as extensively studied, but it is 
believed to play a similar role in embryonic development.
137
 However, all pumilio proteins carry 
a conserved RNA-binding domain or puf domain that consists of a series of eight alpha-helical 
repeats. The mouse pumilio-2 puf domain, donated by Thomas Edwards, has an N-terminal 
glycine residue slightly removed from the globular protein (Figure 2.12) 
 
Following the successful labelling of hMBL with just 1.5 equivalents of dansyl-depsipeptide 
2.36 and 10 mol% SrtA, the same protein-modification procedure was repeated with the mouse 
pumilio-2 puf domain at 20 M. SDS-PAGE analysis of the transpeptidation reaction after 4 
hours incubation indicated the protein had been modified (Figure 2.13a); however, mass 
spectrometry only showed partial labelling. The incubation time of the reaction was extended, 
but this did not increase the total ligation yield. It was proposed that the SrtA-mediated 
transpeptidation reaction was proceeding less efficiently with the puf domain when compared to 
hMBL because the protein substrate concentration was too low; i.e., the concentration of hMBL 
(60 µM) was three fold higher than the amount of puf domain (20 µM). Therefore, the rate of 
Figure 2.12: Crystal structure of mouse pumilio-2 puf domain generated from PDB code of 
atomic coordinates: 3GVO (UniProt code: Q80U58).
137
Green = N-terminus of protein in 
crystal structure. The final N-terminal amino acid residues, GT, are not resolved.
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the ligation reaction was sufficiently reduced to allow the non-enzymatic hydrolysis of dansyl-
depsipeptide 2.36 to compete and prevent high levels of protein modification.  
 
The reaction could not be repeated at a higher protein concentration as there was only a finite 
supply of pumilio-2 puf domain. However, effective protein labelling was observed when the 
reaction was repeated using 3 equivalents of dansyl-depsipeptide 2.36 and 36 mol% SrtA; mass 
spectrometry analysis of the reaction mixture showed no unmodified protein after 5 hours 
incubation (Figure 2.13b). It was postulated that the increase in concentration of both SrtA and 
depsipeptide allowed a build up of the enzyme-thioester intermediate. This prevented significant 
loss of the depsipeptide through non-enzymatic hydrolysis and gave enough time for the slower 
protein ligation to take place.    
2.4.3 Myoglobin  
Myoglobin is a cytoplasmic hemoprotein that is found in the cardiac tissue and oxidative muscle 
fibres of vertebrate organisms.
141,142
 The protein transports oxygen from the sarcolemma to the 
mitochondria of muscle cells during periods of increased metabolic activity. In addition, it also 
acts as an oxygen store in muscle tissue to allow aquatic mammals, such as seals, to function 
normally throughout prolonged periods of apnoea. The protein is formed from eight alpha-
helical structures assembled around a central heme subunit. The N-terminal glycine residue is 
Figure 2.13: a) Polyacrylamide gel (12%) of the SrtA-mediated ligation of dansyl-
depsipeptide 2.36 (30 1.5 equivalents) to mouse pumilio-2 puf domain (20 M) after 4 
hours incubation with SrtA (10 mol %) at 37ºC. Lane 1: reaction mixture, lane 2: UV 
irradiation of reaction mixture. b) Mass spectrum of the modified mouse pumilio after 
treatment with 3 equivalents of dansyl-depsipeptide 2.36 and 36 mol% SrtA. Calculated 
mass change after modification, 1036 Da - observed mass change, 1035 Da.    
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one amino acid removed from an alpha-helix that makes up the globular structure of the protein 
(Figure 2.14).   
 
Following the mixed success of the previous protein-labelling experiments, myoglobin was 
incubated with increasing concentrations of dansyl-depsipeptide 2.36 and SrtA. In addition, the 
protein substrate concentration was raised to 119 µM to reduce the possibility that it would limit 
the rate of the transpeptidation reaction. The assays were monitored at 4 hour intervals by mass 
spectrometry, but modified protein was not detected under any of the conditions of the ligation 
reaction. Interestingly, SDS-PAGE analysis did reveal an extremely faint fluorescent band on a 
gel at the position corresponding to myoglobin after a 12 hour incubation with 3 equivalents of 
depsipeptide substrate and 10 mol% SrtA (Figure 2.15). This suggests that the protein was being 
labelled by SrtA, but the level was negligible as the fluorescent band was barely visible and 
mass spectrometry could not detect any modified protein. There is the possibility that the 
modified protein was not ionising as readily as the starting material and as a result was not 
being detected. However, if significant labelling was taking place, a more intense fluorescent 
band would be visible on a gel after SDS-PAGE analysis, but this was not observed. A final 
ligation experiment using 5 equivalents of dansyl-depsipeptide 2.36 failed to improve the 
efficiency of the ligation reaction. Therefore, it likely that myoglobin was simply not a 
favourable substrate for the SrtA-transpeptidation reaction.  
Figure 2.14 Crystal structure of myoglobin from equine heat. Green = N-terminus of 
protein. Generated from PDB code of atomic coordinates: 1DWR (UniProt code: 
P68082).
181 
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2.4.4 Investigation into the inefficient and failed SrtA-mediated 
labelling of protein substrates   
There were two possible explanations as to why SrtA had failed to label myoglobin. One reason 
could be that the N-terminal peptide sequence was not recognised by SrtA, but this seems 
unlikely as there is plenty literature precedent demonstrating the ability of SrtA to accept a wide 
variety of substrates, including non-peptides, as long as there is glycine residue present at the N-
terminus.
111
 The second more plausible explanation could be that the steric bulk of the globular 
protein in the vicinity of the N-terminal glycine residue was preventing SrtA-substrate binding. 
The N-terminal glycine residue of myoglobin is only one residue removed from an alpha helical 
structure. This suggests that there must be a minimal unstructured region at the N-terminus of a 
protein to allow SrtA binding.  In addition to the failed myoglobin labelling, modification of the 
mouse pumilio-2 puf domain had been inefficient. We proposed that the low concentration of 
the protein substrate was reducing the rate of the transpeptidation reaction. However, further 
investigation into the effectiveness of the SrtA-transpeptidation reaction at low concentration 
was required to confirm this hypothesis.  
An HPLC time-course experiment was performed using depsipeptide 2.24 and two short acyl 
acceptor peptides that contained the first four amino residues of myoglobin 2.39 and mouse 
pumilio-2 puf domain 2.40 (Figure 2.16). The peptides also contained a C-terminal tyrosine 
residue to allow detection by HPLC and a glycine residue because they were built on preloaded 
gly-2-chlorotrityl resin. The concentrations used in the time-course experiment were identical to 
the initial mouse pumilio-2 puf labelling experiment; i.e., acyl acceptor 2.39 or 2.40 (20 M), 
depsipeptide 2.24 (30 M, 1.5 equivalents) and SrtA (2M, 10 mol%). This experiment would 
not only help determine if the SrtA reaction was sequence or structure dependent, but it would 
also give an idea of the rate of the reaction when at low concentration of substrate. The results 
Figure 2.15:UV-irradiated  polyacrylamide gel (10%) of the SrtA-mediated ligation of dansyl-
depsipeptide 2.36 (356  3 equivalents) to myoglobin (119 M) after 12 hours incubation 
with SrtA (10 mol %) at 37ºC, 
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were as expected; both acyl acceptor peptides 2.39 and 2.40 were compatible with SrtA and 
shared almost identical initial rates of reactivity. This indicated that the N-terminal amino acid 
sequence of the protein was not inhibiting the reaction. Furthermore, it also showed that the rate 
of the ligation is severally reduced when working at lower concentrations, which is probably 
due to the concentration of the substrate being below its Km. This explains why 36 mol % SrtA 
and 3 equivalents of fluorophore 2.47 was required to drive the mouse pumilio modification to a 
high level of protein labelling. 
 
A second HPLC time-course was performed with the short peptide sequences, but this time the 
concentration of the reactants was increased to match the original depsipeptide 2.24 and 
diglycine peptide 2.8 ligation experiment (Figure 2.17); i.e., acyl acceptor peptides 2.39 or 2.40 
(500 M), depsipeptide 2.34 (500 M, 1 equivalent) and SrtA (11M, 2 mol%) This allowed 
direct comparison of the ligation rates of the diglycine and single glycine substrates. 
Unsurprisingly, the rate of product formation was faster when the diglycine acyl donor 2.8 was 
Figure 2.16: Time-course of the SrtA-mediated ligation of depsipeptide 2.24 (30 M) and 
peptides 2.39 and 2.40 (20 M) 
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used. After 100 minutes, 70% conversion to product was observed compared to the 50% when 
the single N-terminal glycine peptides 2.39 and 2.40 were used (Figure 2.5). This is consistent 
with previously reported observations that the rate of the SrtA ligation is dependent on having 
two or more N-terminal glycine residues.
116,117
 In addition, peptides 2.39 and 2.40 were 
converted to a similar quantity of ligated product; however, total product formation was 5-10% 
lower than what was observed when diglycine peptide 2.8 was the acyl acceptor. This can 
probably be attributed to the difference in the rate of the transpeptidation reaction between the 
single and diglycine peptides. The ligation rates of the single glycine peptides 2.39 and 2.40 
were slower, so more background hydrolysis of the depsipeptide 2.24 could occur before it was 
able to react with SrtA; therefore, the total available depsipeptide 2.24 was reduced limiting the 
amount of product formation.   
 
Figure 2.17: Time-course of the SrtA-mediated ligation of depsipeptide 2.24 (500 M) and 
peptides 2.8, 2.39 and 2.40 (500 M). 
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2.5 Conclusion 
In conclusion, the use of one equivalent of depsipeptide substrate has allowed the near 
quantitative labelling of acyl donor peptides and proteins that carry a single N-terminal glycine. 
This is a huge advancement on current techniques that require a large excess of either the acyl 
donor or acceptor for efficient SrtA-mediated ligation. However, there are two caveats that have 
to be considered for protein labelling to proceed successfully. The concentration of the protein 
has to be >60 M to ensure efficient transpeptidation takes place or the non-enzymatic 
hydrolysis of the depsipeptide substrate will compete to reduce the level of protein labelling. If 
the protein concentration cannot be altered, then efficient modification can be achieved by 
increasing the concentration of both enzyme and depsipeptide. Furthermore, the N-terminal 
glycine residue has to be located in a solvent exposed area of the substrate protein or SrtA will 
not be able to access the intended modification site. However, the space between the globular 
protein mass and the N-terminus does not have to be vast as demonstrated with the successful 
labelling of the pumilio-2 puf domain. SrtA was able to access the N-terminal glycine residue of 
the protein even though there were only three amino acid residues separating it from the 
globular puf domain.  
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Chapter 3: Modified AB5 proteins for cellular 
delivery 
  
60 
3.1 Introduction 
The AB5 proteins, cholera toxin and the heat-labile enterotoxin use a retrograde trafficking 
mechanism to enter mammalian cells and deliver their toxic cargo. Modified analogues of these 
proteins have already been used to transport biological macromolecules and smaller chemical 
probes into cells.
60
 Several strategies have been developed to modify both the AB5 complex and 
the pentameric B-subunit in a site-specific manner (Figure 3.1) - see Chapter 1: Introduction 
for an in-depth discussion of the literature. However, many of the previously reported 
methodologies have limitations. For example, modification to the N-terminus of the pentameric 
B-subunit has often resulted in reduced GM1 binding,
80
 while pentameric instability and 
inhibited AB5 complex formation has been observed with C-terminal modifications.
83
 A more 
robust approach was developed by Ploegh and co-workers.
60
 The authors employed SrtA-
mediated ligation to attach a range of biological probes to the A1-subunit of an AB5 complex 
before delivering them into cells. However, this method utilised a variant of cholera toxin that 
still induced toxicity, so its application as a therapeutic delivery vehicle is limited. Chimeric 
AB5 complexes have also been exploited as delivery vehicles,
64
 but this approach is restricted to 
protein macromolecules. In addition, polylysine-conjugated B-subunits have been used to 
transport DNA into mammalian cells;
66
 however, this method relies on non-specific 
modification.     
 
In this chapter I will outline a simple and robust strategy to chemically-modified AB5 proteins 
that are capable of entering mammalian cell. This was achieved using a combination of chimeric 
AB5 complexes, enzymatic manipulations and SrtA-mediated ligations coupled with 
depsipeptide substrates. 
Figure 3.1: Previously reported bioconjugation strategies used to site-specifically modify 
cholera toxin variants. X = any amino acid R = peptide. 
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3.2 AB5 complex modification strategy  
A chimeric AB5 complex, in which the toxic A1-domain of the A-subunit had been replaced 
with a maltose binding protein domain (MBP), was readily accessible using a technique 
developed by Holmes et al.,
72
 and adapted by James Ross at the University of Leeds (Figure 
3.2).
143
 The MBP-AB5 complex had a Tobacco Etch Virus (TEV) protease-recognition site 
incorporated between the MBP tag and the A2-peptide. Following enzymatic cleavage of MBP, 
the resulting N-terminus of the A2-peptide will display a triglycine sequence that can be 
labelled using SrtA-mediated ligation. This approach could potentially allow quick access to a 
huge variety of modified AB5 proteins by simply varying the depsipeptide substrate for SrtA. 
Furthermore, it was postulated that any modification to the A2-peptide would not interfere with 
the ability of the protein to transfect mammalian cells as it is distal to the binding sites of the B-
subunits.  
 
3.2.1 MBP-AB5 expression and isolation  
The MBP-CTA2 fusion protein was co-expressed with CTB in E. coli C41 cells harbouring the 
pSAB 2.1 plasmid (Appendix). Co-expressing the proteins triggered self-assembly of an MBP-
CTA2/B5 (MBP-AB5) complex in the periplasm of the cells. A combination of amylose and 
nickel affinity chromatography was used to isolate the MBP-AB5 protein complex. Initially, 
amylose affinity chromatography captured any species containing MBP, including the MBP-
AB5 and uncomplexed MBP-CTA2 proteins. A nickel affinity column was used to separate out 
the resulting mixture of proteins; the pentameric B-subunit of the MBP-AB5 complex bound to 
the nickel resin while the remaining MBP-CTA2 protein passed through the column. After 
purification the protein can be seen as a discrete band on an SDS-PAGE gel (Figure 3.3, Lane 
Figure 3.2: AB5 modification strategy of an MBP-CTA2 fusion complexed with pentameric 
CTB. Step 1: Cleavage of MBP tag using TEV protease. Step 2: SrtA-modification of the 
A2-peptide  
62 
2). However, the hexamer appears to be unstable under the detergent conditions of SDS-PAGE 
analysis and it can be seen to partially dissociate on the gel into pentameric CTB and MBP-
CTA2 proteins. If the MBP-AB5 protein is completely denatured by heating before applying to 
the gels, it falls apart into its constituent CTB monomer and MBP-CTA2 proteins (Figure 3.3, 
Lane 1).  
 
3.2.2 Preparation of the AB5 complex for SrtA-mediated ligation  
The MBP-purification tag had to be removed from the AB5 complex in preparation for SrtA-
mediated modification. The MBP-CTA2 construct had been designed to include an optimum 
TEV protease recognition sequence (ENLYFQG) to allow enzymatic cleavage and separation of 
the two proteins. TEV protease will specifically hydrolyse the amide bond between the QG 
amino acid residues to expose a triglycine sequence at the N-terminus of the CTA2-peptide.  
TEV protease expression and purification  
E. coli BL21-Gold (DE3) cells containing a pMAL-C2 expression vector for TEV protease was 
obtained from Dr. T. Edwards at the University of Leeds. The enzyme construct is designed to 
include a His-tag at the N-terminus of the protein followed by a TEV protease recognition 
sequence and MBP (Figure 3.4). Therefore, TEV protease is initially expressed as a fusion 
protein, but the MBP is cleaved in vivo. The protein was overexpressed following induction 
with IPTG and purification was attempted using nickel affinity and size exclusion 
Figure 3.3: Polyacrylamide gel (12%) showing isolated MBP-AB5 protein. Lane 1: Boiled; 
Lane 2: Not boiled 
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chromatographies. However, concentration of the protein prior to size exclusion 
chromatography triggered precipitation and complete loss of the sample. The use of the partially 
purified enzyme after the initial nickel affinity column also proved problematic. The protein 
precipitated during dialysis at 4 °C and it was difficult to determine if any remained in solution. 
After several failed attempts to increase the stability of the protein, the strategy was abandoned.  
 
MBP-TEV chimera expression and purification 
The poor solubility of TEV protease made it extremely difficult to handle. It was postulated that 
the stability of the protein could be increased by permanently fusing it to MBP. Site-directed 
mutagenesis could have been used to mutate the TEV protease recognition sequence in the 
protein construct to inhibit MBP cleavage during expression. However, this would have 
required two or more rounds of mutagenesis. It was, therefore, simpler to introduce the TEV 
protease gene into a different plasmid to form a new MBP protein fusion. This was 
accomplished by subcloning the gene into a pMAL-c5x plasmid as follows (Figure 3.5.): A 
polymerase chain reaction (PCR) was used to copy and amplify the gene from the original 
pMAL-C2 plasmid. In addition, the primers used in the PCR were designed to introduce Bam-
HI and PST restriction sites at the termini of the amplified gene sequence to allow DNA 
ligation. Following digestion of the pMAL-c5x plasmid/genomic DNA with Bam-HI and PST 
restriction enzymes, the DNA parts were stitched together to generate the hybrid pMAL-c5x I 
expression vector (the aforementioned molecular biology required to create the protein fusion 
was conducted by Dr James Ross at the University of Leeds). 
Figure 3.4: Construct of the TEV protease expressed from pMAL-c2
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The pMAL-c5x I expression vector was transformed into E. coli BL21-Gold (DE3) cells and the 
MBP-TEV fusion was overexpressed using IPTG induction. The protein chimera was purified 
using a combination of amylose affinity and size exclusion chromatographies (Figure 3.6). SDS-
PAGE analysis identified an overexpressed protein at ~70 kDa on the gel (Figure 3.6, Lane A). 
Further analysis by ESMS confirmed the mass of the protein to be 71665 Da, which is in good 
agreement with the calculated molecular weight for the MBP-TEV chimera (71633 Da). A 
second overexpressed protein that ran at ~40 kDa on the gel (Figure 3.6, Lane B) was also 
isolated; this was probably native MBP that had been expressed naturally by the E. coli cells.  
Figure 3.5: Formation of the pMAL-c5x I plasmid for MBP-TEV chimeric protein 
expression. Step 1: PCR amplification of the TEV gene. Step 2: Digestion of pMAL-c5x 
vector and gene insert using restriction enzymes BamHI and PST. Step 3: DNA ligation of 
digested DNA to form the pMAL-c5x I expression vector.  
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TEV protease-mediated MBP cleavage  
Treating the MBP-AB5 complex (45 M) with 10 mol% MBP-TEV (4.5 µM) for 1 hour at room 
temperature successfully generated a truncated CTA2-AB5 complex. The reaction was 
monitored by ESMS and the molecular weight of the MBP-CTA2 protein decreased by the mass 
of the CTA2-peptide, 5055 Da. However, at higher MBP-TEV concentrations or longer 
incubation periods, indiscriminate proteolysis of the protein was observed. The truncated AB5 
complex was isolated from the cleavage mixture using nickel affinity chromatography, and two 
sets of signals corresponding to the CTA2 and CTB chains were identified by ESMS (Figure 
3.7). 
 
Figure 3.6: Size exclusion chromatogram and polyacrylamide gel (12%) gel of MBP-TEV 
purification.  
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3.3 Sortase-mediated modification of the AB5 protein  
The CTA2-AB5 complex was now primed for use with SrtA-mediated modification. To 
compare the efficiency of the ligation reaction to previous protein substrates for SrA, 
fluorescent-depsipeptides 2.36 and 2.37 were used to label the complex (Figure 3.8).  
 
3.3.1 Dansyl-depsipeptide ligation     
The CTA2-AB5 complex (44 M) was modified with 1.5 equivalents of dansyl-depsipeptide 
2.36 (71 µM) and 10 mol% SrtA (4.4 M) at 37 °C in just 3 hours (Figure 3.9). The ligation 
reaction was faster than the previous protein-labelling experiments reported in Chapter 2. It was 
postulated that the triglycine sequence at the N-terminus of the A2-peptide was a more 
favourable substrate for SrtA than the single glycine residues displayed by the earlier protein 
Figure 3.7: Mass spectrum of the truncated CTA2-AB5 complex. Green: CTA2 peptide 
(5055 Da); Red: CTB monomer (11611 Da). 
Figure 3.8: Structures of dansyl-depsipeptide 2.36 and fluorescein-depsipeptide 2.37  
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substrates. This observation was in good agreement with the suggestion that SrtA has a 
diglycine binding site.
116
 
 
The A2-domain of the AB5 complex was the only protein species labelled by SrtA, which 
demonstrated the high selectivity of the SrtA-mediated ligation reaction. However, the 
pentameric B-subunit is a very stable and compact protein, so it may be more resistant to non-
specific labelling compared to more flexible proteins.  
3.3.2 Fluorescein-depsipeptide ligation  
The CTA2-AB5 complex (43) was also labelled in 3 hours with 2 equivalents of 
fluorescein-depsipeptide 2.37 (90 ) and 12 mol% SrtA (Figure 3.10). However, the 
efficiency of the SrtA-mediated ligation has been inconsistent; in some instances, it has taken 
between 2-5 equivalents of depsipeptide, 10-20 mol% SrtA and 3-6 hours to achieve complete 
protein modification. There are several factors that could have contributed to the variation in the 
results. These include the hydrolytic stability of the depsipeptide, enzyme activity and protein 
substrate concentration. Rapid hydrolysis of the fluorescein-depsipeptide 2.37 has been 
Figure 3.9 Mass spectra of the dansyl-modified-AB5 complex overlaid on top of the 
unmodified starting material. Blue: CTA2 labelled with dansyl-depsipeptide 2.36 (6091 
Da); opaque green: CTA2 (5055 Da) and red/opaque red: CTB monomer (11611 Da). 
Modification was achieved using 10 mol% SrtA and 1.5 equivalents of depsipeptide 2.36. 
Calculated mass change after SrtA-mediated modification, 1036 Da - observed mass 
change, 1036 Da.    
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observed in previous protein labelling experiments with MBP (Chapter 2). The rate of 
hydrolysis may be sensitive to fluctuations in the pH of the buffer and as a result the amount of 
available substrate may vary in different experiments. It is more likely, however, that the protein 
substrate concentration in each assay was the main contributing factor to the difference in the 
SrtA-mediated transpeptidation reactions. It has been demonstrated that the rate of the ligation is 
slower at lower concentrations (Chapter 2). Therefore, non-enzymatic hydrolysis of the 
depsipeptide substrate will be more significant preventing efficient modification of the protein.  
 
3.3.2.1 Isolation and analysis of fluorescein-AB5 complex  
Nickel affinity chromatography was used to isolate the fluorescein-AB5 complex from the SrtA-
ligation mixture. Although both proteins are able to bind the nickel resin, SrtA binds with much 
higher affinity because it carries an N-terminal His-tag. Conversely, the AB5 complex binds 
through a series of surface exposed histidine residues on the B-pentamer. Therefore, only a 50 
Figure 3.10 Mass spectra of the fluorescein -modified-AB5 complex overlaid on top of the 
unmodified starting material. Blue: CTA2 labelled with fluorescein-depsipeptide 2.37 (5970 
Da); opaque green: CTA2 (5055 Da) and red/opaque red: CTB monomer (11611 Da). 
Modification was achieved using 10 mol% SrtA and 2 equivalents of depsipeptide 2.37. 
Calculated mass change after SrtA-mediated modification, 915 Da - observed mass change, 
915 Da.    
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mM imidazole wash was required to elute the modified AB5 protein and thus separate it from 
the majority of SrtA. A combination of SDS-PAGE analysis and UV irradiation indentified the 
fluorescein-AB5 complex as a fluorescent protein band on the gel (Figure 3.11). In addition, the 
pentameric B-subunit and fluorescein labelled CTA2-peptide were also observed due to partial 
dissociation of the AB5 complex. Two extremely faint fluorescent protein bands were also 
detected; the highest weight band could belong to a multimeric AB5 species because it 
disappears once the sample had been boiled, which suggests it existed as a non-covalently 
linked complex. The other fluorescent band is probably a small amount of the SrtA-acyl 
intermediate that was not removed by nickel affinity purification.   
 
  
Figure 3.11: Polyacrylamide gel (12%) showing isolated fluorescein-AB5 complex. Lane 1: 
Not boiled; lane 2: boiled; lane 3: UV irradiation of lane 1; lane 4: UV irradiation of lane 2.  
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3.4 Transportation of AB5 complex into mammalian cells  
AB5 complexes had been successfully labelled using SrtA-mediated ligations, but their ability to 
enter mammalian cells had yet to be determined. A selection of mammalian cells were treated 
with the fluorescein-AB5 complex and fluorescence microscopy was used to determine protein 
translocation. 
3.4.1 Studies with various mammalian cell lines 
The fluorescein-AB5 complex was initially screened against HeLa cells, which are derived from 
human cervical cancer tissue.
144
 Unfortunately, no fluorescence was detected around or inside 
the cells after several experiments. This was surprising as the ability of cholera toxin to enter 
HeLa cells has been documented.
145
 However, a recent study by Fujitani et al. into the glycome 
of common human cell lines could explain why no protein internalisation was observed.
146
 The 
authors discovered that glycolipids, including the GM1 receptor required for cholera toxin 
binding, were only present in tiny quantities in HeLa cells (Figure 3.12). Therefore, it is likely 
that the AB5 complex was binding to the cells in such small quantities that the fluorescence was 
not detected.   
 
In the same study by Fujitani et al., the GM1 receptor was found to be present in much higher 
concentrations in human embryonic kidney 293 (Hek-293) cells than HeLa cells. Therefore, it 
Figure 3.12: Glycome profile of HEK293 and HeLa cells. The size of each circle and 
constituent fraction represents the absolute quantity of the different classes of glycan (pmol/ 
g protein). The size of the free oligosaccharide circle is increased by 40-fold.146   
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was decided to repeat the protein transportation experiments with Hek-293 cells. Human 
embryonic kidney 293 (Hek-293) cells were treated with the AB5 complex for a one hour 
incubation period before being imaged with a fluorescent microscope (Figure 3.13). 
Translocation of the Hek-293 cells was a success and a large amount of fluorescence was 
detected. Interestingly, there appeared to be small punctate structures in some of the cells, which 
suggests the protein had been internalised and sequestered inside an intracellular compartment. 
However, a large proportion of the fluorescence was localised at the membrane of the cell, so 
translocation was either slow or the cell was being flooded with a large excess of protein. 
Further investigation was required to establish the intracellular fate of the AB5 complex.  
 
Immunostaining coupled with fluorescence microscopy allows the detection of specific 
organelles within a cell. Differentiation of intracellular targets can be difficult in Hek-293 cells, 
so it was decided to switch cell lines. Vero cells, derived from the epithelial cells of African 
green monkeys, were selected as an alternative because they typically give clear 
immunostaining images. Although the absolute quantity of GM1 in Vero cells was not known, 
several studies have successfully used these cells to study cholera toxin translocation.
64,147
 After 
incubation with the fluorescein-AB5 complex, translocation was successfully detected in a 
number of Vero cells, but it appeared to be less homogenous than for the Hek-293 cells. Majoul 
et al. discovered that the life-cycle of Vero cells governs the biosynthesis of surface exposed 
GM1 gangliosides and as a result directly affects the ability of cholera toxin to bind to the 
cells.
147
 Therefore, it is likely that fluorescein-AB5 complex internalisation was only observed in 
Figure 3.13:  Hek-293 cells transfected incubated fluorescence-AB5 protein (~40 g / mL) in 
PBS for 1 hour at 37 °C. Fluorescein-AB5 (green) 
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Vero cells that were at the correct life-cycle stage to display an abundance of GM1 gangliosides 
at their surface.  
 
3.4.2 Organelle-specific immunostaining 
Native cholera toxin is thought to be transported in an endosomal vesicle to the endoplasmic 
reticulum (ER) via the trans-Golgi network. Therefore, it was important to identify all of the 
organelles involved in the trafficking mechanism as it was likely that the modified AB5 complex 
would follow the same intracellular pathway. Furthermore, the majority of unwanted proteins 
are trafficked to lysosomes for degradation, so it was prudent to tag this compartment too. To 
track the intracellular progress of the protein at different time points, Vero cells were incubated 
with the AB5 complex at 37 °C for 15, 30 and 60 minutes before being chemically fixed. 
Additionally, the cells were incubated at 4°C for 15 minutes in an effort to inhibit internalisation 
and observe the protein binding to the cell surface.  
A series of control experiments was conducted to try to avoid the number of false positive 
results. Vero cells that had not been immunostained or treated with fluorescein-AB5 were 
exposed to the blue (408 nm), green (488 nm) and red (555 nm) lasers to establish the level of 
background fluorescence (Figure 3.15). Excitation with the blue laser identified the DAPI 
fluorophore, which is present in the cell mounting agent, but no fluorescence was detected after 
exposure with the green and red laser. Therefore, any fluorescence detected at these 
wavelengths after incubation with the protein could not be attributed to the cell.  
Figure 3.14: Vero cells transfected incubated fluorescence-AB5 protein (~40 g / mL) in PBS 
for 1 hour at 37 °C. Merged image: nuclear stain (blue, DAPI), AB5-fluorescein (green) 
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A secondary antibody, derived from either goat or hamster, linked to the same AlexaFluor® 555 
dye was used in every immunostain experiment. It was important to establish if there was any 
significant emission from the dye after excitation with the green laser, as the fluorescein 
molecule linked to the AB5 protein absorbs in this region (Figure 3.16). Only residual 
fluorescence was detected even when the green laser was set to maximum gain (Figure 3.16 B). 
Therefore, any fluorescence detected after excitation with the green laser can be attributed to the 
presence of the protein and not the AlexaFluor® 555 dye. 
 
Figure 3.15: Vero cells. A) Blue image, nuclear stain (DAPI). B) Green image. C) Red image. 
There is no signal in B and C; therefore, there is no autofluorscence from the Vero cells in the 
green and red channels.  
Figure 3.16 Immunostained Vero cells treated with AlexaFluor® 555 dye linked secondary 
antibody. A) Merged image: nuclear stain (blue, DAPI), Golgi stain (red, AlexaFluor® 555 
dye). B) Green image: Maximum gain  C) Red Image. D) Blue image  
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The immunostaining was successful for the late endosome and Golgi organelles, but only non-
specific staining was observed when the ER, lysosome and early endosome antibodies were 
used. It was postulated that the fixation process might be disrupting antibody recognition by 
altering the structure of the target antigen on the organelles. In an effort to limit antigen 
denaturing, the Vero cells were fixed under different conditions: methanol, 4% para- 
formaldehyde in PBS or 4% formaldehyde in PBS. However, this did not improve the 
specificity of the immunostaining, so further optimisation is required to visualise the remaining 
organelles. 
The surface of the Vero cells was surrounded by the fluorescein-AB5 complex and little, or no, 
internalisation was detected when the cells were incubated at 4 ˚C for 15 minutes (Figure 3.17). 
This suggests the protein was binding to the GM1 receptors on the cell surface, but endocytosis 
was extremely slow or simply inactive; these observations are consistent with findings 
previously reported in the literature.
64
  
 
 
Internalisation of the AB5 complex was observed after 15 minutes incubation at 37 ˚C, but there 
was still a significant amount of protein on the surface of the cell (Figure 3.18). A small amount 
of yellow florescence was detected at the Golgi suggesting some of the protein was starting to 
localise within the organelle. However, most of the flurescein-AB5 complex was spread out 
within the cell in other punctate structures, probably early endosomal vesicles, but it is difficult 
to determine the exact locations without the other immunostaining markers. 
Figure 3.17 Immunostained Vero cells incubated with fluorescence-AB5 protein (~40 g / mL) 
in PBS for 15 minutes at 4 °C. A) Merged image: nuclear stain (blue, DAPI), AB5-fluorescein 
(Green) and Golgi stain (red, AlexaFluor® 555 dye). B) Green image C) Red Image  
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After 30 minutes incubation at 37 ˚C, most of the protein was completely internalised and a 
small proportion appeared to be localised within the late endosome (Figure 3.19). However, 
once again most of the protein florescence did not appear to be concentrated at any specific 
location, but simply extended throughout the cell. In a study by Tinker et al.,
64
 a GFP-AB5 
protein was transported to the Golgi after 30 minutes incubation at 37 °C, but unfortunately 
immunostaining of the Golgi failed at this time point making a direct comparison impossible.   
 
Figure 3.18 Immunostained Vero cells incubated with fluorescence-AB5 protein (~40 g / mL) in 
PBS for 15 minutes at 37 °C. A) Merged image: nuclear stain (blue, DAPI), AB5-fluorescein 
(Green), Golgi stain (red, AlexaFluor® 555 dye) and co-localisation (yellow). B) Green image C) 
Red Image 
Figure 3.19:Immunostained Vero cells incubated with fluorescence-AB5 protein (~40 g / 
mL) in PBS for 30 minutes at 37 °C. A) Merged image: nuclear stain (blue, DAPI), AB5-
fluorescein (Green), late endosome stain (red, AlexaFluor® 555 dye) and co-localisation 
(yellow). B) Green image C) Red Image 
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The fluorescein-AB5 complex appeared to be sequestered in larger punctate structures within the 
cell after 60 minutes incubation at 37 °C (Figure 3.20). There was still a small amount of co-
localisation with the late endosomal markers, but the majority of the fluorescence was situated 
in a compartment directly next to the nucleus; this is most clearly seen when the green 
florescence image is viewed on its own (Figure 3.20 B and E). The punctate structure resembled 
the size and shape of the Golgi, but direct comparison to the immunostained Golgi was not 
conclusive as protein translocation appeared less prevalent in the cells (Figure 3.20). However, 
there was a small quantity of yellow fluorescence, which indicates at least some localisation in 
that compartment. 
 
Figure 3.20: Immunostained Vero cells incubated with fluorescence-AB5 protein (~40 g / 
mL) in PBS for 60 minutes at 37 °C. A) Merged image of B and C: nuclear stain (blue, 
DAPI), AB5-fluorescein (Green), late endosome stain (red, AlexaFluor® 555 dye) and co-
localisation (yellow). B) Green image of late endosome immunostain. C) Red image of late 
endosome immunostain.. C) Merged image of E and F: nuclear stain (blue, DAPI), AB5-
fluorescein (Green), Golgi stain (red, AlexaFluor® 555) and co-localisation (yellow). E) 
Green image of Golgi immunostain. F) Red image of Golgi immunostain. 
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It is quite clear from the preliminary protein translocation assays that the fluorescein labelled 
AB5 complex is easily internalised by different classes of mammalian cells. However, further 
investigation is required to establish the exact intracellular pathway of the modified protein; this 
information will be vital in deciding how best to utilise AB5 delivery vehicles.     
3.5 Conclusion  
Using a series of enzymatic reactions, it has been possible to create a chemically modified AB5 
complex that is capable of transfecting mammalian cells. In theory, this strategy could be used 
to easily create a wide range of modified AB5 proteins that could deliver a variety of different 
therapeutic cargo inside cells. However, more work needs to be done to determine the 
intracellular fate of the modified proteins.   
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Chapter 4: Bioorthogonal depsipeptide substrates 
for Sortase 
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4.1 Introduction 
SrtA-mediated ligations allow the efficient labelling of proteins with a range of different peptide 
substrates. In general, most substrates are synthesised using SPPS; therefore, nucleic acids and 
other non-amino acid-based molecules that are not compatible with this process cannot be 
attached to proteins using SrtA. Alternative bioorthogonal chemistry such as 1,3-dipolar 
cycloadditions and Diels Alder reactions ligations can be used to attach non-peptidic molecules 
onto proteins.
148
 However, these methods often require non-natural amino acids to be introduced 
into the protein of interest before conjugation can take place. In contrast, only a simple N-
terminal oligoglycine sequence or a C-terminal LPXTG recognition motif needs to be present in 
a protein for SrtA-mediated ligations to proceed. Therefore, introducing a bioorthogonal handle 
into a depsipeptide substrate for SrtA would allow efficient site-specific labelling of proteins 
with the prospect of further modifications with non-peptidic molecules.  
Building on our previous work into the SrtA-mediated modification and transportation of AB5 
complexes into mammalian cells, it was postulated that the proteins could be used as 
oligonucleotide delivery vehicles. This chapter describes the development of a method that uses 
a combination of depsipeptide substrates for SrtA and bioorthogonal linkers to attach 
oligonucleotide macromolecules onto an AB5 protein.  
4.2 Bioorthogonal linker selection  
The ultimate aim was to conjugate oligonucleotides onto the AB5 complex; therefore, the 
bioorthogonal linker had to be complementary to the commercially available linkers that are 
routinely attached to oligonucleotides. In addition, it had to be easily incorporated into 
depsipeptide substrates for SrtA and stable throughout the initial protein ligation step. An 
investigation to find a suitable bioorthogonal linker that satisfied the above criteria was 
launched.    
4.2.1 Hydrazone linker    
Hydrazine 4.1 and aldehyde-linked molecules 4.2 can condense under mild aqueous conditions 
to form hydrazones 4.3 (Scheme 4.1)
149-152
 This approach has been used extensively to attach 
both chemical and biological probes to biological macromolecules.
151,153,154
 The structure of the 
hydrazone can directly affect its hydrolytic stability. For example, acyl hydrazones are 
susceptible to hydrolysis under physiological conditions and rapidly hydrolyse below pH 
6.
149,155
 In contrast, bis-aryl hydrazones are stable to hydrolysis at neutral pH and have been 
widely used in the formation of biological conjugates.
149,151,153,154
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Solulink manufacture a protein cross-linking kit that is commonly used to conjugate antibodies 
to oligonucleotides/other proteins (Scheme 4.2). Conjugation is achieved by using a trans-
hydrazonation reaction to form a bis-aryl hydrazone bond between biological macromolecules 
that have been pre-functionalised with either an aryl aldehyde 4.7 or an aryl hydrazone 4.5. The 
aryl aldehyde 4.4 and aryl hydrazone cross-linkers 4.6 are introduced into the biomolecules of 
interest non-specifically. Therefore, the number of cross-linkers per biomolecule is not 
homogenous, which in turn produces a heterogeneous mix of protein-conjugates during the 
trans-hydrazonation reaction. Taking inspiration from this approach, a strategy was developed 
to attach the aryl hydrazone 4.4 onto a depsipeptide substrate for SrtA to allow the site-specific 
incorporation of the linker onto the AB5 complex. This will allow oligonucleotides 
functionalised with aryl aldehyde to be conjugated homogeneously onto the protein. 
Aryl hydrazone 4.4 was synthesised using a slightly modified strategy developed by Grotzky et. 
al.
156
 Initially, chloropyridine 4.9 was treated with hydrazine monohydrate to give hydrazinium 
salt 4.10 in 52% yield (Scheme 4.3). Without further purification, the hydrazinium salt 4.10 was 
exposed to acetone under basic conditions before the addition of N-hydroxysuccinimide formed 
aryl hydrazone 4.4 in a modest 46 % yield. 
Scheme 4.1: Hydrazonation reaction between hydrazine 4.1 and aldehyde 4.2 to form 
hydrazone 4.3. R1 = acyl or aryl group. R2 = aryl, alkyl or hydrogen.  
Scheme 4.2:  General protein labelling and conjugation procedure using cross-linkers 4.4 and 
4.6 produced by Solulink. A and B = biological macromolecules.  
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The aryl hydrazone 4.4 could have been coupled onto a depsipeptide substrate during SPPS; 
however, it was predicted that the aryl hydrazone would hydrolyse under the strong acidic 
conditions used in the peptide cleavage step to form an aryl hydrazine 4.11 (Figure 4.1). In 
principle, the aryl hydrazine 4.11 could attack the ester linkage in the depsipeptide to form 
polymerised byproducts 4.12. Therefore, it was decided to couple the aryl hydrazone 4.4 to a 
depsipeptide in solution after SPPS.  
 
Depsipeptide 4.13 carrying the minimal SrtA recognition sequence was conjugated to aryl 
hydrazone 4.4 in DMF under basic conditions (Scheme 4.4). The reaction was monitored by 
LCMS and was typically complete within 2-4 hours. Hydrazone depsipeptide 4.14 was 
successfully isolated using mass-directed HPLC, but after the fractions were combined and 
lyophilised, the product had hydrolysed to form hydrazine depsipeptide 4.15. The ester linkage 
in the depsipeptide appeared to be stable to the aryl hydrazine functionality and it was predicted 
to be more reactive to aldehyde compounds than the original hydrazone depsipeptide 4.1. 
Therefore, it was used in subsequent experiments.  
Scheme 4.3: Synthesis of hydrazone cross-linker 5.4. 
Figure 4.1: Structure of aryl hydrazine 4.11 and polymerised byproducts 4.12 that could form 
during the SPPS of depsipeptides containing aryl hydrazone 4.4. 
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4.2.1.1 Conjugation of hydrazine onto the protein  
The CTA2-AB5 protein was treated with hydrazine depsipeptide 4.15 and SrtA in a similar 
manner to previous transpeptidation experiments. The ligation was monitored by ESMS and 
modification of the protein was observed (Figure 4.2). However, after a prolonged incubation 
time, the signal of the ligated product decreased by approximately 14 Da. It was postulated that 
the hydrazine functionality on the pyridine ring was being hydrolysed to generate a 2-
hydroxypyridine as this agreed with the change in mass. To further investigate the stability of 
the hydrazine functionality, the hydrazine depsipeptide 4.15 was incubated in HEPES buffer at 
37 °C and LCMS was used at intermittent intervals to monitor any change in its structure. The 
hydrazine functionality appeared to be stable over a 4 hour period, but after an overnight 
incubation a small UV absorbance signal corresponding to the 2-hydroxypyridine hydrolysed-
depsipeptide was observed. In conclusion, the hydrazine functionality would be sufficiently 
stable during the time period required for an average SrtA-ligation reaction to reach completion, 
but it is also likely that the hydrazine linkage would hydrolyse during the subsequent protein 
Scheme 4.4: Synthesis of hydrazine depsipeptide 4.15. 
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purification steps. Therefore, this class of linkage was deemed unsuitable for further use and an 
alternative was found.  
 
4.2.2 Strained cyclooctyne linker  
One of the most important bioorthogonal reactions is the 1,3-dipolar cycloaddition of an azide 
and alkyne to from a triazole (Scheme 4.5).
157,158
 Sharpless and co-workers coined the term 
“click chemistry” to describe this type of cycloaddition and pioneered the use of the reaction as 
an effective method to combine a variety of different molecules under relatively mild 
conditions.
159
 However, a toxic Cu(I) catalyst is required in the reaction, which limits its 
application in many biological systems. An alternative strategy was devised by Bertozzi and co-
workers.
160
 The authors’ approach utilised the properties of a strained cyclooctyne to promote 
the cycloaddition of an azide without the use of a Cu(I) catalyst; this 1,3-dipolar cycloaddition is 
commonly referred to as a strained-promoted alkyne-azide cycloaddition (SPAAC) (Scheme 
4.5). 
 
Figure 4.2: Mass spectrum of the hydrazine-linked AB5 complex. Red: CTB (11611 Da) 
Blue: CTA2 modified with hydrazine depsipeptide 4.15 (5717 Da). Calculated mass change 
after SrtA-mediated modification, 661 Da - observed mass change, 662 Da.    
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The Cu-promoted azide-alkyne cycloaddition (CuAAC) and SPAAC could both have been used 
to link oligonucleotides onto the AB5 protein. However, the CuAAC was avoided as the toxic 
catalyst might have caused complications in vivo if it was not completely removed. Therefore, it 
was decided to attach a strained cyclooctyne onto the AB5 protein via a SrtA-mediated ligation. 
This strategy could have been reversed by incorporating the azide into a depsipeptide substrate, 
but oligonucleotides functionalized with azides are more common. While these studies were in 
progress Ploegh and co-workers reported a similar strategy to introduce a strained cyclooctyne 
into a protein using SrtA-mediated ligations.
161
 The authors used SPAACs to create unnatural 
chimeric proteins linked through their N-termini. Several synthetic strategies have now been 
reported to a range of different strained cyclooctynes;
162
 however, these procedures can be non-
trivial and often convoluted. For example, the aza-dibenzocyclooctyne used by Ploegh and co-
workers is reported to take seven steps to synthesise.
161,163
 In contrast, a relatively simple 
synthetic route to activated cyclooctyne 4.26 (Scheme 4.6) has been developed by Dommerholt 
et al.
164
 It was postulated that the activated cyclooctyne 4.26 could be coupled through its 
carbonate linkage onto a growing depsipeptide during SPPS.  
 
Cyclooctadiene 4.21 was treated with ethyl diazoacetate 4.22 in the presence of a Rhodium(II) 
catalyst to form bicyclic alkene 4.23 in an 80% yield and a 1:2 endo:exo diastereomeric ratio. 
Although it was possible to separate the two diastereoisomers, it was more convenient to carry 
Scheme 4.5: Cu-promoted azide-alkyne cycloaddition (CuAAC) between terminal alkyne 
4.16 and azide 4.17 forming triazole 4.18. Strained-promoted alkyne-azide cycloaddition 
(SPAAC) between strained cyclooctyne 4.19 and azide 4.17 forming triazole 4.20 
Scheme 4.6: Synthetic route to cyclooctyne 4.26.  
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the mixture through to the next step. The bicyclic alkene 4.23 was reduced, dibrominated and 
exposed to strong basic conditions to form cyclooctyne alcohol 4.24 in 40% yield across the 
three steps. The first two steps were practically quantitative, but the yield of the final double 
elimination reaction varied quite dramatically. Interestingly, decreasing the concentration of the 
reactants seemed to increase the yield. This suggests that the side reactions taking place were 
concentration dependent. The hydroxyl group on cyclooctane dibromide 4.27 would be 
deprotonated under the basic conditions of the reaction, so the corresponding nucleophilic 
alkoxide could have displaced a bromine atom on another molecule of cyclooctane dibromine 
4.27 to form a dimeric species 4.28 (Scheme 4.7). Additionally, elimination could have occurred 
at a different location on the cyclooctane ring forming an allyl bromine species 4.29, which is 
primed to undergo further elimination or nucleophilic substitution. Therefore, lowering the 
concentration of the reaction reduced the chance of unwanted nucleophilic substitutions, thus 
increasing the yield. Finally, activated cyclooctyne 4.26 was synthesised in 76% yield by 
conjugating chloroformate 4.25 onto cyclooctyne alcohol 4.24.  
 
Activated cyclooctyne 4.26 was used as building block in the SPPS of alkyne depsipeptide 4.31 
(Scheme 4.8). However, unconjugated depsipeptide 4.32 was the only product isolated after 
peptide cleavage, which suggests the activated cyclooctyne 4.26 did not couple onto the 
growing peptide chain correctly or the carbonate linkage did not survive the cleavage 
conditions. Therefore, it was decided to change strategy and couple the activated cyclooctyne 
4.26 to depsipeptide 4.32 in solution. This approach led to the formation of alkyne depsipeptide 
4.31 in a modest 26% yield.  
 
Scheme 4.7: Theoretical byproducts formed during the synthesis of cyclooctyne alcohol 4.24 
from cyclooctane dibromine 4.27   
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4.2.2.1 Conjugation of a cyclooctyne onto the AB5 protein. 
The CTA2-AB5 complex (56 M) was incubated with alkyne depsipeptide 4.31 (140 M, 2.5 
equivalents) in the presence of SrtA (11 M, 20 mol%) at 37 °C. After 3 hours, ESMS 
identified the presence of a significant amount of ligated product and a small signal for the +6 
charged state of the unmodified protein (Figure 4.3). In addition, the ESMS also detected the 
presence of alkyne depsipeptide 4.31 and hydrolysed depsipeptide 4.33. An additional 
equivalent of alkyne depsipeptide 4.31 was added to the ligation mixture and incubation was 
continued for another hour before the protein was purified using Ni-affinity chromatography. 
SDS-PAGE analysis identified the protein as a band at ~58 kDa on a gel that dissociated upon 
boiling (Figure 4.4, lanes 4 and 5). This suggests the protein was still stable as an AB5 complex 
after the strained cyclooctyne had been attached. Further analysis by ESMS detected a small 
signal corresponding to unlabelled starting material, but quantifying this by SDS-PAGE was 
difficult. The AB5 complex was poorly defined on a gel as a result of it partially dissociating 
into the pentameric B-subunit and A2-peptide. Therefore, it is not possible to state with 
complete certainty if it was a single band that belonged to the modified AB5 complex or two 
overlapping bands that corresponded to modified and unmodified protein. Although it was not 
clear how much of the AB5 complex had been labelled with alkyne depsipeptide 4.31, the 
protein was still functional and was deemed suitable for use in subsequent SPAAC experiments 
 
Scheme 4.8: Synthesis of alkyne depsipeptide 4.31 
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Figure 4.3: Mass spectrum of the alkyne-linked AB5 complex. Red: CTB (11611 Da); blue: CTA2 
modified with alkyne depsipeptide 4.31 (5892 Da); green: Unlabelled CTA2 protein (5055 Da); 
purple: Adducts of hydrolysed depsipeptide 4.33; orange: Adduct of alkyne depsipeptide 4.31. 
Calculated mass change after SrtA-mediated modification, 865 Da - observed mass change, 837 
Da.    
  
Figure 4.4: Polyacrylamide gel (12%) showing the isolated alkyne-AB5 complex. Lane 1: SrtA; 
Lane 2: CTB (boiled); Lane 3: CTB; Lane 4: Alkyne-AB5 (boiled); Lane 5: Alkyne-AB5  
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4.2.3 Strain-promoted cycloadditions with the AB5 complex     
A strategy now existed to site-specifically incorporate a strained cyclooctyne onto the AB5 
complex, but the SPAAC had yet to be tested. Additionally, it was also important to establish if 
the reaction could be performed directly after the initial SrtA-mediated modification of the AB5 
complex as this could potentially reduce the number of purification steps. Therefore, the 
efficiency of a sequential SrtA ligation and SPAAC was probed using a simple galactosyl azide 
4.34 (Scheme 4.9) acquired from Dr. Tom McAllister (University of Leeds).  
 
The CTA2-AB5 complex (56 M) and alkyne depsipeptide (138 M, 2.5 equivalents) were 
incubated at 37 °C with SrtA (11 M, 20 mol%). ESMS was used to monitor the ligation and 
after 3 hours, only a trace amount of unlabelled protein was detected. At this point, galactosyl 
azide 4.34 (2.25 mM) and an extra equivalent of depsipeptide 4.34 were added to the reaction 
mixture before incubation was continued at room temperature overnight. The extra depsipeptide 
substrate was added to reduce the possibility of SrtA hydrolysing the labelled protein during the 
extended incubation period. After the overnight incubation, ESMS analysis identified the 
triazole product without any obvious alkyne starting material (Figure 4.5). There also appeared 
to be a small signal that corresponded to the +6 charge state of the CTA2-fragment, which was 
either the result of incomplete protein labelling or enzymatic hydrolysis of the ligated product. 
These results demonstrated that the SPAAC can be successfully performed in HEPES buffer 
Scheme 4.9: Sequential modification of the AB5 complex. Step 1: SrtA-mediated modification 
of CTA2-AB5 complex with alkyne depsipeptide 4.32. Step 2: SPAAC between alkyne-AB5 
complex and galactosyl azide 4.34 
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without having to isolate the alkyne-AB5 complex from the SrtA-ligation mixture. However, the 
reaction still needed to be optimised as there was a 9-fold excess of azide to alkyne. 
 
 
4.2.4 Oligonucleotide conjugation to AB5 protein  
RNA oligonucleotides containing 2ʹ-methoxy groups, phosphorothioate linkages and a 5ʹ-azido 
functional group or a 5ʹ-fluorescein fluorophore (Figure 4.6) had been synthesised by Darren 
Machin (University of Leeds). The 5ʹ-fluorescein oligonucleotide 4.36 is a variant of an intron 
skipper drug used by GlaxoSmithKline to treat Duchenne Muscular Dystrophy and 5ʹ-azido 
oligonucleotide 4.35 is its complementary strand.
165
 Combining the two oligonucleotides leads 
to the formation of a duplex structure with an azide functional group and a fluorescein probe. It 
was postulated that the alkyne-AB5 protein could be linked to the duplex and the formation of 
the protein-conjugate could be directly visualised as a fluorescent band on an SDS-PAGE gel.  
Figure 4.5: Mass spectrum of the triazole-linked AB5 complex. Red: CTB (11611 Da); blue: 
CTA2 modified with galactosyl azide 4.34 (6098 Da); green: CTA2 protein (5055 Da). 
Calculated mass change after SrtA-mediated modification and SPAAC, 1042 Da - observed 
mass change, 1043 Da.     
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Oligonucleotides 4.35 and 4.36 were combined in equal concentrations, heated to 95 °C and 
cooled to room temperature to allow formation of the duplex structure. The duplex (100 M, 
3.33 equivalents) was incubated with the alkyne-AB5 complex (27 M) at room temperature 
before SDS-PAGE analysis was performed (Figure 4.7). It is important to note that the initial 
SrtA-ligation reaction to generate the alkyne-AB5 complex had not gone to completion (See 
previous section), so the large band at ~56 kDa on the gel (Lane 3) could actually be two 
overlapping bands that had not resolved. Therefore, it is possible that the two discrete bands that 
can be detected at the same position on the gel after the SPAAC (Lane 5) are simply labelled 
and unlabelled protein from the previous reaction rather than oligonucleotide-conjugated 
protein. Interestingly, a new faint protein band was identified on the gel at ~24 kDa when the 
samples were boiled (Lane 6), which was not present in the unboiled sample or starting material 
(lanes 3 and 5). This suggests the oligonucleotide duplex had been successfully linked to the 
alkyne-CTA2 fragment; although, the mass of the protein conjugate is ~21 kDa, which is 
slightly lower than the mass of the new species on the gel. However, as SDS-PAGE is designed 
primarily to analyse proteins and not oligonucleotides, the observed mass was probably not an 
accurate representation of the species in solution. The new band was also fluorescent after it was 
irradiated with UV light (Lane 12), which is compelling evidence that it was duplexed 
Figure 4.6: Sequence and structure of the 5ʹ-azido complementary and 5ʹ-fluorescein intron 
skipper oligonucleotide strands 4.35 and 4.36 respectively. 
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oligonucleotide conjugated to the alkyne-CTA2 peptide. Furthermore, the fluorescent band 
shifted up the gel when the sample was not boiled (Lane 11) indicating it was linked to the 
higher weight AB5 complex. 
 
The preliminary results were encouraging, but it is extremely difficult to draw too many 
conclusions about the efficiency of the SPAAC for a number of reasons. The purity of the 
alkyne-AB5 starting material was not known at the beginning of the experiment, so there may 
have been a significant amount of unlabelled CTA2-AB5 complex in solution reducing the 
effective concentration of the alkyne. When the samples were boiled, the alkyne-CTA2 band 
was either not visible or indistinguishable from the monomeric B-subunit on the gel, so it could 
not be directly compared to the oligonucleotide-CTA2 band (Lanes 4 and 6). Furthermore, the 
unboiled AB5 complex looked practically identical before and after conjugation; once again, 
making comparison difficult (Lane 3 and 5). However, a very approximate assessment can be 
made by comparing the intensity of the fluorescent bands. There was roughly three times more 
oligonucleotide duplex than the AB5 complex; therefore, if the protein was completely labelled, 
it should fluoresce at roughly 1/3 the intensity of the excess oligonucleotide duplex, but it seems 
considerably less intense.  
There are several factors that could have reduced the efficiency of the oligonucleotide protein 
conjugation, but the low concentration of the reactants was probably the primary cause. The 
SPAAC is a bimolecular reaction, so if the concentration of the azide and alkyne was too low, 
the rate of the reaction would have been reduced decreasing product formation. Therefore, 
Figure 4.7: Polyacrylamide gel (12%) showing the duplex oligonucleotide conjugation to 
alkyne-AB5 protein. Red circle = new protein band. Lane 1: Duplex Oligonucleotide; lane 
2: Duplex oligonucleotide (boiled); lane 3: Alkyne-AB5 lane 4: Alkyne-AB5 (boiled); lane 
5: Reaction mixture; lane 6: Reaction mixture boiled; lane 7-12: UV exposed lanes 1-6. 
AB5 complex A = Alkyne-AB5 B = Oligonucleotide-conjugated AB5. 
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increasing the temperature and concentration of the reaction in future experiments may aid the 
formation of the conjugated product.  
4.2.4.1 Redesigning the alkyne-depsipeptide linker 
An alternative strategy to identify oligonucleotide conjugation was also being developed. 
Incorporating a fluorescent group into an alkyne-depsipeptide substrate would allow direct 
visualisation of the alkyne-labelled protein on an SDS-PAGE gel making any subsequent 
oligonucleotide conjugation more obvious. Therefore, it was decided to synthesise bifunctional 
depsipeptide 4.37, which had both a fluorescein probe and an alkyne group in its structure 
(Scheme 4.10). The backbone of the depsipeptide, including the fluorescein group, was built 
using SPPS before it was cleaved and subsequential coupled to activated cyclooctyne 4.26 to 
produce octyne/fluorescent bifunctional depsipeptide 4.37 in 33% yield.  
 
The CTA2-AB5 complex (37 M) was treated with bifunctional depsipeptide 4.37 (110 M, 3 
equivalents) in the presence of SrtA (7.7 M, 20 mol %). However, modification of the protein 
proved problematic. ESMS showed the formation of ligated product, but the unmodified protein 
was the dominant signal even after an extended incubation time with an extra 2 equivalents of 
bifunctional depsipeptide 4.37 and 30 mol% SrtA. The protein was isolated using lactose-
affinity chromatography and its absorbance at 495 nm and 280 nm was measured to determine 
the fluorescein:protein ratio. The absorbance was extremely weak at 495 nm suggesting the 
labelling had been negligible. It is quite likely that the bulky substituents at the N-terminus of 
the bifunctional depsipeptide 4.37 were interfering with SrtA-substrate binding and slowing or 
inhibiting the ligation reaction. If the rate of the ligation reaction was significantly reduced, the 
Scheme 4.10: Synthesis of octyne/fluorescent bifunctional depsipeptide 4.37. 
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depsipeptide substrate could undergo non-enzymatic hydrolysis before it could interact with 
SrtA. A simple solution to reduce SrtA-substrate interference would be to include additional 
amino acid residues between the LPXTG recognition site and the N-terminal chemical probes.  
4.3 Conclusion  
A synthetic route to a depsipeptide substrate with cyclooctyne functionality has been developed 
for use with SrtA to allow the introduction of a bioorthogonal handle site-specifically into a 
protein.  The SPAAC expands the range of modifications that can be performed on a protein by 
simply using SrtA-mediated ligations. Furthermore, using SrtA to incorporate the cyclooctyne 
means only a simple LPXTG recognition site or an N-terminal glycine sequence needs to be 
incorporated into the protein of interest, unlike other methods that require prior chemical or 
biological modification to attach the linker.  
The alkyne depsipeptide has been successfully coupled onto an AB5 protein and then conjugated 
to an azide linked oligonucleotide. However, the SrtA ligation needs to be optimised as the AB5 
complex was not completely modified with the depsipeptide substrate. Further investigation is 
also required into the SPAAC as currently only a very approximate qualitative assessment of the 
oligonucleotide-protein bioconjugation has been performed. These issues need to be addressed 
before this bioorthogonal approach can be used as a viable method to attach oligonucleotides 
onto the AB5 complex. 
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Chapter 5: Conclusions and future work 
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5.1 Summary  
The SrtA-mediated ligation reaction has been optimised with the use of depsipeptide substrates 
to allow the efficient N-terminal labelling of proteins/peptides. A range of depsipeptides has 
been synthesised by conventional SPPS, using an Fmoc-protected amino acid precursor that was 
obtained in two simple solution phase steps. The proteins hMBL, mouse pumilio and the CTA2-
AB5 complex have been modified with 1.5-5 equivalents of depsipeptide demonstrating the 
versatility of this approach. However, the efficiency of the ligation is dependent on the 
concentration of the protein substrate as non-enzymatic hydrolysis of the depsipeptide can 
compete with the reaction at low concentrations.  
A new methodology has been developed to generate an AB5 complex that is primed for SrtA-
mediated modification. This was achieved by overexpressing a chimeric MBP-AB5 complex 
that was subsequently truncated with TEV protease to leave an activated protein for SrtA 
ligation. The AB5 complex has been derivatised at the N-terminus of the CTA2 domain with 
fluorescent probes and bioorthogonal functionalities. Crucially, when mammalian cells were 
treated with a fluorescein-labelled AB5 protein, translocation of the complex across the cell 
membrane barrier to intracellular targets was observed. It is reasonable to assume that further 
modifications to the protein at the N-terminus of the CTA2 domain will not interfere with its 
ability to be endocytosed. Therefore, a wide selection of biological probes could potentially be 
transported inside cell using this approach.  
The SrtA-mediated modification of the AB5 complex is limited to molecules that can be coupled 
to depsipeptide substrates. To increase the number of potential modifications that can 
performed, a strained alkyne was linked to a depsipeptide and site-specifically incorporated onto 
the protein. This allowed an azide-linked RNA therapeutic to be attached onto the AB5 complex 
using a SPAAC. Although the efficiency of the conjugation reaction needs to be optimised, it 
has successfully generated an oligonucleotide-protein conjugate under mild conditions. 
5.2 Future work  
Now that a simple and robust SrtA-mediated labelling strategy has been developed to label AB5 
complexes there are several avenues of research that can be investigated.  
5.2.1 Development and application of RNA-conjugated AB5 complexes  
The immediate priority is to optimise the RNA conjugation as only a small amount of the RNA-
AB5 conjugate appears to have been formed; although, this has not been quantified. There are 
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several variables that could be altered to improve the yield of the bioconjugation reaction. These 
include temperature, buffer identity and reactant concentration; as the SPAAC is a bimolecular 
reaction, increasing the reactant concentration should immediately boost the efficiency of the 
bioconjugation.        
The ability of the RNA-protein conjugates to enter mammalian cells needs to be assessed using 
cell culture and immunofluorescence. In addition, an investigation into the efficacy of the 
therapeutic RNA in vivo compared to that of the unconjugated RNA is also required. Issues 
regarding immune response to the oligonucleotide-protein conjugates could be a potential 
stumbling block in the development of this technology. If in vivo testing is successful, this 
methodology could be applied to other oligonucleotide therapeutics that are unable to enter 
mammalian cells. 
5.2.2 Controlled release of cargo from AB5 protein conjugates     
Currently the AB5 delivery vehicles are permanently linked to their molecular cargo. 
Introducing a labile linker into the CTA2 peptide either synthetically or genetically would allow 
the controlled release of the cargo within a mammalian cell. This could alter how the cargo is 
trafficked and may allow it to reach different intracellular targets to the parent protein. There are 
several strategies, such as photocleavable and pH sensitive linkers, that could be used to achieve 
this, but incorporating a disulfide bond is probably the most practical.       
5.2.2.1 Disulfide linkers  
The A1-domain and A2-domain of cholera toxin are linked by a single disulfide bride that is 
reduced by a PDI in the ER of mammalian cells. The A1-domain is then liberated from the rest 
of the protein enabling it to induce toxicity. In principle, this mechanism could be exploited to 
release covalently-linked cargo from AB5 delivery vehicles. This could be achieved by simply 
introducing a disulfide bond and an endoprotease cleavage site, such as Factor Xa, into the 
CTA2-peptide sequence (Figure 5.1). The original SrtA-mediated modification strategy could 
then be used to label the AB5 complex, but prior to cell internalisation the extended A2-domain 
would be treated with Factor Xa. The enzyme will cleave the CTA2-domain into two peptide 
fragments that are held together by a single disulfide bond. After the AB5 complex has been 
transported inside a mammalian cell, the PDI will reduce the disulfide bond releasing the cargo 
from the parent protein. 
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Alternatively, a disulfide bond could be synthetically incorporated into an AB5 complex without 
having to reengineer the protein.  The synthesis of an Fmoc-protected disulfide amino acid 5.1 
(Figure 5.1) has been reported in previous scientific literature.
166
 Depsipeptide substrates 5.2 
containing the unnatural amino acid 5.1 could be readily synthesised using SPPS and ligated 
onto the AB5 complex. This would introduce a synthetic disulfide bond into the protein that 
would still be reduced by PDI allowing the conjugated cargo to be released inside mammalian 
cells.  
Figure 5.1: Introduction of a disulfide bridge into the AB5 complex to PDI-mediated cargo 
release. Strategy 1: Reengineer protein. Strategy 2: Synthesis of depsipeptide substrate 5.2 
from unnatural amino acid 5.1. X = any amino acid.   
98 
5.2.3 Anticipated problems with bacterial toxin based delivery 
systems.  
Although this thesis has demonstrated that modified AB5 complexes are able to enter 
mammalian cells, there may be problems regarding their use as therapeutic delivery agents.  
5.2.3.1 Endosomal entrapment of the delivery vehicle  
Once cholera toxin has entered a target cell, the catalytic A1-domain is able to reach the cytosol 
using the sec61p channel in the ER;
167
 this channel is used by cells to remove damaged and 
unfolded proteins from the ER.
168
 Non-protein cargo that has been delivered and subsequently 
released from modified AB5 complexes (see above) will be unable to use this mechanism to 
enter the cytosol. Consequently, the efficacy of the cargo could be severally limited if it is 
unable to reach its intracellular target.  
Other classes of delivery vehicle also suffer similar limitations. For example, CPPs frequently 
become trapped in endosomal compartments after internalisation;
31,33
 however, the introduction 
of repeating membrane destabilising peptide sequences, such as KALA, can help trigger 
endosomal escape. Therefore, it may be possible to use this approach to disrupt the endosomes 
that transport the modified AB5 complexes inside a cell. The peptide sequences could be 
installed at the N- and/or C-termini of the pentameric B-subunits to create a network of 
membrane destabilising motifs that could disrupt a vesicle membrane, thus allowing the cargo to 
enter the cytosol.  
5.2.3.2 Development of stealth delivery vehicle 
The immunogenicity of AB5 delivery vehicles may also be a potential hurdle in its development 
as a clinical tool. It has been widely reported that cholera toxin can act as a powerful 
adjuvant.
169,170
 Therefore, there is a strong possibility that modified AB5 complexes could only 
be administered to a subject a limited number of times without inducing a massive immune 
response. Gene delivery agents, such as adenoviral vectors,
171
 have been modified with PEG 
groups to mask them from the immune system;
172
 this approach could be used to reduce the 
immunogenicity of the AB5 delivery vehicles. Succinimidyl PEG groups could be non-
specifically conjugated to the surface exposed lysine residues on the pentameric B-subunit 
(Figure 5.2). This would suppress the antigenic features present on the surface of the AB5 
complex and as a result make detection by the immune system more difficult. 
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Paulson and co-workers devised a more elegant solution to mask liposomal delivery vehicles 
from the immune system.
173
 The authors decorated the surface of their liposomes with various 
protein antigens, and synthetic carbohydrate ligands 5.3 that are recognised by the CD22 
receptors on B-cells. The CD22 receptors regulate the activity of B-cells by inducing apoptosis 
upon activation. The B-cells are brought into close proximity with the carbohydrate ligands 5.3 
when they detect the antigens on the surface of the liposomes. Once in close enough proximity, 
the carbohydrate ligands 5.3 stimulate the CD22 receptors to trigger apoptosis of the cell. The 
authors’ ingenious approach specifically reduces the number of antigen-active B-cells that 
recognise the functionalised liposomes and it has been demonstrated both in vitro and in vivo. 
Once again, this technology could be adopted for use with the AB5 delivery vehicles.   
  
Figure 5.2: Modification of AB5 complex with functional groups to mask the immune 
system. CD22 ligand 5.3 and PEG.  
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Chapter 6: Chemical and biological experimental 
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6.1 Chemical experimental 
6.1.1 General methods  
Commercial reagents were used without purification, unless otherwise stated. Analytical grade 
reagents were supplied by Sigma-Aldrich, Fisher Scientific, Melford laboratories and VWR 
International. All concentrations were performed in vacuo, unless otherwise stated. All reactions 
were carried out at room temperature unless stated otherwise 
1
H NMR spectra were recorded using a Bruker Avance 500 instrument at 500 MHz or on a 
Bruker Avance 400 instrument at 400 MHz. 
13
C
 
NMR spectra were recorded on a Bruker 
Avance 300 instument at 75 MHz or a Bruker Avance 500 instrument at 125 MHz. Coupling 
constants (J) are given in MHz. Chemical shifts are given in ppm downfield from 
tetramethylsilane (TMS). The following abbreviations are used in 1H NMR analysis: s = singlet, 
d = doublet, t = triplet, q = quartet, m = multiplet, dd = double doublet, dt = double triplet, ddd= 
double double doublet etc. All peptides are assigned according to IUPAC recommendations.
174
 
Low resolution electrospray (ES+) ionisation mass spectra were obtained on a Bruker HCT 
Ultra mass spectrometer, and high resolution (ES+) were performed on a Bruker Daltonics 
MicroTOF mass spectrometer. HPLC analysis was done using the Agilent technologies 1290 
infinity. Freeze drying of compounds was done using Virtis Benchtop K freeze dryer. 
Centrifugation was achieved using the Eppendorf Centrifuge 5810. 
6.1.2 Small molecule synthetic data  
n-Butyl [(tert-Butyldimethylsilyl)oxy]acetate 2.22 
 
TBSMCl (7.9 g, 53 mmol) was added to a stirred solution of butyl glycolate (5.8 mL, 45 mmol) 
and imidazole (8.9 g, 132 mmol) in DMF (40 mL) at 0 °C. The reaction mixture was stirred for 
15 minutes at 0 °C and then a further 2.5 h at r.t. before being diluted with EtOAc (250 mL) and 
washed with 1 N HCl (2 × 200 mL), water (200mL) and brine (200 mL). The organic layer was 
concentrated and the crude product purified by flash column chromatography (silica; 95:5 (v/v) 
hexane- EtOAc) to afford 2.22 as a clear oil (8.95 g, 78%). RF 0.79 (1:1 (v/v) hexane-EtOAc);
 
1
H NMR (500 MHz,CD3OD)  = 4.21 (2H, s, H6), 4.12 (2H, t, J H4-H3 6.7 Hz, H4), 1.66-1.56 
(2H, m, H3), 1.36 (2H, app hex, J H2-H3/1 7.4 Hz, H2), 0.91 (3H, t, J H1-H2 7.4 Hz, H1), 0.90 (9H, s, 
102 
H10), 0.08 (6H, s, H7/8). 
13
C NMR (125 MHz, CD3OD):  = 171.9 (CO), 64.7 (C4), 61.9 (C6) 30.8 
(C3), 25.8 (C10), 19.2 (C2), 18.5 (C9), 13.8 (C1), -5.4 (C8/7). The NMR spectra were in good 
agreement with the previously reported literature values.
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Benzyloxycarbonylmethyl-(2S,3R)-3-tertbutyloxy-2-(((9H-fluoren-9-ylmethoxy)carbonyl)a
mino)butanoate 2.29 
 
DIPEA (1.9 mL, 11 mmol) was added to a stirred solution of Fmoc-Thr(OtBu)-OH (4.0 g, 10 
mmol), benzyl 2-bromoacetate (2.4 mL, 15 mmol) and TBAI (1.4 g, 4 mmol) in THF (10 mL). 
The reaction mixture was stirred at r.t. for a few minutes before the solution turned yellow and a 
precipitate started to form. The reaction mixture was left stirring overnight, before it was diluted 
with H2O (200 mL) and extracted with EtOAc (2  200 mL). The organic layers were 
combined, washed with 10% sodium thiosulfate (400 mL), H2O (400 mL) and concentrated to 
leave an oil. The crude product was purified by flash column chromatography (silica; 4:1 (v/v) 
hexane- EtOAc) to afford 2.29 (5.2 g, 95%) as a glassy solid, RF 0.53 (2:1 (v/v) hexane- 
EtOAc); [α]D
22.7 
-0.4 (c 1, DCM); 1H NMR (500 MHz,CDCl3)  = 7.77 (2H, d, J H19-H20  6.2 Hz, 
H22), 7.65-7.63 (2H, m, H19), 7.41-7.39 (2H, m, H21), 7.38-7.29 (2H, m, H20), 7.38-7.29 (5H, m, 
H1-3), 5.21 (2H, s, H5/5
,
), 4.76 (1H, d, J H7-H7
,
  15.9 Hz, H7
,
), 4.66 (1H, d, J H7-H7
,
 15.9 Hz, H7), 
4.44-4.35 (1H, m, H9),  4.44-4.35 (2H, m, H15/15
,
), 4.32-4.25 (1H, m, H16),  4.32-4.25 (1H, m, 
H10), 1.26 (3H, d, J H11-H10 6.2 Hz, H11), 1.15 (9H, s, H13). 
13
C NMR (125 MHz, CDCl3):  = 
170.6 (CO), 167.1(CO),  156. 8 (CO), 144.2 (ArC), 141.4 (ArC), 128.8 (ArC), 128.7(ArC), 
128.5(ArC), 127.8 (ArC), 127.2 (ArC), 125.2 (ArC), 120.1 (ArC), 79.4 (C12), 67.4 (C15), 67.4 
(C5), 67.3 (C10), 61.4 (C7), 59.9 (C9), 47.2 (C16) 28.5(C13), 21.0 (C11).  IR (vmax/ cm 
-1
) 3440 
(NH); 2976 (CH); 1755, 1725, 1648 (C=O). HRMS: Found [M+Na]
+
 568.2321, C32H35NO7Na 
requires 568.2306. 
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Benzyloxycarbonylmethyl-((2S,3R)-3-tertbutyloxy-2-(((9H-fluoren-9-ylmethoxy)carbonyl)
amino)butanoyloxy)acetic acid 2.30 
 
Benzyloxycarbonylmethyl-(2S,3R)-3-tertbutyloxy-2-(((9H-fluoren-9-ylmethoxy)carbonyl)amin
o)b utanoate 2.29 (1 g, 1.8 mmol) was dissolved in THF and H2O (3:1, 21 mL), before Pd/C 
(10%, 50 mg) was added. Under a H2 atmosphere, the reaction mixture was stirred at r.t for 40 
minutes before being filtered through celite and concentrated to leave a clear oil. The crude 
product was purified by flash column chromatography (silica; 9:1 (v/v) DCM-methanol) to 
afford 2.30 (726 mg, 87%) as a white lyophilisate, RF 0.63 (9:1 (v/v) DCM- EtOAc and 1% 
acetic acid);  [α]D
22.5 
-0.5 (c 1, DCM); 1H NMR (500 MHz, CDCl3) = 7.65 (2H, d, J H17-H16  7.6 
Hz, H17), 7.57-7.54 (2H, m, H14), 7.29-7.26 (2H, m, H16), 7.21-7.19 (2H, m, H15), 4.55 (1H, d, J 
H2-H2’ 14.4 Hz, H2), 4.44-4.29 (1H, m, H2’), 4.44-4.29 (2H, m, H10/10’),  4.30-4.22 (1H, m, H4), 
4.22-4.11 (1H, m, H11), 4.22-4.11 (1H, m, H5), 1.09 (3H, d, J H6-H5 5.9 Hz, H6), 1.04 (9H, s, H6) 
13
C NMR (125 MHz, CDCl3):  = 174.1 (CO), 170.5 (CO),  157.6 (CO), 144.3 (ArC), 143.9 
(ArC) 141.3 (ArC), 127.6 (ArC), 127.0 (ArC), 125.3 (ArC), 119.9 (ArC), 74.2 (C7), 67.8 (C10), 
67.0 (C5), 63.3 (C2), 60.4 (C4), 47.3 (C11), 28.5 (C8), 21.0 (C6)  IR (vmax/ cm 
-1
) 3436 (NH); 3436 
(OH); 2977 (CH); 1749, 1720, (C=O). HRMS: Found [M+Na]
+
 478.1837, C25H29NO7Na 
requires 478.1836. 
2,5-Dioxo-1-pyrrolidinyl 6-(isopropylidenehydrazino)nicotinate 4.4 
  
6-Choronicotinic acid (1.9 g, 12.1 mmol) was dissolved in hydrazine monohydrate (10 mL). 
The reaction mixture was stirred under reflux for 6 h and allowed to cool to r.t. before being 
concentrated under vacuo to leave a yellow solid. The crude product was dissolved in H2O (30 
mL) and the pH of the stirred solution was adjusted to pH 5 triggering precipitate formation. 
The precipitate was filtered and washed with EtOH (2 × 10 mL) to afford hydrazine salt 4.10 as 
a yellow solid (1.2 g, 52%). Without further purification hydrazine salt 4.10 (1.05 g, 5.5 mmol) 
was added at r.t. to stirred solution of acetone (0.564 mL) and Et3N (4 mL) in anhydrous DMF 
(20 mL). After 3.5 h EDC (1.27 g, 6.6 mmol) and N-hydroxysuccinimide (759 mg, 6.6 mmol) 
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were added to the reaction mixture and it was stirred at r.t. overnight. The reaction mixture was 
diluted with H2O (50 mL) and extracted with CH2Cl2 (3 × 50 mL). The organic layers were 
combined, washed with brine (150 mL) and concentrated under vacuo to leave a yellow solid. 
The crude product was precipitated from MeCN to afford 4.4 as an off white amorphous solid 
(0.740 g, 46%). δH (500 MHz, DMSO-d6) = 10.38 (1H, s, NH), 8.79 (1H, dd, J H8-H6 2.5 Hz, J 
H8-H5 0.7 Hz, H8), 8.14 (1H, dd, J H6-H5 9.0 Hz, J H6-H8 2.5 Hz, H6), 7.20 (1H, dd, J H5-H6 9.0 Hz, J H5-
H8 0.7 Hz, H5), 2.90 (4H, s, H11), 2.03 (3H, s, H1/2), 2.01 (3H, s, H1/2). 
13
C NMR (125 MHz, 
DMSO-d6):  = 170.5 (C10), 161.1 (C4), 169.9 (C9), 152.3 (C3), 151.6 (C8), 138.8 (C6), 110.0 
(C7), 106.0 (C5), 25.5 (C11), 25.2 (C1/2), 17.4 (C1/2). HRMS: Found [M+H]
+
 291.1075, 
C13H15N4O4 requires 291.1088. The compound spectra were in good agreement with the 
previously reported literature values.
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(1R,8S,9r,Z)-Ethyl bicyclo[6.1.0]non-4-ene-9-carboxylate (exo) and (1R,8S,9s,Z)-ethyl bicy
clo[6.1.0]non-4-ene-9-carboxylate (endo) 4.23 
 
1,5-Cyclooctoadiene (19.6 mL, 160 mmol), rhodium(II) acetate (380 mg. 0.86 mmol) and DCM 
(10 mL) were stirred under an atmosphere of N2 before ethyl diazoacetate (85% in DCM, 2.4 
mL, 20 mmol) as a solution in DCM (10 mL) was added dropwise at r.t over a 3 h period. The 
reaction mixture was left stirring for 3.5 days at r.t. before being concentrated in vacuo and 
passed through a plug of silica (1:1 (v/v) hexane-EtOAc) to remove the excess 1,5-
cyclohexadiene. The crude product was purified by flash column chromatography (silica; 20:0.5 
(v/v) hexane-EtOAc) to afford 4.23 as clear oil (3.1g, 80%, 2:1 exo:endo ratio). Exo: RF 0.32 
(20:1 (v/v) hexane-EtOAc).
 1
H NMR (500 MHz,CDCl3) = 5.59-5.58 (2H, m, H1), 4.10 (2H, q, 
J H7-H8 7.1 Hz,  H7), 2.37-2.35 (1H, m, H2), 2.24-2.14 (2H, m, H3), 2.13-2.02 (2H, m, H2’), 1.60-
1.52 (2H, m, H4), 1.54-1.42 (2H, m, H3’) 1.25 (3H, t, J H7-H8 7.1 Hz,  H8), 1.18 (1H,d, J H5-H4 4.2 
Hz,  H5) 
13
C NMR (125 MHz,CDCl3):  = 174.6 (C6), 130.1 (C1), 60.4 (C7), 28.4 (C3), 28.0 (C5), 
27.9 (C4), 26.8 (C2), 14.4 (C8). Endo: RF 0.42 (20:1 (v/v) hexane-EtOAc).
 
 
 1
H NMR (500 
MHz,CDCl3) = 5.63-5.54 (2H, m, H1), 4.10 (2H, q, J H7-H8 7.1 Hz  H7), 2.55-2.45 (2H, m, H2), 
2.26-2.12 (2H, m, H3), 2.09-2.00 (2H, m, H2’), 1.60-1.52 (2H, m, H3’), 1.69 (1H, t, J H5-H4 8.8 Hz  
H5), 1.44-1.32 (2H, m, H4) 1.25 (3H, t, J H8-H7 7.1 Hz,  H8) 
13
C NMR (125 MHz,CDCl3):  = 
172.4 (C6), 129.6 (C1), 59.8 (C7), 27.2 (C2), 22.8 (C4), 21.4 (C3), 26.8 (C5), 14.5 (C8). IR (vmax/ 
cm 
-1
) 2979 (CH); 1719.12 (C=O). HRMS: Found [M+H]
+
 195.1371, C12H19O2 requires 
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195.1380. The compound spectra were in good agreement with the previously reported literature 
values.
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(1R,8S,9s)-Bicyclo[6.1.0]non-4-yn-9-ylmethanol (exo) and (1R,8S,9r)-Bicyclo[6.1.0]non-4-
yn-9-ylmethanol (endo) 4.24 
 
Under a N2 atmosphere, a solution of 4.23 (800 mg, 4.1 mmol) in DCM (15 mL) was added 
dropwise to a stirred suspension of lithium aluminium hydride (135 mg, 3.5 mmol) in DCM (15 
mL) at 0 °C. The suspension was stirred at r.t. for 25 minutes before being cooled to 0 ˚C and 
quenched with the addition of sodium sulfate hexahydrate (3 g). The reaction mixture was 
filtered through celite, concentrated and azeotroped with toluene to leave a clear oil (660 mg).  
Under a N2 atmosphere, the crude product was dissolved in DCM (15 mL) with stirring at 0 ˚C 
before a solution of Bromine (265 L, 5.2 mmol) in DCM (2.5 mL) was added dropwise until a 
persistent red colour was observed. The reaction was quenched with the addition of 10% sodium 
thiosulfate (40 mL) before the organic layer was separated; washed with H2O (100 mL) and 
brine (100 mL); concentrated and azeotroped with toluene to leave a white solid. Under a N2 
atmosphere, the crude product was dissolved in THF (50 mL) with stirring at 0 ˚C before a 
solution 1 M potassium tert-butoxide in THF (12 mL) was added dropwise. After the addition 
the reaction mixture was heated to reflux for 5.5 h before being cooled to r.t., quenched with 
saturated ammonium chloride solution (50 mL) and extracted with DCM (3 × 100 mL). The 
organic layers were combined and concentrated to leave a crude residue that was purified using 
flash chromatography (silica; 1.5:1 (v/v) hexane-EtOAc) to afford 4.24 as clear oil. (242 mg, 
40%, 2:1 exo: endo ratio).
 
 Exo RF 0.33 (1:1 (v/v) hexane-EtOAc).
1
H NMR (500 MHz,CDCl3) 
= 3.55 (2H, d, J H6-H5 6.3 Hz, H6), 2.45-2.36 (2H, m,  H3), 2.34-2.12 (4H, m, H2/2’), 1.45-1.29 
(2H, m, H3'), 0.74-0.63 (1H, m, H5), 0.74-0.63 (2H, m, H4).
13
C NMR (125 MHz,CDCl3):  = 
98.8 (C1), 67.2 (C6), 33.4 (C3), 27.3 (C4/5), 22.6 (C4/5), 21.5 (C2). Endo: RF 0.33 (1:1 (v/v) 
hexane-EtOAc). 
1
H NMR (500 MHz,CDCl3) = 3.73 (2H, d, J H6-H5 7.9 Hz, H6), 2.34-2.12 (2H, 
m, H3), 2.34-2.12 (4H, m, H2/2’), 1.66-1.54 (2H, m, H3'), 1.45-1.29 (1H, m, H5),  0.98-0.89 (2H, 
m, H4). 
13
C NMR (125 MHz,CDCl3):  = 98.9 (C1), 60.0 (C6), 29.1 (C3), 21.5 (C2), 21.5 (C4/5), 
20.0 (C4/5). IR (vmax/ cm 
-1
) 3320 (OH). 2988 (CH); HRMS: Found [M+H]
+
 150.1051, C10H14O 
requires 150.1045. The compound spectra were in good agreement with the previously reported 
literature values.
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(1R,8S,9s)-Bicyclo[6.1.0]non-4-yn-9-ylmethyl (4-nitrophenyl) carbonate and (1R,8S,9r)-
Bicyclo[6.1.0]non-4-yn-9-ylmethyl (4-nitrophenyl) carbonate 4.26 
 
4-Nitrophenyl chloroformate (202 mg, 1 mmol) and pyridine (109 l, 1.35 mmol) were added to 
a stirred solution of 4.24 (100 mg, 0.67 mmol) in DCM (10 mL). The solution was stirred at r.t. 
for 20 minutes before saturated ammonium chloride solution (10 mL) was added and the crude 
product extracted with DCM (2 × 10mL). The organic layers were combined and concentrated 
to leave yellow oil that was purified using flash chromatography (silica; 6:1 (v/v) hexane-
EtOAc) to afford 4.26 as an amorphous solid (160 mg, 76%, 2:1 exo: endo ratio). Exo: RF 0.37 
(6:1 (v/v) hexane-EtOAc).
 
 
1
H NMR (500 MHz,CDCl3) = 8.25 (2H, d, J H10-9 9.1 Hz, H10), 7.37 
(2H, d, J H9-H10 9.1 Hz, H9), 4.22 (2H, app d, J H6-H5 6.7 Hz, H6) 2.47-2.39 (2H, m  H3), 2.36-2.10 
(4H, m,  H2/2’), 1.45-1.34 (2H, m, H3'), 0.88-0.76 (2H, m, H4), 0.88-0.76 (1H, m, H5).
 13
C NMR 
(125 MHz, CDCl3):  = X (C7), X (C11), X (C9), 125.4 (C10), 124.8 (C9), 98.7 (C1), 74.0 (C6), 
33.2 (C3), 23.3 (C4/5), 23.0 (C4/5), 21.3 (C2). Endo: RF 0.37 (6:1 (v/v) hexane-EtOAc).
 
 
1
H NMR 
(500 MHz,CDCl3) = 8.26 (2H, d, J H10-9 9.4 Hz, H10), 7.37 (2H, d, J H9-H10 9.4 Hz, H9), 4.38 
(2H, app d, J H6-H5 8.2 Hz, H6) 2.36-2.10 (2H, m  H3), 2.36-2.10 (4H, m,  H2/2’), 1.66-1.53 (2H, 
m, H3'), 1.55-1.44 (1H, m, H5), 1.09-0.99 (2H, m, H4).
 13
C NMR (125 MHz,CDCl3):  = X (C7), 
X (C11), X (C9), 125.4 (C10), 124.8 (C9), 98.8 (C1), 68.1 (C6), 29.1 (C3), 21.3 (C2), 20.6 (C4/5), 
17.3 (C4/5). IR (vmax/ cm 
-1
) 3118, 2974 (CH), 1750 (CO); HRMS: Found [M+Na]
+
 338.0985, 
C17H17NO5Na requires 338.0999.  The compound spectra were in good agreement with the 
previously reported literature values.
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6.1.3 Solid phase peptide synthesis  
6.1.3.1 General Reagents and Equipment  
All amino acids, resins and coupling reagents were purchased from Sigma Aldrich, VWR 
International and Cambridge Bioscience. All chemical compounds were used as received. 
Fritted polypropylene tubes (10 mL) purchased from Grace and Co were used as a vessel for all 
solid phase reactions. Agitation of the solid phase reaction mixture was achieved by rotation on 
a Stuart rotator which allowed multiple fritted polypropylene tubes to be spun simultaneously.  
H-Gly-2-ClTrt (Sigma, loading: 1.1 mmol/g), H-Thr-2-ClTrt (Sigma, loading: 1.1 mmol/g) and 
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Rink Amide NovaGel (Novabiochem, loading: 0.66 mmol/g) were used for solid phase peptide 
synthesis. 
Peptides having a C-terminal glycine residue were synthesised on H-Gly-2-ClTrt resin (Sigma). 
Peptides having a C-terminal amide group were synthesised on Rink Amide NovaGel resin 
(Novabiochem). Depsipeptide building block 12 was incorporated into the peptides using the 
standard coupling and deprotection methods described below. 
Peptides were analysed using an Agilent 1290 affinity LC system equipped with an Ascentis 
Express 10 cm × 2.1 mm, 2.7 μm ES-C18 peptide column (0.5 mL min−1) and ultraviolet (UV) 
detection at 220 nm - 280 nm. Gradient from 0.1% TFA/5% MeCN (vol/vol) in H2O to 0.1% 
TFA/95% MeCN in H2O over 5 min 40 s.  
6.1.3.2 General procedure for solid phase peptide synthesis  
Method One: Coupling amino acids onto solid phase resin. 
The resin was swollen in DMF for 30 minutes. HCTU (4.9 equiv) and an Fmoc-amino acid (5 
equiv) were dissolved in DMF (6 mL), followed by the addition of DIPEA (10 equiv).  The 
solution was transferred to the swelled resin and the mixture was left to spin for 1 h at room 
temperature. The resin was isolated by filtration and washed with DMF (3 × 6 mL × 2 min 
spins). 
Method Two: Coupling reaction analysis  
A small sample of beads from the isolated Fmoc-amino acid-resin were exposed to TFA (100 
l) for 2 minutes before the solution was quenched with methanol (1 mL). The solution was 
filtered and analysed by LCMS. If any starting material was detected method one was repeated.  
Method Three: Fmoc deprotection and peptide elongation  
The Fmoc-amino acid-resin was treated with piperidine (20% in DMF) (10 mL) and left to spin 
for 2 min at rt. This process was repeated five times before the amino acid resin was washed 
with DMF (4 × 10 mL × 2 min spins). The peptide sequence was elongated by repeating 
methods 1-3 (excluding the resin swelling step) until the correct peptide was synthesised.  
Method Four: Fluorescein labelling (optional)  
After elongation of the peptide to the desired length, a final coupling step using a Boc-Lys-OH 
or GABA residue was performed. After this coupling step, the resin was treated with a solution 
of f (FITC, 6 equiv) and DIPEA (14 equiv) dissolved in a minimal amount of DMF. The 
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reaction was spun at r.t., overnight in the dark. The resin was drained and washed with DMF (4 
× 10 mL × 2 min spins), before method five was initiated.   
Method Five: Cleavage and isolation 
The amino acid-resin was washed with DMF (3× 6 mL × 2 min spins), DCM (3 × 6 mL × 2 min 
spins) and methanol (3 × 6 mL × 2 min spins). The resin was isolated by filtration before being 
dried under high vacuum for 3 h.  A cleavage cocktail consisting of H2O: TIS: TFA (2.5: 2.5: 
95) (3 mL) was added to the resin and the mixture was left to spin for 2 h at rt. The resin was 
filtered and washed with TFA (2 × 3 mL). The washings were combined and added to cold 
diethyl ether (40 mL) to precipitate the peptide. The precipitate was pelleted by centrifugation 
(6,000 × g, 10 min) and the cold diethyl ether discarded. The peptide pellet was re-suspended in 
cold diethyl ether (40 mL) and the process repeated three times. The peptide was analysed by 
LCMS before being dissolved in the minimal amount of water and freeze dried. 
6.1.4 Spectral data for peptides 
H2N-YALPETGKSG-COOH 2.4  
 
Yield: 120 mg, >99% 
1
H NMR (500 MHz, CD3OD):  = Y1: 4.06 (1H, dd, J3- 8.4 Hz, J2-2 
5.5 Hz, H), 3.18 (1H, dd, J2-2 5.5 Hz, J 2-3 14.4 Hz, H2), 2.94 (1H, dd, J3-2 8.4 Hz, J 3-2 
14.4 Hz, H3), 7.11 (2H, d, J1/2-1/2 8.5 Hz, H1/2), 6.77 (2H, d, J1/2-1/2 8.5 Hz, H1/2). A2: 4.45 
(1H, q, J-2 7.1 Hz, H), 1.39 (3H, d, J2- 7.1 Hz, H2). L3: 4.69 (1H, dd, J-2 8.7 Hz, J-3 5.3 
Hz, H), 1.72-1.59 (2H, m, H2/3), 1.82-1.72 (1H, m, H), 0.99 (6H, app d, J1/2- 6.5 Hz, H1/2). 
P4: 4.42 (1H, dd, J-2 8.1 Hz, J-3 5.5 Hz, H), 2.30-2.20 (1H, m, H2) 2.06-1.94 (1H, m, H3), 
2.15-2.06 (1H, m, H2), 2.06-1.95 (1H, m, H3), 3.94-3.75 (1H, m, H), 3.75-3.67 (1H, m, H). 
E5: 4.35 (1H, dd, J3- 5.0 Hz, J2- 9.3 Hz, H), 2.20-2.12 (1H, m, H2), 2.06-1.95 (1H, m, H3), 
2.52-2.41 (2H, m, H2/3).T6: 4.26 (1H, d, J-2 4.2 Hz, H), 4.24 (1H, qd, J- 4.2 Hz, J-2 6.3 
Hz, H), 1.22 (3H, d, J2- 6.2 Hz, H2). G7: 4.02-3.75 (2H, m, H2/3). K8: 4.49 (1H, dd, J-2 
4.1 Hz, J-3 5.6 Hz, H

), 2.30-2.20 (1H, m, H2) 1.96-1.85 (1H, m, H
3
), 1.53-1.40 (2H, m, 
H23), 1.72-1.59 (2H, m, H/3), 1.97-1.90 (2H, m, H/3). S9: 4.48-4.45 (1H, m, H), 3.90-3.77 
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(2H, 1H, m, H23), G10: 4.02-3.75 (2H, m, H2/3).
13
C NMR (75 MHz, CD3OD):  = Y1: 
169.7 (CO), 55.0 (C), 37.8 (C), 126.0 (C), 116.9 (C), 131.7 (C), 158.2 (C). A2: 174.0 (CO), 
50.3 (C), 18.3 (C). L3: 173.4 (CO), 51.4 (C), 40.9 (C), 25.9 (C), 23.7 (C1), 22.0 (C2). P4: 
175.0 (CO), 62.2 (C), 26.1 (C), 30.4 (C), 49.7 (C). E5: 174.7 (CO), 55.3 (C), 27.6 (C), 
31.9 (C), 177.6 (CO. T6: 174.4 (CO), 60.1 (C), 68.4 (C), 20.2 (C). G7: 173.6 (CO), 43.5 
(C). K8: 173.7 (CO), 54.4 (C), 32.4 (C), 23.5 (C), 27.7 (C), 40.6 (C).  172.2 S9: (CO), 56.9 
(C), 63.0 (C). G10: 171.9 (CO), 44.0 (C). Analytical HPLC (below). HRMS of peak eluting 
at 1.19 min: Found [M + H
+
] 1022.5158, C45H72N11O16 requires 1022.5153.  
 
H2N-Y-A-L-P-E-T-G-G-COOH 2.5  
 
Yield: 140 mg, 98%
1
H NMR (500 MHz, CD3OD):  = Y1: 4.07 (1H, dd, J-3 8.6 Hz, J-2 5.3 
Hz, H), 3.21 (1H, dd, J2- 5.3 Hz, J2-3 14.4 Hz, H2), 2.94 (1H, dd, J3- 8.6 Hz, J3-2 14.4 
Hz, H3), 7.14 (2H, d, J1/2-1/2 8.6 Hz, H1/2), 6.80 (2H, d, J1/2-1/2 8.6 Hz, H1/2). A2: 4.45 (1H, q, 
J-2 7.1 Hz, H), 1.39 (3H, d, J2- 7.1 Hz, H2). L3: 4.67 (1H, dd, J-2 8.4 Hz, J-3 6.0 Hz, 
H), 1.67-1.59 (2H, m, H2/3), 1.82-1.73 (1H, m, H), 0.99 (3H, d, J1- 6.6 Hz, H1), 0.99 (3H, 
d, J2- 6.6 Hz, H2). P4: 4.45-4.41 (1H, m, H), 2.30-2.09 (2H, m, H2) 2.06-1.94 (1H, m, H3), 
2.30-2.09 (1H, m, H2), 2.06-1.94 (1H, m, H3), 4.00-3.84 (1H, m, H), 3.95-3.76 (1H, m, H). 
E5: 4.36 (1H, dd, J-3 5.0 Hz, J-2 9.2 Hz, H), 2.30-2.09 (1H, m, H2), 2.06-1.94 (1H, m, H3), 
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2.57-2.44 (2H, m, H
2/3
).T6: 4.31 (1H, d, J- 3.7 Hz, H), 4.25 (1H, qd, J- 3.7 Hz, J-2 6.2 Hz, 
H), 1.18 (3H, d, J2- 6.2 Hz, H2). G7: 4.91 (1H, d, J2-3 17.8 Hz, H2), 3.94 (1H, d, J3-2 17.8 
Hz, H3). G8: 4.13 (1H, d, J2-3 16.6 Hz, H2), 3.93 (1H, d, J3-2 16.6 Hz, H3).
13
C NMR (125 
MHz, CD3OD):  = Y1: 55.7 (C), 37.8 (C), 125.9 (C), 131.6 (C), 116.9 (C), 158.3 (C). A2: 
50.2 (C), 18.2 (C). L3: 51.2 (C), 41.1 (C), 25.8 (C), 23.7 (C1), 21.9 (C2). P4: 61.9 (C), 
26.1 (C), 30.4 (C), 48.6 (C). E5: 55.0 (C), 27.7 (C), 31.3 (C). T6: 60.5 (C), 68.2 (C), 20.1 
(C

). G7: 41.8 (C). G8: 43.5 (C). CO (× 9): 176.9, 174.9, 174.3, 174.1, 173.6, 173.0, 172.9, 
172.0, 169.5. Analytical HPLC (below). HRMS of peak eluting at 1.66 min: Found [M + H
+
] 
807.3901, C36H55N8O13  requires 807.3883.   
 
H2N-Y-A-L-P-E-T-G-COOH 2.6 
 
Yield: 80 mg, 98% 
1
H NMR (500 MHz, CD3OD):  = Y1: 4.04 (1H, dd, J3- 8.5 Hz, J2-2 5.3 
Hz, H), 3.18 (1H, dd, J2-2 5.3 Hz, J 2-3 14.6 Hz, H2), 2.92 (1H, dd, J3-2 8.5 Hz, J3-2 14.6 
Hz, H3), 7.11 (2H, d, J1/2-1/2 8.5 Hz, H1/2), 6.77 (2H, d, J1/2-1/2 8.6 Hz, H1/2). A2: 4.45 (1H, q, 
J-2 7.1 Hz, H), 1.37 (3H, d, J2- 7.1 Hz, H2). L3: 4.67 (1H, dd, J-2 8.9 Hz, J-3 5.6 Hz, 
H), 1.66-1.60 (2H, m, H2/3), 1.82-1.73 (1H, m, H), 1.00 (3H, d, J1- 6.6 Hz, H1), 0.99 (3H, 
d, J1- 6.6 Hz, H2). P4: 4.46-4.42 (1H, m, H), 2.30-2.18 (1H, m, H2) 2.06-1.95 (1H, m, H3), 
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2.15-2.06 (1H, m, H2), 2.06-1.95 (1H, m, H3), 3.91-3.77 (1H, m, H), 3.72-3.59 (1H, m, H). 
E5: 4.37 (1H, dd, J3- 5.1 Hz, J2- 9.2 Hz, H), 2.20-2.15 (1H, m, H2), 2.06-1.95 (1H, m, H3), 
2.53-2.41 (2H, m, H2/3).T6: 4.35 (1H, d, J-2 3.8 Hz, H), 4.22 (1H, qd, J- 3.8 Hz, J-2 6.4 
Hz, H), 1.20 (3H, d, J2- 6.4 Hz, H2). G7: 4.00 (1H, d, J2-3 17.8 Hz, H2), 3.94 (1H, d, J3-2 
17.8 Hz, H3). 
13
C NMR (125 MHz, CD3OD):  = Y1: 169.4 (CO), 54.7 (C), 37.8 (C), 125.9 
(C), 116.8 (C), 131.6 (C), 158.3 (C). A2: 174.3 (CO), 50.2 (C), 18.2 (C). L3: 173.4 (CO), 
51.1 (C), 41.1 (C), 25.8 (C), 23.7 (C1), 21.9 (C2). P4: 174.8 (CO), 61.7 (C), 26.1 (C), 30.4 
(C), 48.6 (C), E5: 173.8 (CO), 55.7 (C), 27.8 (C), 31.3 (C), 176.8 (CO. T6: 172.8 (CO), 
60.1 (C), 68.3 (C), 20.0 (C). G7: 172.9 (CO), 42.0 (C). Analytical HPLC (below). HRMS 
of peak eluting at 1.26 min: Found [M + H
+
] 750.3659, C34H52N7O12  requires 750.365.   
 
H2N-Y-A-L-P-E-T-G-CONH2 2.7 
 
Yield: 94 mg, 98% 
1
H NMR (500 MHz, CD3OD):  = Y1: 4.04 (1H, dd, J-3 8.4 Hz, J-2 5.4 
Hz, H), 3.18 (1H, dd, J2- 5.4 Hz, J 2-3 14.5 Hz, H2), 2.91 (1H, dd, J3- 8.4 Hz, J 3-2 14.5 
Hz, H3), 7.11 (2H, d, J1/2-1/2 8.5 Hz, H1/2), 6.77 (2H, d, J1/2-1/2 8.5 Hz, H1/2). A2: 4.44 (1H, q, 
J-2 7.1 Hz, H), 1.36 (3H, d, J2- 7.1 Hz, H2). L3: 4.67 (1H, dd, J-2 8.1 Hz, J-3 6.3 Hz, 
H), 1.69-1.58 (2H, m, H2/3), 1.84-1.71 (1H, m, H), 0.99 (6H, app d, J1- 6.4 Hz, H1), 0.99 
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(6H, app d, J2- 6.4 Hz, H2). P4: 4.42 (1H, dd, J-2 8.3 Hz, J-3 5.3 Hz H), 2.26-2.06 (1H, m, 
H2) 2.07-1.95 (1H, m, H3), 2.26-2.06 (1H, m, H2), 2.07-1.95 (1H, m, H3), 3.92-3.77 (1H, m, 
H), 3.72-3.60 (1H, m, H). E5: 4.37 (1H, dd, J-3 5.1 Hz, J-2 9.2 Hz, H), 2.26-2.06 (1H, m, 
H2), 2.07-1.95 (1H, m, H3), 2.56-2.38 (2H, m, H2/3).T6: 4.28 (1H, d, J-2 3.7 Hz, H), 4.22 
(1H, qd, J- 3.7 Hz, J-2 6.4 Hz, H), 1.20 (3H, d, J2- 6.4 Hz, H2). G7: 3.94 (1H, d, J2-3 17.1 
Hz, H2), 3.84 (1H, d, J3-2 17.1 Hz, H3).
13
C NMR (125 MHz, CD3OD):  = Y1: 55.8 (C), 
37.8 (C), 125.9 (C), 131.6 (C), 116.9 (C), 158.3 (C). A2: 50.2 (C), 18.2 (C). L3: 51.2 (C), 
41.0 (C), 25.8 (C), 23.7 (C1), 21.9 (C2). P4: 61.9 (C), 26.1 (C), 30.4 (C), 48.7 (C), E5: 
55.0 (C), 27.6 (C), 31.3 (C). T6: 60.6 (C), 68.3 (C), 20.1 (C). G7: 43.3 (C). CO (× 8): 
176.8, 174.9, 174.4, 174.3, 174.1, 173.6, 173.0, 169.5. Analytical HPLC (below). HRMS of 
peak eluting at 1.64 min: Found [M + H
+
] 749.3844, C34H53N8O11  requires 749.3828.   
 
H2N-G-G-S-E-F-G-COOH 2.8 
 
Yield: 120 mg, 97%. 
1
H NMR (500 MHz, D2O):  = G1: 3.85 (1H, s, H2/3) G2: 4.01 (1H, d, 
J2-3 17.8 Hz, H2), 3.96 (1H, d, J3-2 17.8 Hz, H3) S3: 4.66 (1H, dd, J-2 5.9 Hz, J-3 9.4 Hz, 
H), 3.81 (1H, dd, J2- 6.0 Hz, J2-3 11.5 Hz, H2), 3.75 (1H, dd, J3- 5.2 Hz, J3-2 11.5 Hz, 
H3) E4: 4.24 (1H, dd, J-3 6.1 Hz, J-2 8.5 Hz, H), 1.78-1.94 (1H, m, H2/3), 2.31-2.21 (1H, m, 
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H2), 2.19-2.10 (1H, m, H3) F5: 4.41 (1H, app q, J-3/2  5.7 Hz, H), 2.06 (1H, dd, J2- 6.0 Hz, 
J2- 13.5 Hz, H2), 1.79 (1H, dd, J3- 9.4 Hz, J3- 13.5 Hz, H3), 7.34-7.39 (2H, m, H1/2), 
7.28-7.21 (2H, m, H1/2), 7.28-7.21 (1H, m, H). G6: 4.09 (1H, s, H2/3).
13
C NMR (125 MHz, 
CD3OD):  = G1: 36.8 (C). G2: 41.2 (C). S3: 55.3 (C), 60.9 (C). E4: 53.3 (C), 25.8 (C), 
29.6 (C). F5:  54.5 (C), 36.8 (C), 136.3 (C), 128.6 (C), 129.0 (C), 128.0  (C). G6: 42.2 
(C). CO (× 7): 176.9, 173.1, 173.1, 172.7, 171.8, 171.3, 167.7. Analytical HPLC (below). 
HRMS of peak eluting at 1.47 min: Found [M - H
+
] 551.2117, C23H31N6O10  requires 551.2107 
 
H2N-Y-A-L-P-E-T-G-G-S-E-F-G-COOH 2.9 
 
Purified by HPLC: Yield: 80 mg, 40% 
1
H NMR (500 MHz, CD3OD):  = Y1: 4.05 (1H, dd, 
J-3 8.6 Hz, J-2 5.3 Hz, H), 3.18 (1H, dd, J2- 5.3 Hz, J2-3 14.2 Hz, H2), 2.91 (1H, dd, J3- 
8.6 Hz, J3-2 14.2 Hz, H3), 7.11 (2H, d, J1/2-1/2 8.6 Hz, H1/2), 6.77 (2H, d, J1/2-1/2 8.6 Hz, 
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H1/2). A2: 4.48-4.44 (1H, m, H), 1.35 (3H, d, J2- 7.1 Hz, H2). L3: 4.71-4.64 (1H, m, H), 
1.67-1.61 (2H, m, H2/3), 1.81-1.71 (1H, m, H),  0.99 (3H, d, J1- 6.5 Hz, H1), 0.98 (3H, d, J2- 
6.6 Hz, H2). P4: 4.42 (1H, dd, J-2 8.5 Hz, J-3 5.2 Hz H), 2.28-2.07 (1H, m, H2) 2.05-1.95 
(1H, m, H3), 2.28-2.07 (1H, m, H2), 2.05-1.95 (1H, m, H3), 4.00-3.84 (1H, m, H), 3.72-3.65 
(1H, m, H).E5: 4.37 (1H, dd, J-2 5.0 Hz, J-3 9.2 Hz, H), 2.28-2.07 (1H, m, H2), 2.05-1.95 
(1H, m, H3), 2.47 (2H, app t, J2/3-2/3 7.2 Hz H2/3).T6: 4.33 (1H, d, J- 3.9 Hz, H), 4.29-4.24 
(1H, m, H), 1.20 (3H, d, J2- 6.4 Hz, H2). G7: 4.00-3.84 (2H, m, H2/3). G8: 4.00-3.84 (2H, m, 
H2/3). S9: 4.48-4.44 (1H, m, H), 4.00-3.84 (2H, m, H2), 3.75-3.65 (1H, m, H3). E10: 4.29-
4.24 (1H, m, H), 1.94-1.87 (1H, m, H2), 1.81-1.79 (1H, m, H3), 2.28-2.07 (1H, m, H). F11: 
4.71-4.64 (1H, m, H), 3.28 (1H, dd, J2- 4.9 Hz, J2- 14.0 Hz, H2),  2.88 (1H, dd, J3- 10.1 
Hz, J3- 14.0 Hz, H3), 7.29-7.23 (2H, m, H1/2), 7.29-7.23 (2H, m, H1/2), 7.21-7.16 (1H, m, 
H). G12: 4.00-3.84 (2H, m, H2/3).
13
C NMR (125 MHz, CD3OD):  = Y1: 55.8 (C), 38.5 (C), 
125.9 (C), 131.6 (C), 116.9 (C), 158.3 (C). A2: 50.2 (C), 18.3 (C). L3: 51.2 (C), 41.0 (C), 
25.9 (C), 23.7 (C1), 21.9 (C2). P4: 62.1 (C), 26.1 (C), 30.4 (C), 49.7 (C), E5: 55.2 (C), 
27.6 (C), 31.3 (C), 176.9 (CO. T6: 60.6 (C), 68.3 (C), 20.1 (C). G7: 43.8 (C), G8: 41.9 
(C), S9: 56.0 (C), 62.9 (C). E10: 55.0 (C), 27.6 (C), 31.0 (C). F11: 56.9 (C), 37.9 (C), 
138.6 (C), 130.3 (C), 129.5 (C), 128.0 (C). G12: 44.0 (C). CO (× 14): 177.0, 176.6, 174.9, 
174.3, 174.2, 173.8, 173.7, 173.6, 173.5, 173.2, 172.7, 172.5, 171.9, 169.4. Analytical HPLC 
(below). HRMS of peak eluting at 1.96 min: Found [M - H
+
] 1225.5391, C55H77N12O20  requires 
1225.5383 
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H2N-Y-A-L-P-E-T-[G]-G-COOH 2.24 
 
Purified by mass directed HPLC: Yield: 60 mg, 67% 
1
H NMR (500 MHz, CD3OD):  = Y1: 
4.00 (1H, dd, J-2 5.5 Hz, J-3 8.5 Hz, H), 3.17 (1H, dd, J2- 5.5 Hz, J 2-3 14.3 Hz, H2), 2.90 
(1H, dd, J3- 8.5 Hz, J 3-2 14.3 Hz, H3), 7.10 (2H, d, J1/2-1/2 8.4 Hz, H1/2), 6.76 (2H, d, J1/2-
1/2 8.4 Hz, H1/2). A2: 4.47-4.35 (1H, m, H), 1.36 (3H, d, J2- 7.1 Hz, H2). L3: 4.73-4.64 (1H, 
m, H), 1.67-1.57 (2H, m, H2/3), 1.82-1.70 (1H, m, H),  0.99 (3H, d, J1- 6.5 Hz, H1), 0.98 
(3H, d, J2- 6.5 Hz, H2). P4: 4.47-4.35 (1H, m, H), 2.29-2.05 (1H, m, H2) 2.05-1.95 (1H, m, 
H3), 2.29-2.05 (1H, m, H2), 2.05-1.95 (1H, m, H3), 3.89-3.79 (1H, m, H), 3.72-3.61 (1H, m, 
H). E5: 4.47-4.35 (1H, m, H), 2.29-2.05 (1H, m, H2), 2.05-1.95 (1H, m, H3), 2.48-2.43 (2H, 
m, H2/3).T6: 4.60 (1H, d, J- 3.2 Hz, H), 4.47-4.35 (1H, m, H), 1.20 (3H, d, J2- 6.4 Hz, 
H2). G7: 4.73-4.64 (2H, m, H2/3), G8: 3.89-3.79 (2H, m, H2/3).
13
C NMR (125 MHz, CD3OD): 
 = Y1: 56.0 (C), 38.1 (C), 126.3 (C), 131.6 (C), 116.8 (C), 158.3 (C). A2: 50.5 (C), 18.2 
(C). L3: 51.2 (C), 41.1 (C), 25.9 (C), 23.7 (C1), 21.9 (C2). P4: 62.0 (C), 26.1 (C), 30.4 
(C), 48.8 (C), E5: 54.6 (C), 28.1 (C), 31.9 (C). T6: 59.6 (C), 68.6 (C), 20.1 (C). G7: 64.0 
(C). G8: 43.5 (C).  CO (× 9): 175.3, 174.3, 174.4, 174.2, 173.7, 173.5, 170.8, 170.1, 169.5. . 
Analytical HPLC (below). HRMS of peak eluting at 1.81 min: Found [M + H
+
] 808.3698, 
C36H54N7O14 requires 808.3723 
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H2N-Y-A-L-P-E-T-[G]-CONH2 2.25 
 
Yield: 90 mg, 87% 
1
H NMR (500 MHz, CD3OD):  = Y1: 4.03 (1H, dd, J-3 8.6 Hz, J-2 5.3 
Hz, H), 3.18 (1H, dd, J2- 5.3 Hz, J 2-3 14.6 Hz, H2), 2.91 (1H, dd, J3- 8.6 Hz, J 3-2 14.6 
Hz, H3), 7.11 (2H, d, J1/2-1/2 8.6 Hz, H1/2), 6.77 (2H, d, J1/2-1/2 8.6 Hz, H1/2). A2: 4.44-4.41 
(1H, m, H), 1.37 (3H, d, J2- 7.1 Hz, H2). L3: 4.68-4.63 (1H, m, H), 1.68-1.59 (2H, m, 
H2/3), 1.82-1.73 (1H, m, H), 0.99 (3H, d, J1- 6.6 Hz, H1), 0.99 (3H, d, J2- 6.6 Hz, H2). P4: 
4.44-4.41 (1H, m, H), 2.25-2.06 (1H, m, H2) 2.04-1.94 (1H, m, H3), 2.25-2.06 (1H, m, H2), 
2.04-1.94 (1H, m, H3), 3.90-3.85 (1H, m, H), 3.70-3.61 (1H, m, H). E5: 4.44-4.41 (1H, m, 
H), 2.25-2.06 (1H, m, H2), 2.04-1.94 (1H, m, H3), 2.49-2.44 (2H, m, H2/3).T6: 4.58 (1H, d, 
J- 3.2 Hz, H), 4.40 (1H, qd, J- 3.2 Hz, J-2 6.6 Hz, H), 1.21 (3H, d, J2- 6.6 Hz, H2). G7: 
4.68-4.65 (2H, m, H2/3).
13
C NMR (125 MHz, CD3OD):  = Y1: 55.7 (C), 37.8 (C), 125.9 
(C), 131.6 (C), 116.9 (C), 158.3 (C). A2: 50.2 (C), 18.1 (C). L3: 51.2 (C), 41.1 (C), 25.9 
(C), 23.7 (C1), 21.9 (C2). P4: 61.6 (C), 26.0 (C), 30.4 (C), 48.6 (C), E5: 54.3 (C), 28.1 
(C), 31.2 (C). T6: 59.7 (C), 68.6 (C), 19.9 (C). G7: 63.6 (C). CO (× 8): 176.8, 174.3, 
174.3, 174.2, 173.4, 172.5, 171.2, 169.5. Analytical HPLC (below). HRMS of peak eluting at 
1.78 min: Found [M + H
+
] 750.3667, C34H52N7O12 requires 750.3668: 
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H2N-Y-A-L-P-E-T-OMe 2.35 
 
BocHN-Y(OtBu)ALPE(OtBu)T-OH was synthesised on H-Thr-2-chloro-trityl resin (Sigma) 
following standard methods 1-3 (above) and cleaved from the resin using 30% 
hexafluoroisopropanol in DCM (2  3 mL). Following precipitation in cold ether (50 mL) and 
lyophilisation, the partially protected peptide (61 mg, 0.06 mmol) was converted to the methyl 
ester using iodomethane (18 mg, 0.127 mmol) and cesium carbonate (19.5 mg, 0.06 mmol) in 
dry DMF (0.5 mL). The reaction mixture was stirred at r.t., overnight under N2. The solvent was 
removed by evaporation to leave a yellow solid. The solid was dissolved in DCM (10 mL), 
washed with H2O (2  25 mL) and brine (2  25 mL), before being concentred to leave a clear 
oil. The oil was treated with a solution of TFA:H2O:TIS (95:2.5:2.5, 3 mL) for 1 h with stirring. 
The cleavage mixture was precipitated into cold ether (50 mL) and freeze dried to leave the 
titled white fluffy peptide (11.2 mg, 26%) 
1
H NMR (500 MHz, CD3OD):  = Y1: 4.03 (1H, dd, 
J-3 8.6 Hz, J-2 5.3 Hz, H), 3.18 (1H, dd, J2- 5.3 Hz, J 2-3 14.6 Hz, H2), 2.91 (1H, dd, J3- 
8.6 Hz, J 3-2 14.6 Hz, H3), 7.11 (2H, d, J1/2-1/2 8.5 Hz, H1/2), 6.77 (2H, d, J1/2-1/2 8.5 Hz, 
H1/2). A2: 4.47-4.42 (1H, m, H), 1.37 (3H, d, J2- 7.1 Hz, H2). L3: 4.66 (1H, dd, J3- 8.4 Hz, 
J2-2 6.0 Hz, H), 1.66-1.58 (2H, m, H2/3), 1.81-1.73 (1H, m, H), 0.99 (3H, d, J1- 6.6 Hz, 
H1), 0.99 (3H, d, J2- 6.6 Hz, H2). P4: 4.74-4.42 (1H, m, H), 2.25-2.06 (1H, m, H2) 2.05-
1.94 (1H, m, H3), 2.25-2.06 (1H, m, H2), 2.05-1.94 (1H, m, H3), 3.89-3.82 (1H, m, H), 3.70-
3.61 (1H, m, H). E5: 4.47-4.42 (1H, m, H), 2.25-2.06 (1H, m, H2), 2.05-1.94 (1H, m, H3), 
2.49-2.44 (2H, m, H2/3).T6: 4.47-4.42 (1H, m, H), 4.40 (1H, qd, J- 3.1 Hz, J-2 6.4 Hz, H), 
1.18 (3H, d, J2- 6.4 Hz, H2). OMe: 3.74 (1H, s, H). 
13
C NMR (125 MHz, CD3OD):  = Y1: 
55.8 (C), 37.8 (C), 126.0 (C), 131.6 (C), 116.9 (C), 158.3 (C). A2: 50.2 (C), 18.2 (C). L3: 
51.1 (C), 41.0 (C), 25.9 (C), 23.7 (C1), 21.9 (C2). P4: 61.5 (C), 26.0 (C), 30.4 (C), 48.7 
(C), E5: 54.2 (C), 28.2 (C), 31.1 (C). T6: 59.3 (C), 68.4 (C), 20.3 (C). OMe: 52.7 (C). 
CO (X 7): 176.7, 174.3, 174.3, 174.0, 173.4, 172.3, 169.5. Analytical HPLC (below). HRMS 
of peak eluting at 1.90 min: Found [M + H
+
] 707.3621, C33H51N6O11 requires 707.3610. 
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H2N-K(Dansyl)-Y-A-L-P-E-T-[G]-G-COOH 2.36 
 
Yield: 120 mg, 89% 
1
H NMR (500 MHz, CD3OD):  = Dansyl: 8.56 (1H, d, 8.5 Hz, Ar-H), 
8.37 (1H, d, 8.7 Hz, Ar-H), 8.20 (1H, d, 7.3 Hz, Ar-H), 7.64-7.57 (2H, m, Ar-H), 7.32 (1H, d, 
7.5 Hz, Ar-H), 2.92 (6H, s, N(CH3)2) K1: 3.76 (1H, app t, J-2/3 6.3 Hz, H), 1.78-1.69 (2H, m, 
H2/3), 1.78-1.69 (2H, m, H2/3), 1.78-1.69 (2H, m, H2/3), 2.91-2.77 (2H, m, H2/3). Y2: 4.67-4.60 
(1H, m, H), 3.10 (1H, dd, J2- 4.9 Hz, J 2-3 14.2 Hz, H2), 2.91-2.77 (1H, m, H3), 7.10 (2H, 
d, J1/2-1/2 8.5 Hz, H1/2), 6.70 (2H, d, J1/2-1/2 8.5 Hz, H1/2). A3: 4.42-4.37 (1H, m, H), 1.33 
(3H, d, J2- 7.1 Hz, H2). L4: 4.63-4.60 (1H, m, H), 1.64-1.54 (2H, m, H2/3), 1.80-1.68 (1H, 
m, H),  0.99 (6H, d, J1- 6.4 Hz, H1), 0.99 (6H, d, J2- 6.4 Hz, H2), P5: 4.42-4.37 (1H, m, H), 
2.23-2.03 (1H, m, H2) 2.02-1.92 (1H, m, H3), 2.23-2.03 (1H, m, H2), 2.02-1.92 (1H, m, H3), 
3.86-3.79 (1H, m, H), 3.69-3.59 (1H, m, H). E6: 4.42-4.37 (1H, m, H), 2.23-2.03 (1H, m, 
H2), 2.02-1.92 (1H, m, H3), 2.51-2.44 (2H, m, H2/3).T7: 4.58 (1H, d, J-2 3.2 Hz, H), 4.42-
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4.37 (1H, m, H), 1.20 (3H, d, J2- 6.4 Hz, H2). G8: 4.74-4.67 (2H, m, H2/3), G9: 3.94 (1H, d, 
J2-3 17.7 Hz, H2), 3.99 (1H, d, J3-2 17.7 Hz, H3).
13
C NMR (125 MHz, CD3OD):  = 
Dansyl:  152.5, 137.0, 131.0, 131.0, 130.9, 130.3, 129.2, 124.6, 121.0 (Ar-C), 46.0 (N(CH3)2). 
K1: 54.1 (C), 31.2 (C), 22.5 (C), 30.4 (C), 43.3 (C), 158.3. Y2: 56.5 (C), 37.9 (C), 128.8 
(C), 131.3 (C), 116.3 (C), 157.4 (C). A3: 50.2 (C), 18.1 (C). L4: 51.3 (C), 41.1 (C), 25.8 
(C), 23.7 (C1), 22.0 (C2). P5: 61.7 (C), 26.0 (C), 30.3 (C), 48.7 (C), E6: 54.3 (C), 28.0 
(C), 32.1 (C). T7: 59.5 (C), 68.5 (C), 20.0 (C). G8: 63.9 (C). G9: 41.5 (C).  CO (× 10): 
176.8, 174.6, 174.4, 174.2, 173.5, 173.3, 173.1, 172.6, 170.9, 170.1. Analytical HPLC (below). 
HRMS of peak eluting at 2.18 min: Found [M + Na
+
] 1191.4994, C54H76N10NaO17S  requires  
1191.5003. 
 
Fluorescein-GABA-L-P-E-T-[G]-G-COOH 2.37  
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Yield: 60 mg, 52% 
1
H NMR (500 MHz, CD3OD):  = Fluorescein: 8.24 (1H, s, Ar-H), 7.93-
7.78 (1H, m, Ar-H), 7.22 (1H, d, 8.2 Hz, Ar-H), 6.99-6.87 (2H, m, Ar-H), 6.85 (2H, s, Ar-H), 
6.75-6.60 (2H, m, Ar-H) GABA1: 2.37 (2H, app t, J-2/3 6.9 Hz, H), 2.11-1.91 (2H, m, H2/3), 
3.78-3.58 (2H, m, H2/3) L2: 4.66 (1H, dd, J-2 9.8 Hz, J-3 4.7 Hz  H), 1.67-1.56 (2H, m, 
H2/3), 1.82-1.69 (2H, m, H2/3), 0.98 (3H, d, J1- 6.4 Hz, H1), 0.97 (3H, d, J2- 6.4 Hz, H2). 
P3: 4.49-4.38 (1H, m, H), 2.11-1.91 (2H, m, H2/3), 2.26-2.11 (1H, m, H), 2.11-1.91 (1H, m, 
H) 3.90-3.83 (1H, m, H), 3.72-3.58 (1H, m, H), E4: 4.49-4.38 (1H, m, H), 2.26-2.11 (1H, 
m, H), 2.26-2.11 (1H, m, H), 2.45 (2H, app t, J- 7.5 Hz H) T5: 4.58 (1H, d, J- 7.5 Hz 
H), 4.49-4.38 (1H, m, ), 1.21 (3H, d, J- 7.5 Hz, H)  G8: 4.70 (2H, s, H2/3) G9: 3.99 (1H, 
d, J2-3 17.7 Hz H2), 3.94 (1H, d, J3-2 17.7 Hz H3),
13
C NMR (125 MHz, CD3OD):  = 
Fluorescein: 155-103 broad signals (Ar-C) GABA1: 44.0 (C), 26.1 (C) 45.4 (C), L2: 51.5 
(C), 41.5 (C), 26.0 (C), 23.6 (C1), 21.8 (C) P3: 61.8 (C), 26.1 (C), 30.3 (C), 48.4 (C), 
E4: 54.3 (C), 28.0 (C), 31.2 (C). T5: 59.5 (C), 68.6 (C), 20.0 (C), G6: 63.9 (C), G7: 40.8 
(C).  CO and CS: 183-170 broad signals. Analytical HPLC (below). HRMS of peak eluting 
at 2.57 min: Found [M + H
+
] 1048.3594, C49H57N7O17S  requires 1048.3604. 
 
H2N-G-L-S-D-Y-G-COOH 2.39 
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Yield: 40 mg, 60% 
1
H NMR (500 MHz, D2O):  = G1: 3.95-3.79 (2H, m, H2/3), L2: 4.41 (1H, 
dd, J-2 5.5 Hz, J-3 9.2 Hz, H), 1.75-1.59 (2H, m, H2/3), 1.75-1.59 (1H, m, H) 0.96 (3H, d, 
J-y 6.2 Hz, H), 0.92 (3H, d, J-y 6.2 Hz, H)  S3: 4.48 (1H, app t, J-2/3 5.6 Hz, H) 3.95-
3.79 (2H, m, H2/3), D4: 4.67 (1H, dd, J-2  5.6 Hz, J-3 7.8 Hz, H), 2.78 (1H, dd, J2- 5.6 Hz, 
J-3 16.7 Hz, H), 2.69 (1H, dd, J3- 7.8 Hz, J-2 16.7 Hz, H), Y5: 4.64 (1H, dd, J-2 5.9 
Hz, J-3 8.9 Hz, H), 3.16 (1H, dd, J2- 5.9 Hz, J2-3 14.1 Hz, H2), 2.95 (1H, dd, J3- 8.9 Hz, 
J3- 14.1 Hz, H3), 7.17 (2H, d, J1/2-1/2 8.6 Hz, H1/2), 6.88 (2H, d, J1/2-1/2 8.6 Hz, H1/2). G6: 
3.95-3.79 (2H, m, H2/3).
13
C NMR (125 MHz, D2O):  = G1: 42.2 (C). L2: 52.9 (C), 39.8 (C) 
24.3 (CCC S3: 55.3 (C) 60.9 (C) D4: 50.7 (C), 36.1 (C), Y5:  55.0 (C), 
36.3 (C), 128.3 (C), 130.5 (C), 115.5 (C), 154.4 (C). G6: 40.4 (C). CO (× 7): 175.2, 174.8, 
174.5, 172.9, 172.1, 171.3, 167.3. Analytical HPLC (below). HRMS of peak eluting at 1.56 
min: Found [M + Na
+
] 633.2463, C26H38N6O11Na requires 633.2491. 
 
H2N-G-T-G-R-Y-G-COOH 2.40 
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Yield: 36 mg, 53% 
1
H NMR (500 MHz, D2O):  = G1: 4.01-3.91 (2H, m, H2/3), T2: 4.46 (1H, 
d, J-2 3.9 Hz, H), 4.30 (1H, qd, J1- 3.9 Hz, J2- 6.4 Hz, H1), 1.27 (1H, dd, J- 6.4 Hz, H) 
G3: 4.01-3.91 (2H, m, H2/3)  R4: 4.44 (1H, app t, J-2/3  7.2 Hz, H), 1.70-1.63 (2H, m, H2/3), 
1.47-1.39 (2H, m, 2/3), 3.13 (2H, app t, J-y2/3  7.2 Hz  ), Y5: 4.70 (1H, dd, J-3 9.3 Hz, J-2 
5.9 Hz, H), 3.20 (1H, dd, J2- 5.9 Hz, J2-3 14.0 Hz, H2), 2.94 (1H, dd, J3- 9.3 Hz, J3-2 14.0 
Hz, H3), 7.19 (2H, d, J1/2-1/2 8.1 Hz, H1/2), 6.87 (2H, d, J1/2-1/2 8.1 Hz, H1/2). G6: 4.01-3.91 
(2H, m, H2/3)
13
C NMR (125 MHz, D2O):  = G1: 42.4 (C). T2: 59.1 (C), 67.1 (C) 18.6 (C. 
G3: 41.4 (C) R4: 53.6 (C), 28.9 (C), 24.0 (C) 40.4 (C). Y5:  54.6 (C), 36.0 (C), 128.3 
(C), 130.6 (C), 115.4 (C), 154.4 (C). G6: 40.5 (C). CO (× 6): 173.4, 173.3, 173.3, 172.4, 
171.3, 167.3 (CNH): 156.7. Analytical HPLC (below). HRMS of peak eluting at 1.26 min: 
Found [M + H
+
] 610.2958, C25H40N9O9 requires 610.2944. 
 
Hydrazine-GABA-L-P-E-T-[G]-T-OH 4.15 
 
H2N-(GABA)-LPET[G]T-OH was synthesised on H-Thr-2-chloro-trityl resin and isolated 
(Sigma) using standard SPPS methods (listed above). The lyophilised peptide (9.5 mg, 0.014 
mmol) was dissolved in DMF (0.5 mL) before NEt3 (3.9 L, 0.028 mmol) and 2,5-Dioxo-1-
pyrrolidinyl 6-(isopropylidenehydrazino)nicotinate 4.4 (7.5 mg, 0.025 mmol) were added. The 
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reaction mixture was stirred at r.t. for 4 hours and concentrated before the hydrazone-linked 
product was isolated using mass-directed HPLC. The HPLC fractions were combined and 
lyophilised to leave 4.15 as a white fluffy peptide (5 mg, 43%). Analytical HPLC (below). 
HRMS of peak eluting at 1.77 min: Found [M + H
+
] 838.3920, C36H56N9O14 requires 838.3941. 
 
Alkyne-G-Y-L-P-E-T-[G]-G-OH 4.31 
 
H2N-GLPET[G]G-OH was synthesised on H-Gly-2-chloro-trityl resin and isolated (Sigma) 
using standard SPPS methods (listed above). The lyophilised peptide (21 mg, 0.028 mmol) and 
a diastereomeric mixture of (1R,8S,9r)-Bicyclo[6.1.0]non-4-yn-9-ylmethyl (4-nitrophenyl) 
carbonate 4.26 (14 mg, 0.043 mmol) were dissolved in DMF (2 mL) before NEt3 (6 L, 0.043 
mmol) was added. The reaction mixture was stirred at r.t. overnight before being concentrated 
to leave an oil that was purified using mass-directed HPLC. The HPLC fractions were combined 
and lyophilised to leave 4.31 as a white fluffy peptide (7 mg, 26%). Analytical HPLC (below). 
HRMS of peak eluting at 3.14 min: Found [M + H
+
] 970.4407, C46H64N7O16 requires 970.4404. 
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Alkyne-K(FITC)-Y-L-P-E-T-[G]-G-OH 4.37 
 
H2N-K(FITC)YLPET[G]G-OH was synthesised on H-Gly-2-chloro-trityl resin and isolated 
(Sigma) using standard SPPS methods (listed above). The lyophilised peptide (10 mg, 0.008 
mmol) and a diastereomeric mixture of (1R,8S,9r)-Bicyclo[6.1.0]non-4-yn-9-ylmethyl (4-
nitrophenyl) carbonate 4.26 (3.5 mg, 0.0011 mmol) were dissolved in DMF (2 mL) before NEt3 
(1.6 L, 0.011 mmol) was added. The reaction mixture was stirred at r.t. for 6.5 h before an 
additional equivalent of both NEt3 and the diastereomeric mixture of (1R,8S,9r)-
Bicyclo[6.1.0]non-4-yn-9-ylmethyl (4-nitrophenyl) carbonate 4.26 were added. After stirring 
overnight at r.t., the reaction mixture was concentrated and the resulting oil purified by mass-
directed HPLC. The HPLC fractions were combined and lyophilised to leave 4.37 as a white 
fluffy peptide (3.8 mg, 33%). Analytical HPLC (below). HRMS of peak eluting at 2.72 and 
2.97 min: Found [M + 2H
+
] 715.7786, C71H85N9O21S requires 715.7785. 
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6.2 Biological material and methods 
6.2.1 Instrumentation and materials. 
Sterilisation of media, buffers and appropriate equipment was achieved using either a Prestige 
Medical bench top autoclave or a LTE Touchclave-R autoclave. Thermo Electron Corporation 
SAFE 2010 Class II laminar flow cabinet or a bench-top bunsen burner were used to maintain a 
sterilise environment. Bacterial cultures were incubated in a Kuhner ShakerX ISF1-X or Stuart 
Orbital Incubator. LB-agar plates and small scale assays were incubated in a Binder BD23 
incubator.  
Centrifugation was performed using either a Beckman Coulter™ Avanti™ J-30I Centrifuge, a 
Heraeus multifuge 3 S-R centrifuge or a Heraeus pico centrifuge. Lactose affinity and size 
exclusion chromatography was achieved using a GE Pharmacia ÄKTA FPLC system. 
Spectrophotometric readings were measured using either a Thermo scientific Nanodrop 2000 or 
WPA Biowave II spectrometer. SDS-PAGE and agarose electrophoresis was performed using a 
Bio-Rad mini protean 3 apparatus and SCIE-PLAS Midi Horizontal Unit respectively. BIO 
RAD molecular imager
R 
Gel Doc
TM
 XR was used to visualise both the agarose and 
polyacrylamide gels using a combination of UV and white light. Protein concentrations were 
conducted using either a 10k or 30k MWCO Amicon® Ultra-15Centrifugal Filter Device. 
Dialysis was accomplished using SnakeSkin® pleated dialysis tubing (Thermo Scientific, 7k 
MWCO). 
Mass spectrometry analysis of proteins was done using a using a Bruker HCT Ultra MS system 
equipped with an Agilent 1200 series autosampler. Protein samples were loaded directly into the 
instrument before they were automatically diluted into 0.1% TFA/50% MeCN (v/v) in H2O prior 
mass spectrometry analysis.  
Analytical grade reagents were supplied by Sigma-Aldrich, Fisher Scientific, Melford 
laboratories and VWR International. 
Mammalian cell culture manipulations were performed inside a Thermo Scientific MSC-
Advantage Class II Biological Safety Cabinet. A Sanyo CO2 cell culture incubator was used to 
grow the cells  Florescence microscopy analysis of mammalian cell culture slides was 
performed using a Zeiss LSM700 inverted confocal microscope coupled with ZEN imaging 
software. Wavelengths at 408 nm, 488 nm and 555 nm were used to excite the DAPI, Alexa 
fluor 555 and fluorescein fluorophores respectively. Primary and secondary antibodies for 
immunofluorescence were supplied by either Millipore or Invitrogen 
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6.2.2 Buffer solutions and media for biochemistry  
All solutions were made up to 1 L, unless otherwise stated, with 18.2 MΩ purified water. The 
pH of the solutions were adjusted using 1M NaOH and/or 4M HCl  
Standard buffers  
TRIS buffer I (pH 7.2): 150 mM NaCl (8.7 g), 50 mM tris(hydroxymethyl)aminomethane (Tris, 
6.1 g) and 10 % (v/v) glycerol  
TRIS buffer II (pH 7.8): 1.25 M NaCl (72.5 g), 25 mM Tris (3.1 g) and 25 mM CaCl2 (2.8 g) 
TRIS buffer III (pH 7.8): 1.25 M NaCl (72.5 g), 25 mM Tris (3.1 g) and 2.5 mM 
Ethylenediaminetetraacetic acid (EDTA, 0.73 g)  
TRIS buffer IV (pH 8.0): 50 mM Tris (6.1 g) and 1 mM -mercaptoethanol (BME, 68 L)  
TRIS buffer V (pH 8.0): 150 mM NaCl (8.7 g), 50 mM Tris (6.1 g) and 1 mM BME (68 L) 
HEPES buffer (pH 7.5): 50 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES, 
11.9 g) 200 mM NaCl (11.6 g), and 5mM CaCl2 (0.55 g) 
Bacteria growth media components   
20 × NPSC (100 mL, pH 6.8): 443 mM NH4Cl (2.35 g), 227 mM Na2SO4 (3.22 g), 500 mM 
KH2PO4 (6.8 g) and 500 mM Na2HPO4 (7.1 g). The solution was autoclaved for 20 minutes at 
121 °C.    
50 × 5052 (100 mL): 2.7 M Glycerol (25 g), 138 mM glucose (2.5 g) and 292 mM α-lactose (10 
g). The solution was heated in microwave until all the solids had dissolved before being filtered 
(0.20 m) into a sterile container.   
1000 × Metals Stock (100 mL): 50 mM FeCl3.6H2O (1.35 g), 20 mM CaCl2.6H2O (438 mg), 
100 mM MnCl2.4H2O (198 mg), 100 mM ZnSO4.7H2O (288 mg), 1.7 mM CoCl2.6H2O (47.6 
mg), 2 mM CuCl2.2H2O (34.1 mg), 4.1 mM Na2MoO4.2H2O (48.8 mg), 2 mM Na2SeO3 (34.6 
mg), 2 mM H3BO3 (12.4 mg), 2 mM NiSO4.6H2O (52.6 mg) and 60 M HCl. 
50 × Salts Stock (500 mL): 1.25 mM Na2HPO4 (88.7 mg), 1.25 mM KH2PO4 (85 mg), 2.5 mM 
NH4Cl (67 mg) and 250 mM Na2SO4 (17.8 g)     
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Bacterial growth media 
Auto Inducing media: Tryptone (10 g), yeast extract (5 g), 50 × salts (20 mL), 1000 × metals 
(200 l), 2 mM MgCl2 (48 mg) and 0.5% (v/v) glycerol (10 ml from a 50% (v/v) glycerol stock). 
The solution was autoclaved for 20 minutes at 121 °C before the remaining components of 
0.05% (w/v) glucose (1 ml from a 50% (v/v) glucose stock) and 0.2% (w/v) lactose (4 ml from a 
50% (v/v) lactose stock) solutions (sterile filtered, 0.2 m Sartorius Minisart) and ampicillin 
(100 g/mL) were added. 
Lysogeny broth (LB): Tryptone (10 g), 172 mM NaCl (10 g) and Yeast Extract (5 g). The 
solution was autoclaved for 20 minutes at 121 °C. 
Buffers for DNA analysis and manipulations    
50 × TAE Buffer: 2 M Tris-HCl (314 g), concentrated acetic acid (57.1 mL) and EDTA (0.5 M 
at pH 8.0, 100 mL) 
6 × Agarose electrophoresis loading buffer (10 ml, pH 7.6): 15% (w/v) Ficoll 400, 66 mM 
EDTA (193 mg), 19.8 mM Tris-HCl (31 mg), 0.12% (w/v) SDS and 0.9% (w/v) Orange G.  
10 × EcoRI buffer (10 mL, pH 7.5): 1 M Tris-HCl (1.57 g), 500 mM NaCl (292 mg), 100 mM 
MgCl2 (95 mg) and 0.25% (v/v) Triton X-100  
10 × Ligase Buffer (10 mL pH 7.5): 500 mM Tris-HCl (7.85 g), 100 mM MgCl2 (95 mg) 10 mM 
adenosine triphosphate  (ATP, 55 mg) and 100 mM dithiothreitol (DTT, 154 mg)  
Buffers and solutions for protein analysis  
SDS-PAGE loading buffer (10 mL, pH 6.8): 50 mM Tris-HCl (61 mg), 2% (w/v) SDS, 200 mM 
DTT (0.31 mg), 10% (v/v) glycerol, bromophenol blue (2 mg) and water (7.2 mL). 
5× SDS-PAGE running buffer: 125 mM tris base (15.15 g), 960 mM glycine (72.1 g) and 0.5% 
(w/v) SDS  
Coomassie stain: Coomassie G250, 40% (v/v) methanol and 10% (v/v) acetic acid  
Coomassie destain: 40% (v/v) methanol and 10% (v/v) acetic acid 
129 
6.2.3 Molecular biology  
6.2.3.1 Subcloning of the SrtA gene into Pet28A 
The SrtA gene was subcloned from the pETMCS-III plasmid donated by Dr. C. Neylon 
(University of Southampton) into a pET28a plasmid using the molecular biology techniques 
described below.    
Restriction digest 
Insert preparation - A restriction digest was used to extract the SrtA gene from the pETMCS-III 
plasmid. The plasmid DNA (5 L) was added to a solution of EcoRI (1 L, 20 U), NdeI (1 L, 
20 U), 10 × EcoRI buffer (2 L) and sterile water (11 L). The reaction mixture was incubated 
at 37 °C for 1.5 h before the digested DNA was isolated by agarose gel electrophoresis and 
purified using a QIAquick Gel Extraction Kit.  
Vector preparation - The pET28a vector was prepared for DNA ligation using a slightly 
modified restriction digest procedure. The plasmid DNA (5 L) was added to a solution of 
EcoRI (1 L, 20 U), NdeI (1 L, 20 U), 10 × EcoRI buffer (2 L) and sterile water (11 L). 
The reaction mixture was incubated at 37 °C for 1 h before calf-intestinal phosphatase (1 L, 10 
U) was added. The incubation was continued at 37 °C for an additional hour before the 
linearised plasmid was isolated and purified as previously described.  
DNA ligation 
The SrtA gene insert and linear pET28a vector were ligated together to form a pET28a-I hybrid 
plasmid using the following procedure. A ligation mixture was prepared over ice using the 
linear plasmid vector (50 ng), gene insert (3:1 molar ratio of insert to vector), 10 × ligase buffer 
(1 µL), T4 ligase (1 µL, 20 U) and H2O to make a total volume of 10 mL. The reaction mixture 
was incubated at 4 °C overnight before being transformed into chemically competent E. coli 
XL10 cells. 
DNA transformation  
Freshly thawed chemically competent E. coli XL10 cells (5 mL) were held on ice for 10 
minutes before the ligation mixture (2 mL) was added and thoroughly mixed. The 
transformation mixture was incubated on ice for 20 minutes before being heated to 42 °C for 45 
seconds and immediately returned to the ice for a further 10 minutes. LB media (900 l) was 
added and the solution was incubated with shaking at 37 °C for 1 h. A sample of the culture 
(100 l) was used to inoculate an LB-agar plate containing kanamcyin (50 mg/ml). The 
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remaining culture was centrifuged at 13 × kg for 1 minute and the excess supernatant was 
discarded. The cell pellet was resuspended in the residual supernatant (100 L) and applied to 
another LB-agar plate containing kanamcyin (50 mg/ml). The LB-agar plates were incubated at 
37 °C overnight. 
A single colony from the LB-agar plates was used to inoculate LB media (5 ml) containing 
kanamcyin (50 g/ml). The mini culture was incubated at 37 °C overnight before an aliquot (0.5 
ml) was mixed with 80% (v/v) glycerol and stored at -80 °C as a cell stock. The remaining 
culture was centrifuged at 10 × kg for 10 minutes, the supernatant discarded and the cell pellet 
retained for DNA analysis.  
DNA purification and sequence determination     
The DNA was extracted from the bacterial cell pellet using a QIAprep Spin Mini Prep Kit and 
sequenced by GATC Biotech. The results were analysed by BioEdit sequence alignment editor 
ClustalW,
175
 which confirmed the transformed pET28a-I plasmid contained the SrtA gene. The 
pET28a-I plasmid was extracted from the frozen stock of E. coli XL10 cells and transformed 
into E. coli BL21-Gold (DE3) cells for protein overexpression.  
6.2.3.2 DNA analysis     
DNA concentrations   
The DNA concentration and yield were estimated using Equation 6.1 and the absorbance 
measurements at 260 nm and 320 nm. 
                                        
    
                                              
Agarose gel electrophoresis 
The purity of plasmid and digested DNA was assessed using agarose gel electrophoresis. 
Agarose gels (1.2% w/v) were prepared by dissolving agarose (380 mg) in TEA buffer (40 mL) 
using microwave assisted heating for 1-2 minutes. The solution was allowed to cool for 5-10 
minutes before ethidium bromide (1.2 µL, 0.3 g / ml) was added and mixed. The solution was 
then immediately poured into a mould and a comb added before the gel was left to set. DNA (5 
L) was mixed with 6 × loading buffer (1 µL) and loaded onto the gel. Electrophoresis was 
 Equation 6.1: DNA concentration and yield calculations. A260 and A320 is the absorbances at 
260 nm and 320 nm respectively  
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performed at 100 V for approximately 20 min in TAE buffer. Gels were then visualised under 
UV light using the Gel Doc system. 
6.2.4 Protein overexpression, purification and analysis  
6.2.4.1 Sortase overexpression from E. coli   
A single colony of E. coli BL21-Gold (DE3) cells harbouring the pET28a-SrtA plasmid was 
used to inoculate LB media (5 mL, 50 g/mL kanamycin). The starter culture was incubated at 
37 °C for 18 h before 1 mL was added to auto-inducing media (1 L, 50 g/mL kanamycin). The 
culture was grown at 37 °C for 24 h and the cells isolated by centrifugation (10 × kg, 10 min), 
the supernatant discarded and the bacterial pellet stored at -80 °C.  
The frozen bacteria pellet was resuspended in Tris buffer I (10 mL) containing DNase I (5,000 
units/mL) at 0 °C. The suspension was mechanically disrupted using a Constant Systems Cell 
Disruptor (20 kpsi, 10 mL injections, 4 °C), the lysate cleared by centrifugation (30 × kg, 45 
minutes), the pellet discarded and the supernatant passed down a nickel affinity column 
(Qiagen, 10 ml) pre-equilibrated in Tris buffer I . The column was washed sequentially with 
Tris buffer I  (5 × CV) and Tris buffer I supplemented with 50 mM imidazole (5 × CV) before 
the protein was eluted with Tris buffer I containing 500 mM imidazole (5 × CV). Protein-
containing fractions were identified by SDS-PAGE and concentrated to a total volume of 1 mL 
by centrifugal concentration at 4 °C. The protein solution was applied to a Superdex 200 26/60 
size-exclusion column and isocratically eluted into HEPES buffer before the purity of the 
isolated SrtA protein was analysed by SDS-PAGE (Figure 6.1). The protein concentration was 
measured by UV spectroscopy at 280 nm using a theoretical extinction molar coefficient of 
17420 M
-1 
cm
-1
.
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Figure 6.1: a) Chromatogram from the gel filtration of SrtA.  b) Polyacrylamide gel (10%) of 
fractions recovered from the gel filtration indicates that both peaks are SrtA. c) ESMS 
spectrum of SrtA (Charge-states only partially labelled for clarity). Calculated molecular 
weight (23029 Da) is 131 Da higher than observed mass due to loss of N-terminal methionine 
residue during E. coli protein expression.   
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6.2.4.2 hMBL overexpression from E. coli   
A frozen glycerol stock of E. coli Gold (DE3) cells harbouring the hMBP302 expression vector 
was used to inoculate LB media (5 mL, 100 g/mL ampicillin). The starter culture was 
incubated at 37 °C for 18 h before 1 mL was added to LB media (100 mL, 100 g/mL 
ampicillin), which was then grown at 30 ºC overnight before 20 mL was added to LB media (1 
L, 100 g/mL ampicillin). After 3.5 h at 24.5 ºC, expression was induced by addition of IPTG 
(10 mg, 40 M) and 1M CaCl2 (100 mL). After incubation overnight at 24.5 ºC, the cells were 
isolated by centrifugation at (10 kg, 15 min) and stored at −80 ºC.  
The frozen cell pellet was resuspended in Tris buffer II (10 mL) and mechanically disrupted 
using a Constant Systems Cell Disruptor (25 kpsi, 4 ºC). The lysate was cleared by 
centrifugation (35 × kg,  45 min) and the supernatant filtered (0.8 m filter, Sartorius Minisart) 
before loading onto a lactose-sepharose 6B affinity column (10 mL) equilibrated with Tris 
buffer II.  The column was washed with Tris buffer II (5 × CV) before the protein was eluted 
with Tris buffer III (5 × CV). Protein-containing fractions were identified by SDS-PAGE, 
combined, concentrated by centrifugal concentration at 4 °C and extensively dialysed into Tris 
buffer II. The protein concentration was measured by UV spectroscopy at 280 nm using a 
theoretical extinction molar coefficient of 25230 M
-1 
cm
-1 
 
6.2.4.3 MBP-AB5 overexpression from E. coli   
A frozen glycerol stock of E. coli BL21 Gold cells harboring the pSAB2.1 plasmid was used to 
inoculate LB media (5 mL, 100 g/mL ampicillin). The starter culture was incubated at 37 °C 
for 18 h before 2.5  ml was added to LB media (1 L, 100 g/mL ampicillin), which was then 
grown at 37 °C. Protein overexpression was induced once the OD600 had reached ~ 0.6 with the 
addition IPTG (1ml, 300 mM). Incubation was continued for 20 h at 30 °C before the cells were 
isolated by centrifugation (10 × kg, 10 min), the cell pellet discarded and the supernatant 
retained. 
The supernatant was filtered (0.8 m filter, Sartorius Minisart) and passed down an amylose 
column to capture MBP-AB5 and uncomplexed MBP-CTA2 proteins. The column was washed 
with HEPES buffer (5 × CV) and the proteins eluted with HEPES buffer supplemented with 10 
mM maltose (5 × CV). Protein-containing fractions were identified by SDS-PAGE and applied 
to either a Nickel (Qiagen) or lactose (resin supplied by Sigma) affinity columns to isolate the 
MBP-AB5 complex. 
134 
Nickel affinity purification: The column was washed sequentially with HEPES buffer (5 × CV) 
and HEPES buffer supplemented with 25 mM imidazole (5 × CV) before the protein was eluted 
with HEPES buffer containing 500 mM imidazole (5 × CV).  
Lactose affinity purification: The column was washed with HEPES buffer (5 × CV) and the 
protein eluted with HEPES buffer containing 300 mM lactose (5 × CV).  
The protein solution was concentrated to a total volume of 1 mL by centrifugal concentration at 
4 °C before it was extensively dialysed into HEPES buffer at 4 °C. The purity of the isolated 
protein was determined by SDS-PAGE and the concentration measured by UV spectroscopy at 
280 nm using a theoretical extinction molar coefficient of 128120 M
-1 
cm
-1  
6.2.4.4 MBP-TEV overexpression from E. coli   
A single colony of E. coli BL21-Gold (DE3) cells harbouring the pMAL-MBP-TEV plasmid 
was used to inoculate LB media (5 mL, 100 g/mL ampicillin). The starter culture was 
incubated at 37 °C for 18 h before 3 ml was added to LB media (1 L, 100 g/mL ampicillin), 
which was then grown at 37 °C. Protein overexpression was induced once the OD600 had 
reached ~ 0.7 with the addition IPTG (1ml, 500 mM). Incubation was continued for 20 h at 20 
°C before the cells were isolated by centrifugation (10 × kg, 10 min), the supernatant discarded 
and the cell pellet retained.  
The frozen bacteria pellet was resuspended in Tris buffer IV (10 mL) at 0 °C. The suspension 
was mechanically disrupted using a Constant Systems Cell Disruptor (20 kpsi, 10 mL injections, 
4 °C), the lysate cleared by centrifugation (30 × kg, 45 minutes), the pellet discarded and the 
supernatant passed down a Amylose affinity column (Qiagen, 20 ml) equilibrated in Tris buffer 
IV . The column was washed with Tris buffer IV (5 × CV) and the protein eluted with Tris buffer 
V containing 10 mM Maltose (5 × CV). Protein-containing fractions were identified by SDS-
PAGE and concentrated to a total volume of 1 mL by centrifugal concentration at 4 °C. The 
protein solution was applied to a size-exclusion column and isocratically eluted into Tris buffer 
V before the purity of the isolated SrtA was analysed by SDS-PAGE. The protein concentration 
was measured by UV spectroscopy at 280 nm using a theoretical extinction molar coefficient of 
98329 M
-1 
cm
-1 
 
6.2.4.5 Protein analysis  
Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE). 
BioRad tetragel apparatus was used to determine the purity and size of proteins. A resolving gel 
of appropriate percentage was prepared using the materials listed in Table 6.1. After the 
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TEMED was added the solution was thoroughly mixed and immediately added to the apparatus 
before n-butanol (0.5 mL) was loaded onto the top of the gel. Once the resolving gel had set the 
n-butanol was carefully removed with H2O and a stacking gel (5%) was prepared using the 
materials listed in Table 6.1. After the TEMED was added the solution was thoroughly mixed 
and immediately applied to the top of the resolving gel. A comb with a suitable number of lanes 
was inserted into the stacking gel layer before it set 
 
Components  
Resolving gel 
 Volume / mL 
Stacking gel 
 Volume / mL 
10% 12% 15% 5% 
H2O 4 3.2 2.3 2.45 
30 % acrylamide/bisacrylamide mix (37:5:1)  3.3 4 5 0.67 
1.5 M Tris (pH 8.8) 2.5 2.5 2.5 N/A 
1 M Tris (pH 6.8) N/A N/A N/A 0.75 
10%  Sodium dodecyl sulfate (SDS) 0.1 0.1 0.1 0.04 
20% or 10%  Ammonium persulfate (APS) 0.1 0.1 0.1 0.04 
Tetramethylethylenediamine (TEMED) 0.005 0.005 0.005 0.005 
Once the gel had set it was sequestered inside an electrophoresis tank, submerged in an 
optimum volume of SDS running buffer and the comb was removed. Protein samples (10 l) 
were mixed with an equal volume of loading buffer, heated to 95 °C for 10 minutes and applied 
to the lanes on the gel. However, unless AB5 proteins are specifically referred to as “boiled” in 
gel figures the samples were not heated prior to application, but instead immediately loaded 
onto the gel. Electrophoresis was performed between 100-180 V until the blue loading buffer 
could be seen to reach the bottom of the gel. The gel was submerged in Coomassie Blue stain 
overnight before being treated with Coomassie destain for 2-4 h to allow visualisation of the 
protein bands. Alternatively, the gel was incubated directly with Instant Blue Stain (TripleRed) 
for 30 minutes to visualise the protein bands. The stained gel was either imaged straight away 
using or stored for longer periods in H2O. Gels containing fluorescently labelled protein 
samples were imaged prior to staining. 
Protein concentrations 
Protein concentrations were determined using the Beer-Lambert law (Equation 6.2) and the 
absorbance measurement at 280 nm. Expasy ProtParam was used to calculate the theoretical 
molar extinction coefficient for all individual proteins 
Table 6.1: Stacking and resolving gel components for SDS-PAGE analysis. 
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6.2.5 Sortase-mediated chemical ligations 
6.2.5.1 Model peptide ligations  
General procedure for HPLC assay 
All stock solutions were prepared in HEPES buffer at the following concentrations:  Acyl 
acceptor 2.8 (8 mM), acyl donor 2.5, 2.7, 2.24, 2.25 or 2.35 (2 mM), and SrtA (304 M). 
Typical procedure for HPLC assay (1:1 ratio) 
For a total volume of 200 L in the ratio 1:1, acyl acceptor (25 L, 500 M), acyl donor (50 L, 
500 M), SrtA (7.5 L, 11.5 M) and HEPES buffer (117.5 L) were added to a tapered HPLC 
vial. The solution was mixed thoroughly and capped before being immediately incubated at 37 
°C, in the auto loader of a Agilent technologies 1290 HPLC, fitted with Ascentis es-C18 (10 cm 
 2.1 mm, 2.7 m) column.  
Each 5 L sample was injected and analysed using a linear gradient (5% H2O, 0.5% TFA in 
MeCN to 95% H2O, 0.5%TFA over 6.5 min. Typically 5 reactions were assayed in parallel: 
each reaction mixture was prepared in the final 3 minutes of the 1
st
 analysis of the previous 
reaction mixture. After every five analyses, 20 L of water was injected onto the column and 
the column washed with 95% H2O, 5% MeCN, 0.5% TFA for 2.5 min to remove any residual 
peptides prior to the subsequent analyses. The HPLC analysis was carried out over a 9 h period 
(16 analyses per sample). Integrated traces were normalised using the peak intensity for SrtA 
(retention time: 2.2 min).  
 
 
 
 
 
Equation 6.2: Beer-Lambert Law. A = absorbance, ε = molar extinction coefficient (mol-1 cm1), 
c = concentration (mol) and l = path length (cm). 
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 Sample HPLC for typical ligation assay 
 
6.2.5.2 Protein labelling and purification 
General procedure  
SrtA, proteins and depsipeptides stocks were prepared in HEPES buffer.  
 SrtA (10-30 mol%), protein (1 equivalent) and depsipeptide substrate (1.5-5 equivalents) were 
mixed together in the desired volume of HEPES buffer, typically 50-500 L. The ligation 
mixture was incubated with agitation at 37°C for 4-6 h or until ligation was complete. The 
reaction progress was monitored every 2-3 h by ESMS and if necessary additional depsipeptide 
substrate (1.5-5) was added to the reaction mixture to ensure complete modification of proteins.     
Typical procedure for hMBL labelling  
Labelling with dansyl-depsipeptide 2.36: For a total volume of 100 L, hMBL (50 L, 60 M), 
depsipeptide 2.36 (9 L, 90 M, 1.5 equivalents), SrtA (2 L, 6 M, 10 mol%). and HEPES 
Figure 6.2: Sample HPLC for typical SrtA ligation assay between acyl donor 2.5 and acyl 
acceptor 2.8 to form ligated product 2.9. 
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buffer (39 L) were together mixed thoroughly and incubated at 37 °C for 4 h. The reaction was 
monitored by ESMS and SDS-PAGE.  
Labelling with fluorescein-depsipeptide 2.37: For a total volume of 20 L, hMBL (17.5 L, 60 
M), depsipeptide 2.37 (1.25 L, 120 M, 2 equivalents) and SrtA (1.25 L, 9 M, 15 mol%.) 
were together mixed thoroughly and incubated at 37 °C. After 4 h an additional 0.63 L of 
depsipeptide 2.37  (1 mol equivalent) was added and the incubation continued for a further 1.5 
h. The reaction was monitored by ESMS and SDS-PAGE. 
Typical procedure for Mouse pumilio labelling  
Labelling with dansyl-depsipeptide 2.36: For a total volume of 15 L, Mouse pumilio (11 L, 
19 M), depsipeptide 2.36 (1.8 L, 60 M, 3 equivalents), SrtA (0.36 L, 7.2 M, 36 mol%) 
and HEPES buffer (1.9 L) were together mixed thoroughly and incubated at 37 °C for 4 h. The 
reaction was monitored by ESMS and SDS-PAGE.  
Typical procedure for CTA2-AB5 labelling 
Labelling with dansyl-depsipeptide 2.36: For a total volume of 20 L, CTA2-AB5 (17.6 L, 44 
M), depsipeptide 2.36 (1.4 L, 71 M, 1.6 equivalents) and SrtA (1 L, 3.8 M, 9 mol%) 
were mixed together thoroughly and incubated at 37 °C for 3 h. The reaction was monitored by 
ESMS. 
Labelling with fluorescein-depsipeptide 2.37: For a total volume of 250 L, CTA2-AB5 (200 
L, 43 M), depsipeptide 2.37 (11.2 L, 90 M, 2 equivalents), SrtA (4.2 L, 5 M, 12 mol%) 
and HEPES buffer (34.5 L) were mixed together thoroughly and incubated at 37 °C for 2 h. 
The reaction was monitored by ESMS. When this reaction has been repeated it has taken 
anywhere between 2-5 equivalents of depsipeptide, 10-30 mol% of SrtA and 3-6 h to 
achieve complete protein modification.   
Labelling with alkyne depsipeptide 4.31: For a total volume of 126 L, CTA2-AB5 (100 L, 56 
M), depsipeptide 4.31 (17.4 L, 138 M, 2.5 equivalents) and SrtA (8.5 L, 11 M, 20 mol%) 
were mixed together thoroughly and incubated at 37 °C for 3 h. The reaction was monitored by 
ESMS. When the reaction has been repeated it has taken anywhere between 2-5 
equivalents of depsipeptide, 10-20 mol% of SrtA and 2-5 h to achieve complete protein 
modification.   
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Purification of labelled CTA2-AB5 proteins  
Once the protein had been completely modified it was immediately purified using either Nickel 
or lactose affinity chromatography. 
Nickel affinity purification: The column was washed sequentially with HEPES buffer (5 × CV) 
and HEPES buffer supplemented with 25 mM imidazole (5 × CV) before the protein was eluted 
with HEPES buffer containing 50 mM imidazole (5 × CV).  
Lactose affinity purification: The column was washed with HEPES buffer (5 × CV) and the 
protein eluted with HEPES buffer containing 300 mM lactose (5 × CV).  
The modified-protein solution was concentrated to a total volume of 1 mL by centrifugal 
concentration at 4 °C before being extensively dialysed into HEPES buffer. The purity of the 
isolated protein was determined by SDS-PAGE.  
6.2.6 Bioconjugation reactions 
Proteins and azide stocks were prepared in HEPES buffer    
Typical procedure for “one pot” CTA2-AB5 labelling with galactosyl azide 
For a total volume of 283 L, CTA2-AB5 (200 L, 30 M), alkyne-depsipeptide 4.31 (38 L, 
150 M, 5 equivalents), SrtA (37 L, 6 M, 20 mol%) and HEPES buffer (8 L) were 
thoroughly mixed together and incubated at 37 °C for 3 h. A further 6.9 L of alkyne 
depsipeptide (30 M, 1 equivalent) and galactosyl azide 4.34 (14.6 L, 2.1 mM) were added 
giving a 1:12 alkyne:zide ratio. The incubation was continued at room temperature overnight 
and extent of the azide /protein bioconjugation was monitored by ESMS.  
Typical procedure for Alkyne-AB5 labelling with duplex-RNA azide  
For a total volume of 20 L, Alkyne-AB5 (10 L, 27.5 M, 1 equivalent), duplex-RNA azide 
(3.2 L, 100 M, 3 equivalents) and HEPES buffer (6.8 L) were thoroughly mixed together 
and incubated at 37 °C overnight. The extent of the RNA/protein bioconjugation was analysed 
by SDS-PAGE  
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6.2.7  Other enzyme reactions   
Tobacco Etch Virus protease cleavage of MBP-AB5 
Typical procedure: MBP-AB5 (500 L, 90 M) was incubated in the presence of TEV protease 
(40 L, 4.4 M, 4 mol%) at room temperature for 60-120 minutes. The reaction was monitored 
by ESMS until only cleavage product could be observed. The reaction mixture was immediately 
passed down a Nickel affinity column (Qiagen) pre-equilibrated in HEPES buffer. The column 
was washed with HEPES buffer (5 × CV) and the protein eluted with HEPES buffer 
supplemented with 500 mM imidazole (5 × CV). Protein-containing fractions were combined, 
centrifugally concentrated at 4 °C and dialysed extensively into HEPES buffer at 4 °C. 
6.2.8  Mammalian cell culture  
Media, buffers and reagents  
PBS (100 mL): A single phosphate buffered saline (PBS) tablet was dissolved H2O. The 
solution was autoclaved for 20 minutes at 121 °C.    
1X trypsin solution (50 mL): Trypsin-EDTA Solution 10X (Sigma, 5 mL) was diluted (0.2 m) 
into to PBS and filter-sterilised (0.2 m).  
DMEM (500 mL): Dulbecco's modified Eagle media with high glucose and L-glutamine (GE 
healthcare) additional supplemented with penicillin (100 unit /ml), streptomycin (100 g/ml), 
10% (v/v) foetal calf serum and glutamine (4 mM).  
1% or 4% BSA (50 mL): 1% or 4% (w/v) bovine serum albumin was dissolved in PBS 
0.1 % Triton (50 mL): 0.1% (v/v) triton (50 L) was dissolved in PBS 
4% PFA (100 mL): 4% (w/v) paraformaldehyde was dissolved in PBS with heating (70 °C), 
filtered (0.2 m) and left to cool to room temperature before use.   
General passage procedure 
Once the mammalian cells had reached the optimal confluency (~ 80%) the growth media was 
removed and the cells carefully washed with PBS (10 ml) before 1X trypsin solution (4 ml) was 
added. The cells were incubated at 37 °C for 5 minutes before the cleavage reaction was 
quenched with the addition of DMEM (5 ml). The excess cell suspension was removed and 
either retained for further experiments or disposed off.  DMEM was added to the remaining cell 
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suspension leaving a total volume of 12 ml with a 1:3 cell suspension: media ratio. The cell 
culture was then incubated at 37 °C (5% CO2) for roughly 2 days before the process was 
repeated.      
Determining cell number and viability 
Cell suspension (10 L) was mixed with an equal volume of Trypan Blue and applied to a 
haemocytometer. The cells were analysed using a microscope at 100 × magnification and the 
clear viable cells counted – any cells stained blue were dead and not included in the count. 
Using Equation 6.3 the average number of cells per mL was calculated. 
                                                               
Cell preparation for transfection assay  
Cover slips were sequestered in a 12-well plate, sterilised with 70% ethanol (1 mL) and washed 
with PBS (1 mL). If HEK293 cells were used the cover slips were treated with poly-L-lysine (1 
ml) for 15 minutes at room temperature and extensively washed with PBS (5 × 1 mL). The cell 
suspension was diluted into DMEM (Equation 6.4) and 1 mL applied to each cover slip. The 
culture was incubated at 37 °C (5% CO2) for 1-2 days until ~80% confluency was achieved  
                       
                          
       
      
Typical protein transfection procedure  
Mammalian cells were grown in the desired number of well plates and once they had reached 
~80% confluency the growth media was removed and the cells washed with PBS (1 ml) before 
FITC-AB5 in PBS (500 L, 20-40 g per mL) was added. The cells were completely covered 
and incubated at 37°C (5% CO2) or 4 °C for the required time period. The transfection reaction 
was quenched by the chemical fixation of the cells to the cover slips.  
Equation 6.3: Average number of cells per mL in cell suspension. CF = Correction factor (1 
×10
4
) 
Equation 6.4: No. of L of cell suspension required per mL of media for optimal seed cell 
concentration. CF = correction factor for optimum cell growth: 1 for HeLa and HEK293 cells; 
2 for Vero Cells 
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Cell fixation 
The growth media or transfection solution was removed from each well plate and the cells were 
washed with PBS (2 × 1 mL) before being treated with 4% PFA (1 ml) for 10 minutes at room 
temperature. The cells were washed and stored in PBS (2 × 1 mL) at 4 °C for no longer than a 
week. Transfection experiments were stored in the dark to prevent photo-beaching of the 
fluorophore.  
Cell permeabilisation, immunofluorescence staining and slide immobilisation  
The PBS was removed from the fixed cells before they were permeabilised with 0.1 % Triton (1 
mL) for 10 minutes at room temperature. The cells were washed with PBS (1 mL) and incubated 
with 4% BSA (1 mL) for 1 h at room temperature. The BSA was removed and the cells treated 
with the required primary antibody (Error! Reference source not found.) in 1% BSA (500 L) 
or 1 h at room temperature.  The cells were extensively washed with PBS (5 × 1 mL) before the 
secondary antibody (Table 6.3) in 1% BSA (500 L) was added. After 1 h incubation at room 
temperature the cells were washed thoroughly with PBS (5 × 1 mL) before being mounted onto 
a glass slide with ProLong® Gold Antifade Reagent with DAPI (10 L) - DAPI reagent allows 
visualisation of the nucleus. The slides were left overnight in the dark before being sealed with 
nail varnish to preserve the cells. The cells were stored at 4 °C in the dark for weeks to months 
without degradation 
Primary polyclonal antibody  Derivation from Target  Recommended dilution  
EEA1 Rabbit  Early endosome 1/250 
CD63 Mouse  Late Endosome 1/500  
Lamp-1 Rabbit  Lysosome 1/500 
Calreticulin Rabbit  Enoplasmic reticulin 1/500 
Calnexin Rabbit  Enoplasmic reticulin 1/500 
TGN46 Rabbit  Trans-golgi  1/500 
 
Secondary antibody Derivation Target Recommended dilution  
 Alexa Fluorphore  555 Goat  Rabbit  1/300 
 Alexa Fluorphore  555 Hamster Mouse 1/300 
 
     
  
Table 6.2: List of primary antibodies used in immunofluorescence assay 
Table 6.3: List of secondary antibodies used in immunofluorescence assay 
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Chapter 7: Appendix  
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7.1 DNA plasmid sequences  
The genes encoding SrtA, TEV-MBP, CTA2-MBP and CTB are highlighted in blue, orange, 
green and red respectively. 
7.1.1 pET28a I 
 
The pET28a I plasmid was used to express SrtA in E. coli cells (Figure 7.1). It is derived from a 
pET28a plasmid obtained from Dr Jeff Hollins (University of Leeds). The SrtA gene was 
subcloned into the plasmid to form the resulting pET28a I expression vector  
Full sequence 5'-3': 
TGGCGAATGGGACGCGCCCTGTAGCGGCGCATTAAGCGCGGCGGGTGTGGTGGTTACGCGCAGC
GTGACCGCTACACTTGCCAGCGCCCTAGCGCCCGCTCCTTTCGCTTTCTTCCCTTCCTTTCTCG
CCACGTTCGCCGGCTTTCCCCGTCAAGCTCTAAATCGGGGGCTCCCTTTAGGGTTCCGATTTAG
TGCTTTACGGCACCTCGACCCCAAAAAACTTGATTAGGGTGATGGTTCACGTAGTGGGCCATCG
Figure 7.1: Plasmid map for pET28a I 
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CCCTGATAGACGGTTTTTCGCCCTTTGACGTTGGAGTCCACGTTCTTTAATAGTGGACTCTTGT
TCCAAACTGGAACAACACTCAACCCTATCTCGGTCTATTCTTTTGATTTATAAGGGATTTTGCC
GATTTCGGCCTATTGGTTAAAAAATGAGCTGATTTAACAAAAATTTAACGCGAATTTTAACAAA
ATATTAACGTTTACAATTTCAGGTGGCACTTTTCGGGGAAATGTGCGCGGAACCCCTATTTGTT
TATTTTTCTAAATACATTCAAATATGTATCCGCTCATGAATTAATTCTTAGAAAAACTCATCGA
GCATCAAATGAAACTGCAATTTATTCATATCAGGATTATCAATACCATATTTTTGAAAAAGCCG
TTTCTGTAATGAAGGAGAAAACTCACCGAGGCAGTTCCATAGGATGGCAAGATCCTGGTATCGG
TCTGCGATTCCGACTCGTCCAACATCAATACAACCTATTAATTTCCCCTCGTCAAAAATAAGGT
TATCAAGTGAGAAATCACCATGAGTGACGACTGAATCCGGTGAGAATGGCAAAAGTTTATGCAT
TTCTTTCCAGACTTGTTCAACAGGCCAGCCATTACGCTCGTCATCAAAATCACTCGCATCAACC
AAACCGTTATTCATTCGTGATTGCGCCTGAGCGAGACGAAATACGCGATCGCTGTTAAAAGGAC
AATTACAAACAGGAATCGAATGCAACCGGCGCAGGAACACTGCCAGCGCATCAACAATATTTTC
ACCTGAATCAGGATATTCTTCTAATACCTGGAATGCTGTTTTCCCGGGGATCGCAGTGGTGAGT
AACCATGCATCATCAGGAGTACGGATAAAATGCTTGATGGTCGGAAGAGGCATAAATTCCGTCA
GCCAGTTTAGTCTGACCATCTCATCTGTAACATCATTGGCAACGCTACCTTTGCCATGTTTCAG
AAACAACTCTGGCGCATCGGGCTTCCCATACAATCGATAGATTGTCGCACCTGATTGCCCGACA
TTATCGCGAGCCCATTTATACCCATATAAATCAGCATCCATGTTGGAATTTAATCGCGGCCTAG
AGCAAGACGTTTCCCGTTGAATATGGCTCATAACACCCCTTGTATTACTGTTTATGTAAGCAGA
CAGTTTTATTGTTCATGACCAAAATCCCTTAACGTGAGTTTTCGTTCCACTGAGCGTCAGACCC
CGTAGAAAAGATCAAAGGATCTTCTTGAGATCCTTTTTTTCTGCGCGTAATCTGCTGCTTGCAA
ACAAAAAAACCACCGCTACCAGCGGTGGTTTGTTTGCCGGATCAAGAGCTACCAACTCTTTTTC
CGAAGGTAACTGGCTTCAGCAGAGCGCAGATACCAAATACTGTCCTTCTAGTGTAGCCGTAGTT
AGGCCACCACTTCAAGAACTCTGTAGCACCGCCTACATACCTCGCTCTGCTAATCCTGTTACCA
GTGGCTGCTGCCAGTGGCGATAAGTCGTGTCTTACCGGGTTGGACTCAAGACGATAGTTACCGG
ATAAGGCGCAGCGGTCGGGCTGAACGGGGGGTTCGTGCACACAGCCCAGCTTGGAGCGAACGAC
CTACACCGAACTGAGATACCTACAGCGTGAGCTATGAGAAAGCGCCACGCTTCCCGAAGGGAGA
AAGGCGGACAGGTATCCGGTAAGCGGCAGGGTCGGAACAGGAGAGCGCACGAGGGAGCTTCCAG
GGGGAAACGCCTGGTATCTTTATAGTCCTGTCGGGTTTCGCCACCTCTGACTTGAGCGTCGATT
TTTGTGATGCTCGTCAGGGGGGCGGAGCCTATGGAAAAACGCCAGCAACGCGGCCTTTTTACGG
TTCCTGGCCTTTTGCTGGCCTTTTGCTCACATGTTCTTTCCTGCGTTATCCCCTGATTCTGTGG
ATAACCGTATTACCGCCTTTGAGTGAGCTGATACCGCTCGCCGCAGCCGAACGACCGAGCGCAG
CGAGTCAGTGAGCGAGGAAGCGGAAGAGCGCCTGATGCGGTATTTTCTCCTTACGCATCTGTGC
GGTATTTCACACCGCATATATGGTGCACTCTCAGTACAATCTGCTCTGATGCCGCATAGTTAAG
CCAGTATACACTCCGCTATCGCTACGTGACTGGGTCATGGCTGCGCCCCGACACCCGCCAACAC
CCGCTGACGCGCCCTGACGGGCTTGTCTGCTCCCGGCATCCGCTTACAGACAAGCTGTGACCGT
CTCCGGGAGCTGCATGTGTCAGAGGTTTTCACCGTCATCACCGAAACGCGCGAGGCAGCTGCGG
TAAAGCTCATCAGCGTGGTCGTGAAGCGATTCACAGATGTCTGCCTGTTCATCCGCGTCCAGCT
CGTTGAGTTTCTCCAGAAGCGTTAATGTCTGGCTTCTGATAAAGCGGGCCATGTTAAGGGCGGT
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TTTTTCCTGTTTGGTCACTGATGCCTCCGTGTAAGGGGGATTTCTGTTCATGGGGGTAATGATA
CCGATGAAACGAGAGAGGATGCTCACGATACGGGTTACTGATGATGAACATGCCCGGTTACTGG
AACGTTGTGAGGGTAAACAACTGGCGGTATGGATGCGGCGGGACCAGAGAAAAATCACTCAGGG
TCAATGCCAGCGCTTCGTTAATACAGATGTAGGTGTTCCACAGGGTAGCCAGCAGCATCCTGCG
ATGCAGATCCGGAACATAATGGTGCAGGGCGCTGACTTCCGCGTTTCCAGACTTTACGAAACAC
GGAAACCGAAGACCATTCATGTTGTTGCTCAGGTCGCAGACGTTTTGCAGCAGCAGTCGCTTCA
CGTTCGCTCGCGTATCGGTGATTCATTCTGCTAACCAGTAAGGCAACCCCGCCAGCCTAGCCGG
GTCCTCAACGACAGGAGCACGATCATGCGCACCCGTGGGGCCGCCATGCCGGCGATAATGGCCT
GCTTCTCGCCGAAACGTTTGGTGGCGGGACCAGTGACGAAGGCTTGAGCGAGGGCGTGCAAGAT
TCCGAATACCGCAAGCGACAGGCCGATCATCGTCGCGCTCCAGCGAAAGCGGTCCTCGCCGAAA
ATGACCCAGAGCGCTGCCGGCACCTGTCCTACGAGTTGCATGATAAAGAAGACAGTCATAAGTG
CGGCGACGATAGTCATGCCCCGCGCCCACCGGAAGGAGCTGACTGGGTTGAAGGCTCTCAAGGG
CATCGGTCGAGATCCCGGTGCCTAATGAGTGAGCTAACTTACATTAATTGCGTTGCGCTCACTG
CCCGCTTTCCAGTCGGGAAACCTGTCGTGCCAGCTGCATTAATGAATCGGCCAACGCGCGGGGA
GAGGCGGTTTGCGTATTGGGCGCCAGGGTGGTTTTTCTTTTCACCAGTGAGACGGGCAACAGCT
GATTGCCCTTCACCGCCTGGCCCTGAGAGAGTTGCAGCAAGCGGTCCACGCTGGTTTGCCCCAG
CAGGCGAAAATCCTGTTTGATGGTGGTTAACGGCGGGATATAACATGAGCTGTCTTCGGTATCG
TCGTATCCCACTACCGAGATATCCGCACCAACGCGCAGCCCGGACTCGGTAATGGCGCGCATTG
CGCCCAGCGCCATCTGATCGTTGGCAACCAGCATCGCAGTGGGAACGATGCCCTCATTCAGCAT
TTGCATGGTTTGTTGAAAACCGGACATGGCACTCCAGTCGCCTTCCCGTTCCGCTATCGGCTGA
ATTTGATTGCGAGTGAGATATTTATGCCAGCCAGCCAGACGCAGACGCGCCGAGACAGAACTTA
ATGGGCCCGCTAACAGCGCGATTTGCTGGTGACCCAATGCGACCAGATGCTCCACGCCCAGTCG
CGTACCGTCTTCATGGGAGAAAATAATACTGTTGATGGGTGTCTGGTCAGAGACATCAAGAAAT
AACGCCGGAACATTAGTGCAGGCAGCTTCCACAGCAATGGCATCCTGGTCATCCAGCGGATAGT
TAATGATCAGCCCACTGACGCGTTGCGCGAGAAGATTGTGCACCGCCGCTTTACAGGCTTCGAC
GCCGCTTCGTTCTACCATCGACACCACCACGCTGGCACCCAGTTGATCGGCGCGAGATTTAATC
GCCGCGACAATTTGCGACGGCGCGTGCAGGGCCAGACTGGAGGTGGCAACGCCAATCAGCAACG
ACTGTTTGCCCGCCAGTTGTTGTGCCACGCGGTTGGGAATGTAATTCAGCTCCGCCATCGCCGC
TTCCACTTTTTCCCGCGTTTTCGCAGAAACGTGGCTGGCCTGGTTCACCACGCGGGAAACGGTC
TGATAAGAGACACCGGCATACTCTGCGACATCGTATAACGTTACTGGTTTCACATTCACCACCC
TGAATTGACTCTCTTCCGGGCGCTATCATGCCATACCGCGAAAGGTTTTGCGCCATTCGATGGT
GTCCGGGATCTCGACGCTCTCCCTTATGCGACTCCTGCATTAGGAAGCAGCCCAGTAGTAGGTT
GAGGCCGTTGAGCACCGCCGCCGCAAGGAATGGTGCATGCAAGGAGATGGCGCCCAACAGTCCC
CCGGCCACGGGGCCTGCCACCATACCCACGCCGAAACAAGCGCTCATGAGCCCGAAGTGGCGAG
CCCGATCTTCCCCATCGGTGATGTCGGCGATATAGGCGCCAGCAACCGCACCTGTGGCGCCGGT
GATGCCGGCCACGATGCGTCCGGCGTAGAGGATCGAGATCTCGATCCCGCGAAATTAATACGAC
TCACTATAGGGGAATTGTGAGCGGATAACAATTCCCCTCTAGAAATAATTTTGTTTAACTTTAA
GAAGGAGATATACCATGGGCAGCAGCCATCATCATCATCATCACAGCAGCGGCCTGGTGCCGCG
147 
CGGCAGCCATATGAAACCACATATCGATAATTATCTTCACGATAAAGATAAAGATGAAAAGATT
GAACAATATGATAAAAATGTAAAAGAACAGGCGAGTAAAGATAAAAAGCAGCAAGCTAAACCTC
AAATTCCGAAAGATAAATCGAAAGTGGCAGGCTATATTGAAATTCCAGATGCTGATATTAAAGA
ACCAGTATATCCAGGACCAGCAACACCTGAACAATTAAATAGAGGTGTAAGCTTTGCAGAAGAA
AATGAATCACTAGATGATCAAAATATTTCAATTGCAGGACACACTTTCATTGACCGTCCGAACT
ATCAATTTACAAATCTTAAAGCAGCCAAAAAAGGTAGTATGGTGTACTTTAAAGTTGGTAATGA
AACACGTAAGTATAAAATGACAAGTATAAGAGATGTTAAGCCTACAGATGTAGGAGTTCTAGAT
GAACAAAAAGGTAAAGATAAACAATTAACATTAATTACTTGTGATGATTACAATGAAAAGACAG
GCGTTTGGGAAAAACGTAAAATCTTTGTAGCTACAGAAGTCAAATAATCGAATTCGAGCTCCGT
CGACAAGCTTGCGGCCGCACTCGAGCACCACCACCACCACCACTGAGATCCGGCTGCTAACAAA
GCCCGAAAGGAAGCTGAGTTGGCTGCTGCCACCGCTGAGCAATAACTAGCATAACCCCTTGGGG
CCTCTAAACGGGTCTTGAGGGGTTTTTTGCTGAAAGGAGGAACTATATCCGGAT 
7.1.2 pMAL-c5x I 
 
Figure 7.2: Plasmid map for pMAL-c5x I 
148 
The pMAL-c5x I plasmid was used to express TEV-MBP in E. coli cells (Figure 7.2). It is 
derived from a pMAL-c5x plasmid obtained from New England Biolabs. The TEV gene was 
introduced by Dr James Ross (University of Leeds) to form the pMAL-c5x I expression vector 
for the TEV-MBP fusion.  
Full sequence 5'-3': 
CCGACACCATCGAATGGTGCAAAACCTTTCGCGGTATGGCATGATAGCGCCCGGAAGAGAGTCA
ATTCAGGGTGGTGAATGTGAAACCAGTAACGTTATACGATGTCGCAGAGTATGCCGGTGTCTCT
TATCAGACCGTTTCCCGCGTGGTGAACCAGGCCAGCCACGTTTCTGCGAAAACGCGGGAAAAAG
TGGAAGCGGCGATGGCGGAGCTGAATTACATTCCCAACCGCGTGGCACAACAACTGGCGGGCAA
ACAGTCGTTGCTGATTGGCGTTGCCACCTCCAGTCTGGCCCTGCACGCGCCGTCGCAAATTGTC
GCGGCGATTAAATCTCGCGCCGATCAACTGGGTGCCAGCGTGGTGGTGTCGATGGTAGAACGAA
GCGGCGTCGAAGCCTGTAAAGCGGCGGTGCACAATCTTCTCGCGCAACGCGTCAGTGGGCTGAT
CATTAACTATCCGCTGGATGACCAGGATGCCATTGCTGTGGAAGCTGCCTGCACTAATGTTCCG
GCGTTATTTCTTGATGTCTCTGACCAGACACCCATCAACAGTATTATTTTCTCCCATGAAGACG
GTACGCGACTGGGCGTGGAGCATCTGGTCGCATTGGGTCACCAGCAAATCGCGCTGTTAGCGGG
CCCATTAAGTTCTGTCTCGGCGCGTCTGCGTCTGGCTGGCTGGCATAAATATCTCACTCGCAAT
CAAATTCAGCCGATAGCGGAACGGGAAGGCGACTGGAGTGCCATGTCCGGTTTTCAACAAACCA
TGCAAATGCTGAATGAGGGCATCGTTCCCACTGCGATGCTGGTTGCCAACGATCAGATGGCGCT
GGGCGCAATGCGCGCCATTACCGAGTCCGGGCTGCGCGTTGGTGCGGATATTTCGGTAGTGGGA
TACGACGATACCGAAGACAGCTCATGTTATATCCCGCCGTTAACCACCATCAAACAGGATTTTC
GCCTGCTGGGGCAAACCAGCGTGGACCGCTTGCTGCAACTCTCTCAGGGCCAGGCGGTGAAGGG
CAATCAGCTGTTGCCCGTCTCACTGGTGAAAAGAAAAACCACCCTGGCGCCCAATACGCAAACC
GCCTCTCCCCGCGCGTTGGCCGATTCATTAATGCAGCTGGCACGACAGGTTTCCCGACTGGAAA
GCGGGCAGTGAGCGCAACGCAATTAATGTAAGTTAGCTCACTCATTAGGCACAATTCTCATGTT
TGACAGCTTATCATCGACTGCACGGTGCACCAATGCTTCTGGCGTCAGGCAGCCATCGGAAGCT
GTGGTATGGCTGTGCAGGTCGTAAATCACTGCATAATTCGTGTCGCTCAAGGCGCACTCCCGTT
CTGGATAATGTTTTTTGCGCCGACATCATAACGGTTCTGGCAAATATTCTGAAATGAGCTGTTG
ACAATTAATCATCGGCTCGTATAATGTGTGGAATTGTGAGCGGATAACAATTTCACACAGGAAA
CAGCCAGTCCGTTTAGGTGTTTTCACGAGCAATTGACCAACAAGGACCATAGATTATGAAAATC
GAAGAAGGTAAACTGGTAATCTGGATTAACGGCGATAAAGGCTATAACGGTCTCGCTGAAGTCG
GTAAGAAATTCGAGAAAGATACCGGAATTAAAGTCACCGTTGAGCATCCGGATAAACTGGAAGA
GAAATTCCCACAGGTTGCGGCAACTGGCGATGGCCCTGACATTATCTTCTGGGCACACGACCGC
TTTGGTGGCTACGCTCAATCTGGCCTGTTGGCTGAAATCACCCCGGACAAAGCGTTCCAGGACA
AGCTGTATCCGTTTACCTGGGATGCCGTACGTTACAACGGCAAGCTGATTGCTTACCCGATCGC
TGTTGAAGCGTTATCGCTGATTTATAACAAAGATCTGCTGCCGAACCCGCCAAAAACCTGGGAA
GAGATCCCGGCGCTGGATAAAGAACTGAAAGCGAAAGGTAAGAGCGCGCTGATGTTCAACCTGC
AAGAACCGTACTTCACCTGGCCGCTGATTGCTGCTGACGGGGGTTATGCGTTCAAGTATGAAAA
149 
CGGCAAGTACGACATTAAAGACGTGGGCGTGGATAACGCTGGCGCGAAAGCGGGTCTGACCTTC
CTGGTTGACCTGATTAAAAACAAACACATGAATGCAGACACCGATTACTCCATCGCAGAAGCTG
CCTTTAATAAAGGCGAAACAGCGATGACCATCAACGGCCCGTGGGCATGGTCCAACATCGACAC
CAGCAAAGTGAATTATGGTGTAACGGTACTGCCGACCTTCAAGGGTCAACCATCCAAACCGTTC
GTTGGCGTGCTGAGCGCAGGTATTAACGCCGCCAGTCCGAACAAAGAGCTGGCAAAAGAGTTCC
TCGAAAACTATCTGCTGACTGATGAAGGTCTGGAAGCGGTTAATAAAGACAAACCGCTGGGTGC
CGTAGCGCTGAAGTCTTACGAGGAAGAGTTGGTGAAAGATCCGCGTATTGCCGCCACTATGGAA
AACGCCCAGAAAGGTGAAATCATGCCGAACATCCCGCAGATGTCCGCTTTCTGGTATGCCGTGC
GTACTGCGGTGATCAACGCCGCCAGCGGTCGTCAGACTGTCGATGAAGCCCTGAAAGACGCGCA
GACTAATTCGAGCTCGAACAACAACAACAATAACAATAACAACAACCTCGGGATCGAGGGAAGG
ATTTCACATATGTCCATGGGCGGCCGCGATATCGTCGACGGATCCGGAAAAAGCTTGTTTAAGG
GGCCGCGTGATTACAACCCGATATCGAGCACCATTTGTCATTTGACGAATGAATCTGATGGGCA
CACAACATCGTTGTATGGTATTGGATTTGGTCCCTTCATCATTACAAACAAGCACTTGTTTAGA
AGAAATAATGGAACACTGTTGGTCCAATCACTACATGGTGTATTCAAGGTCAAGAACACCACGA
CTTTGCAACAACACCTCATTGATGGGAGGGACATGATAATTATTCGCATGCCTAAGGATTTCCC
ACCATTTCCTCAAAAGCTGAAATTTAGAGAGCCACAAAGGGAAGAACGCATATGTCTTGTTACA
ACCAACTTCCAAACTAAGAGCATGTCTAGCATGGTGTCAGACACTAGTTGCACATTCCCTTCAT
CTGATGGCATATTCTGGAAGCATTGGATTCAAACCAAGGATGGGCAGTGTGGCAGTCCATTAGT
ATCAACTAGAGATGGGTTCATTGTTGGTATACACTCAGCATCGAATTTCACCAACACAAACAAT
TATTTCACAAGCGTGCCGAAAAACTTCATGGAATTGTTGACAAATCAGGAGGCGCAGCAGTGGG
TTAGTGGTTGGCGATTAAATGCTGACTCAGTATTGTGGGGGGGCCATAAAGTTTTCATGCCGAA
ACCTGAAGAGCCTTTTCAGCCAGTTAAGGAAGCGACTCAACTCATGAATCGTCGTCGCCGTCGC
TAATAAGGACTGCAGGTAATTAAATAAGCTTCAAATAAAACGAAAGGCTCAGTCGAAAGACTGG
GCCTTTCGTTTTATCTGTTGTTTGTCGGTGAACGCTCTCCTGAGTAGGACAAATCCGCCGGGAG
CGGATTTGAACGTTGCGAAGCAACGGCCCGGAGGGTGGCGGGCAGGACGCCCGCCATAAACTGC
CAGGCATCAAATTAAGCAGAAGGCCATCCTGACGGATGGCCTTTTTGCGTTTCTACAAACTCTT
TCGGTCCGTTGTTTATTTTTCTAAATACATTCAAATATGTATCCGCTCATGAGACAATAACCCT
GATAAATGCTTCAATAATATTGAAAAAGGAAGAGTATGAGTATTCAACATTTCCGTGTCGCCCT
TATTCCCTTTTTTGCGGCATTTTGCCTTCCTGTTTTTGCTCACCCAGAAACGCTGGTGAAAGTA
AAAGATGCTGAAGATCAGTTGGGTGCACGAGTGGGTTACATCGAACTGGATCTCAACAGCGGTA
AGATCCTTGAGAGTTTTCGCCCCGAAGAACGTTTCCCAATGATGAGCACTTTTAAAGTTCTGCT
ATGTGGCGCGGTATTATCCCGTGTTGACGCCGGGCAAGAGCAACTCGGTCGCCGCATACACTAT
TCTCAGAATGACTTGGTTGAGTACTCACCAGTCACAGAAAAGCATCTTACGGATGGCATGACAG
TAAGAGAATTATGCAGTGCTGCCATAACCATGAGTGATAACACTGCGGCCAACTTACTTCTGAC
AACGATCGGAGGACCGAAGGAGCTAACCGCTTTTTTGCACAACATGGGGGATCATGTAACTCGC
CTTGATCGTTGGGAACCGGAGCTGAATGAAGCCATACCAAACGACGAGCGTGACACCACGATGC
CTGTAGCAATGGCAACAACGTTGCGCAAACTATTAACTGGCGAACTACTTACTCTAGCTTCCCG
GCAACAATTAATAGACTGGATGGAGGCGGATAAAGTTGCAGGACCACTTCTGCGCTCGGCCCTT
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CCGGCTGGCTGGTTTATTGCTGATAAATCTGGAGCCGGTGAGCGTGGGTCTCGCGGTATCATTG
CAGCACTGGGGCCAGATGGTAAGCCCTCCCGTATCGTAGTTATCTACACGACGGGGAGTCAGGC
AACTATGGATGAACGAAATAGACAGATCGCTGAGATAGGTGCCTCACTGATTAAGCATTGGTAA
CTGTCAGACCAAGTTTACTCATATATACTTTAGATTGATTTCCTTAGGACTGAGCGTCAACCCC
GTAGAAAAGATCAAAGGATCTTCTTGAGATCCTTTTTTTCTGCGCGTAATCTGCTGCTTGCAAA
CAAAAAAACCACCGCTACCAGCGGTGGTTTGTTTGCCGGATCAAGAGCTACCAACTCTTTTTCC
GAAGGTAACTGGCTTCAGCAGAGCGCAGATACCAAATACTGTCCTTCTAGTGTAGCCGTAGTTA
GGCCACCACTTCAAGAACTCTGTAGCACCGCCTACATACCTCGCTCTGCTAATCCTGTTACCAG
TGGCTGCTGCCAGTGGCGATAAGTCGTGTCTTACCGGGTTGGACTCAAGACGATAGTTACCGGA
TAAGGCGCAGCGGTCGGGCTGAACGGGGGGTTCGTGCACACAGCCCAGCTTGGAGCGAACGACC
TACACCGAACTGAGATACCTACAGCGTGAGCTATGAGAAAGCGCCACGCTTCCCGAAGGGAGAA
AGGCGGACAGGTATCCGGTAAGCGGCAGGGTCGGAACAGGAGAGCGCACGAGGGAGCTTCCAGG
GGGAAACGCCTGGTATCTTTATAGTCCTGTCGGGTTTCGCCACCTCTGACTTGAGCGTCGATTT
TTGTGATGCTCGTCAGGGGGGCGGAGCCTATGGAAAAACGCCAGCAACGCGGCCTTTTTACGGT
TCCTGGCCTTTTGCTGGCCTTTTGCTCACATGTTCTTTCCTGCGTTATCCCCTGATTCTGTGGA
TAACCGTATTACCGCCTTTGAGTGAGCTGATACCGCTCGCCGCAGCCGAACGACCGAGCGCAGC
GAGTCAGTGAGCGAGGAAGCGGAAGAGCGCCTGATGCGGTATTTTCTCCTTACGCATCTGTGCG
GTATTTCACACCGCATATAAGGTGCACTGTGACTGGGTCATGGCTGCGCCCCGACACCCGCCAA
CACCCGCTGACGCGCCCTGACGGGCTTGTCTGCTCCCGGCATCCGCTTACAGACAAGCTGTGAC
CGTCTCCGGGAGCTGCATGTGTCAGAGGTTTTCACCGTCATCACCGAAACGCGCGAGGCAGCTG
CGGTAAAGCTCATCAGCGTGGTCGTGCAGCGATTCACAGATGTCTGCCTGTTCATCCGCGTCCA
GCTCGTTGAGTTTCTCCAGAAGCGTTAATGTCTGGCTTCTGATAAAGCGGGCCATGTTAAGGGC
GGTTTTTTCCTGTTTGGTCACTGATGCCTCCGTGTAAGGGGGATTTCTGTTCATGGGGGTAATG
ATACCGATGAAACGAGAGAGGATGCTCACGATACGGGTTACTGATGATGAACATGCCCGGTTAC
TGGAACGTTGTGAGGGTAAACAACTGGCGGTATGGATGCGGCGGGACCAGAGAAAAATCACTCA
GGGTCAATGCCAGCGCTTCGTTAATACAGATGTAGGTGTTCCACAGGGTAGCCAGCAGCATCCT
GCGATGCAGATCCGGAACATAATGGTGCAGGGCGCTGACTTCCGCGTTTCCAGACTTTACGAAA
CACGGAAACCGAAGACCATTCATGTTGTTGCTCAGGTCGCAGACGTTTTGCAGCAGCAGTCGCT
TCACGTTCGCTCGCGTATCGGTGATTCATTCTGCTAACCAGTAAGGCAACCCCGCCAGCCTAGC
CGGGTCCTCAACGACAGGAGCACGATCATGCGCACCCGTGGCCAGGACCCAACGCTGCCCGAAA
TT 
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7.1.3 pSAB2.1 
 
The pSAB2.1 plasmid was used to express MBP-AB5 in E. coli cells (Figure 7.3). The plasmid 
is derived from pMAL-p5x and was prepared by Dr James Ross (University of Leeds).
176*
 
Full sequence 5'-3': 
CCGACACCATCGAATGGTGCAAAACCTTTCGCGGTATGGCATGATAGCGCCCGGAAGAGAGTCA
ATTCAGGGTGGTGAATGTGAAACCAGTAACGTTATACGATGTCGCAGAGTATGCCGGTGTCTCT
TATCAGACCGTTTCCCGCGTGGTGAACCAGGCCAGCCACGTTTCTGCGAAAACGCGGGAAAAAG
TGGAAGCGGCGATGGCGGAGCTGAATTACATTCCCAACCGCGTGGCACAACAACTGGCGGGCAA
ACAGTCGTTGCTGATTGGCGTTGCCACCTCCAGTCTGGCCCTGCACGCGCCGTCGCAAATTGTC
                                                     
*
 The plasmid sequence in J.F. Ross, PhD thesis is incorrect. Correct sequence given here.   
 
Figure 7.3 Plasmid map for pSAB2.1 
152 
GCGGCGATTAAATCTCGCGCCGATCAACTGGGTGCCAGCGTGGTGGTGTCGATGGTAGAACGAA
GCGGCGTCGAAGCCTGTAAAGCGGCGGTGCACAATCTTCTCGCGCAACGCGTCAGTGGGCTGAT
CATTAACTATCCGCTGGATGACCAGGATGCCATTGCTGTGGAAGCTGCCTGCACTAATGTTCCG
GCGTTATTTCTTGATGTCTCTGACCAGACACCCATCAACAGTATTATTTTCTCCCATGAAGACG
GTACGCGACTGGGCGTGGAGCATCTGGTCGCATTGGGTCACCAGCAAATCGCGCTGTTAGCGGG
CCCATTAAGTTCTGTCTCGGCGCGTCTGCGTCTGGCTGGCTGGCATAAATATCTCACTCGCAAT
CAAATTCAGCCGATAGCGGAACGGGAAGGCGACTGGAGTGCCATGTCCGGTTTTCAACAAACCA
TGCAAATGCTGAATGAGGGCATCGTTCCCACTGCGATGCTGGTTGCCAACGATCAGATGGCGCT
GGGCGCAATGCGCGCCATTACCGAGTCCGGGCTGCGCGTTGGTGCGGATATTTCGGTAGTGGGA
TACGACGATACCGAAGACAGCTCATGTTATATCCCGCCGTTAACCACCATCAAACAGGATTTTC
GCCTGCTGGGGCAAACCAGCGTGGACCGCTTGCTGCAACTCTCTCAGGGCCAGGCGGTGAAGGG
CAATCAGCTGTTGCCCGTCTCACTGGTGAAAAGAAAAACCACCCTGGCGCCCAATACGCAAACC
GCCTCTCCCCGCGCGTTGGCCGATTCATTAATGCAGCTGGCACGACAGGTTTCCCGACTGGAAA
GCGGGCAGTGAGCGCAACGCAATTAATGTAAGTTAGCTCACTCATTAGGCACAATTCTCATGTT
TGACAGCTTATCATCGACTGCACGGTGCACCAATGCTTCTGGCGTCAGGCAGCCATCGGAAGCT
GTGGTATGGCTGTGCAGGTCGTAAATCACTGCATAATTCGTGTCGCTCAAGGCGCACTCCCGTT
CTGGATAATGTTTTTTGCGCCGACATCATAACGGTTCTGGCAAATATTCTGAAATGAGCTGTTG
ACAATTAATCATCGGCTCGTATAATGTGTGGAATTGTGAGCGGATAACAATTTCACACAGGAAA
CAGCCAGTCCGTTTAGGTGTTTTCACGAGCAATTGACCAACAAGGACCATAGATTATGAAAATA
AAAACAGGTGCACGCATCCTCGCATTATCCGCATTAACGACGATGATGTTTTCCGCCTCGGCTC
TCGCCAAAATCGAAGAAGGTAAACTGGTAATCTGGATTAACGGCGATAAAGGCTATAACGGTCT
CGCTGAAGTCGGTAAGAAATTCGAGAAAGATACCGGAATTAAAGTCACCGTTGAGCATCCGGAT
AAACTGGAAGAGAAATTCCCACAGGTTGCGGCAACTGGCGATGGCCCTGACATTATCTTCTGGG
CACACGACCGCTTTGGTGGCTACGCTCAATCTGGCCTGTTGGCTGAAATCACCCCGGACAAAGC
GTTCCAGGACAAGCTGTATCCGTTTACCTGGGATGCCGTACGTTACAACGGCAAGCTGATTGCT
TACCCGATCGCTGTTGAAGCGTTATCGCTGATTTATAACAAAGATCTGCTGCCGAACCCGCCAA
AAACCTGGGAAGAGATCCCGGCGCTGGATAAAGAACTGAAAGCGAAAGGTAAGAGCGCGCTGAT
GTTCAACCTGCAAGAACCGTACTTCACCTGGCCGCTGATTGCTGCTGACGGGGGTTATGCGTTC
AAGTATGAAAACGGCAAGTACGACATTAAAGACGTGGGCGTGGATAACGCTGGCGCGAAAGCGG
GTCTGACCTTCCTGGTTGACCTGATTAAAAACAAACACATGAATGCAGACACCGATTACTCCAT
CGCAGAAGCTGCCTTTAATAAAGGCGAAACAGCGATGACCATCAACGGCCCGTGGGCATGGTCC
AACATCGACACCAGCAAAGTGAATTATGGTGTAACGGTACTGCCGACCTTCAAGGGTCAACCAT
CCAAACCGTTCGTTGGCGTGCTGAGCGCAGGTATTAACGCCGCCAGTCCGAACAAAGAGCTGGC
AAAAGAGTTCCTCGAAAACTATCTGCTGACTGATGAAGGTCTGGAAGCGGTTAATAAAGACAAA
CCGCTGGGTGCCGTAGCGCTGAAGTCTTACGAGGAAGAGTTGGTGAAAGATCCGCGTATTGCCG
CCACTATGGAAAACGCCCAGAAAGGTGAAATCATGCCGAACATCCCGCAGATGTCCGCTTTCTG
GTATGCCGTGCGTACTGCGGTGATCAACGCCGCCAGCGGTCGTCAGACTGTCGATGAAGCCCTG
AAAGACGCGCAGACTAATTCGAGCTCGAACAACAACAACAATAACAATAACAACAACCTCGGGA
TCGAGGGAAGGATTTCACATATGGGATCCGAAAACCTGTACTTTCAGGGTGGCGGTGATGAAAA
AACCCAAAGTCATGGTGTAAAATTCCTTGACGAATACCAATCTAAAGTTAAAAGACAAATATTT
TCAGGCTATCAATCTGATATTGATACACATAATAGAATTAAGGATGAATTATGACCTCGAGGTG
AATTCACGAGCAATTGACCAACAAGGACCATAGATTATGAGCTTTAAGAAAATTATCAAGGCAT
TTGTTATCATGGCTGCTTTGGTATCTGTTCAGGCGCATGCAGCTCCTCAAAATATTACTGATTT
GTGCGCAGAATACCACAACACACAAATATATACGCTAAATGATAAGATCTTTTCGTATACAGAA
TCGCTAGCGGGAAAAAGAGAGATGGCTATCATTACTTTTAAGAATGGTGCAATTTTTCAAGTAG
AGGTACCAGGTAGTCAACATATAGATTCACAAAAAAAAGCGATTGAAAGGATGAAGGATACCCT
GAGGATTGCATATCTTACTGAAGCTAAAGTCGAAAAGTTATGTGTATGGAATAATAAAACGCCT
CATGCGATCGCCGCAATTAGTATGGCAAACTAAGTTTTCCCTGCAGGTAATTAAATAAGCTTCA
AATAAAACGAAAGGCTCAGTCGAAAGACTGGGCCTTTCGTTTTATCTGTTGTTTGTCGGTGAAC
GCTCTCCTGAGTAGGACAAATCCGCCGGGAGCGGATTTGAACGTTGCGAAGCAACGGCCCGGAG
GGTGGCGGGCAGGACGCCCGCCATAAACTGCCAGGCATCAAATTAAGCAGAAGGCCATCCTGAC
GGATGGCCTTTTTGCGTTTCTACAAACTCTTTCGGTCCGTTGTTTATTTTTCTAAATACATTCA
AATATGTATCCGCTCATGAGACAATAACCCTGATAAATGCTTCAATAATATTGAAAAAGGAAGA
GTATGAGTATTCAACATTTCCGTGTCGCCCTTATTCCCTTTTTTGCGGCATTTTGCCTTCCTGT
TTTTGCTCACCCAGAAACGCTGGTGAAAGTAAAAGATGCTGAAGATCAGTTGGGTGCACGAGTG
GGTTACATCGAACTGGATCTCAACAGCGGTAAGATCCTTGAGAGTTTTCGCCCCGAAGAACGTT
153 
TCCCAATGATGAGCACTTTTAAAGTTCTGCTATGTGGCGCGGTATTATCCCGTGTTGACGCCGG
GCAAGAGCAACTCGGTCGCCGCATACACTATTCTCAGAATGACTTGGTTGAGTACTCACCAGTC
ACAGAAAAGCATCTTACGGATGGCATGACAGTAAGAGAATTATGCAGTGCTGCCATAACCATGA
GTGATAACACTGCGGCCAACTTACTTCTGACAACGATCGGAGGACCGAAGGAGCTAACCGCTTT
TTTGCACAACATGGGGGATCATGTAACTCGCCTTGATCGTTGGGAACCGGAGCTGAATGAAGCC
ATACCAAACGACGAGCGTGACACCACGATGCCTGTAGCAATGGCAACAACGTTGCGCAAACTAT
TAACTGGCGAACTACTTACTCTAGCTTCCCGGCAACAATTAATAGACTGGATGGAGGCGGATAA
AGTTGCAGGACCACTTCTGCGCTCGGCCCTTCCGGCTGGCTGGTTTATTGCTGATAAATCTGGA
GCCGGTGAGCGTGGGTCTCGCGGTATCATTGCAGCACTGGGGCCAGATGGTAAGCCCTCCCGTA
TCGTAGTTATCTACACGACGGGGAGTCAGGCAACTATGGATGAACGAAATAGACAGATCGCTGA
GATAGGTGCCTCACTGATTAAGCATTGGTAACTGTCAGACCAAGTTTACTCATATATACTTTAG
ATTGATTTCCTTAGGACTGAGCGTCAACCCCGTAGAAAAGATCAAAGGATCTTCTTGAGATCCT
TTTTTTCTGCGCGTAATCTGCTGCTTGCAAACAAAAAAACCACCGCTACCAGCGGTGGTTTGTT
TGCCGGATCAAGAGCTACCAACTCTTTTTCCGAAGGTAACTGGCTTCAGCAGAGCGCAGATACC
AAATACTGTCCTTCTAGTGTAGCCGTAGTTAGGCCACCACTTCAAGAACTCTGTAGCACCGCCT
ACATACCTCGCTCTGCTAATCCTGTTACCAGTGGCTGCTGCCAGTGGCGATAAGTCGTGTCTTA
CCGGGTTGGACTCAAGACGATAGTTACCGGATAAGGCGCAGCGGTCGGGCTGAACGGGGGGTTC
GTGCACACAGCCCAGCTTGGAGCGAACGACCTACACCGAACTGAGATACCTACAGCGTGAGCTA
TGAGAAAGCGCCACGCTTCCCGAAGGGAGAAAGGCGGACAGGTATCCGGTAAGCGGCAGGGTCG
GAACAGGAGAGCGCACGAGGGAGCTTCCAGGGGGAAACGCCTGGTATCTTTATAGTCCTGTCGG
GTTTCGCCACCTCTGACTTGAGCGTCGATTTTTGTGATGCTCGTCAGGGGGGCGGAGCCTATGG
AAAAACGCCAGCAACGCGGCCTTTTTACGGTTCCTGGCCTTTTGCTGGCCTTTTGCTCACATGT
TCTTTCCTGCGTTATCCCCTGATTCTGTGGATAACCGTATTACCGCCTTTGAGTGAGCTGATAC
CGCTCGCCGCAGCCGAACGACCGAGCGCAGCGAGTCAGTGAGCGAGGAAGCGGAAGAGCGCCTG
ATGCGGTATTTTCTCCTTACGCATCTGTGCGGTATTTCACACCGCATATAAGGTGCACTGTGAC
TGGGTCATGGCTGCGCCCCGACACCCGCCAACACCCGCTGACGCGCCCTGACGGGCTTGTCTGC
TCCCGGCATCCGCTTACAGACAAGCTGTGACCGTCTCCGGGAGCTGCATGTGTCAGAGGTTTTC
ACCGTCATCACCGAAACGCGCGAGGCAGCTGCGGTAAAGCTCATCAGCGTGGTCGTGCAGCGAT
TCACAGATGTCTGCCTGTTCATCCGCGTCCAGCTCGTTGAGTTTCTCCAGAAGCGTTAATGTCT
GGCTTCTGATAAAGCGGGCCATGTTAAGGGCGGTTTTTTCCTGTTTGGTCACTGATGCCTCCGT
GTAAGGGGGATTTCTGTTCATGGGGGTAATGATACCGATGAAACGAGAGAGGATGCTCACGATA
CGGGTTACTGATGATGAACATGCCCGGTTACTGGAACGTTGTGAGGGTAAACAACTGGCGGTAT
GGATGCGGCGGGACCAGAGAAAAATCACTCAGGGTCAATGCCAGCGCTTCGTTAATACAGATGT
AGGTGTTCCACAGGGTAGCCAGCAGCATCCTGCGATGCAGATCCGGAACATAATGGTGCAGGGC
GCTGACTTCCGCGTTTCCAGACTTTACGAAACACGGAAACCGAAGACCATTCATGTTGTTGCTC
AGGTCGCAGACGTTTTGCAGCAGCAGTCGCTTCACGTTCGCTCGCGTATCGGTGATTCATTCTG
CTAACCAGTAAGGCAACCCCGCCAGCCTAGCCGGGTCCTCAACGACAGGAGCACGATCATGCGC
ACCCGTGGCCAGGACCCAACGCTGCCCGAAATT 
7.2 Protein sequences  
SrtA:  
Protein sequence obtained from pET28a I plasmid  
        10         20         30         40         50         60  
MGSSHHHHHH SSGLVPRGSH MKPHIDNYLH DKDKDEKIEQ YDKNVKEQAS KDKKQQAKPQ  
 
        70         80         90        100        110        120  
IPKDKSKVAG YIEIPDADIK EPVYPGPATP EQLNRGVSFA EENESLDDQN ISIAGHTFID  
 
       130        140        150        160        170        180  
RPNYQFTNLK AAKKGSMVYF KVGNETRKYK MTSIRDVKPT DVGVLDEQKG KDKQLTLITC  
 
154 
       190        200  
DDYNEKTGVW EKRKIFVATE VK  
 
TEV-MBP: 
Protein sequence obtained from pMAL-c5x I plasmid  
        10         20         30         40         50         60  
MKIEEGKLVI WINGDKGYNG LAEVGKKFEK DTGIKVTVEH PDKLEEKFPQ VAATGDGPDI  
 
        70         80         90        100        110        120  
IFWAHDRFGG YAQSGLLAEI TPDKAFQDKL YPFTWDAVRY NGKLIAYPIA VEALSLIYNK  
 
       130        140        150        160        170        180  
DLLPNPPKTW EEIPALDKEL KAKGKSALMF NLQEPYFTWP LIAADGGYAF KYENGKYDIK  
 
       190        200        210        220        230        240  
DVGVDNAGAK AGLTFLVDLI KNKHMNADTD YSIAEAAFNK GETAMTINGP WAWSNIDTSK  
 
       250        260        270        280        290        300  
VNYGVTVLPT FKGQPSKPFV GVLSAGINAA SPNKELAKEF LENYLLTDEG LEAVNKDKPL  
 
       310        320        330        340        350        360  
GAVALKSYEE ELVKDPRIAA TMENAQKGEI MPNIPQMSAF WYAVRTAVIN AASGRQTVDE  
 
       370        380        390        400        410        420  
ALKDAQTNSS SNNNNNNNNN NLGIEGRISH MSMGGRDIVD GSGKSLFKGP RDYNPISSTI  
 
       430        440        450        460        470        480  
CHLTNESDGH TTSLYGIGFG PFIITNKHLF RRNNGTLLVQ SLHGVFKVKN TTTLQQHLID  
 
       490        500        510        520        530        540  
GRDMIIIRMP KDFPPFPQKL KFREPQREER ICLVTTNFQT KSMSSMVSDT SCTFPSSDGI  
 
       550        560        570        580        590        600  
FWKHWIQTKD GQCGSPLVST RDGFIVGIHS ASNFTNTNNY FTSVPKNFME LLTNQEAQQW  
 
       610        620        630        640  
VSGWRLNADS VLWGGHKVFM PKPEEPFQPV KEATQLMNRR RRR 
 
CTB: 
Protein sequence obtained from pSAB2.1 plasmid  
        10         20         30         40         50         60  
APQNITDLCA EYHNTQIYTL NDKIFSYTES LAGKREMAII TFKNGAIFQV EVPGSQHIDS  
 
        70         80         90        100  
QKKAIERMKD TLRIAYLTEA KVEKLCVWNN KTPHAIAAIS MAN  
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CTA2-MBP: 
Protein sequence obtained from pSAB2.1 plasmid.The TEV protease cleavage site in the MBP-
CTA2 sequence is marked in purple. The sequence for CTA2, highlighted in green, begins at 
G399 in the MBP-CTA2 sequence. 
        10         20         30         40         50         60  
KIEEGKLVIW INGDKGYNGL AEVGKKFEKD TGIKVTVEHP DKLEEKFPQV AATGDGPDII  
 
        70         80         90        100        110        120  
FWAHDRFGGY AQSGLLAEIT PDKAFQDKLY PFTWDAVRYN GKLIAYPIAV EALSLIYNKD  
 
       130        140        150        160        170        180  
LLPNPPKTWE EIPALDKELK AKGKSALMFN LQEPYFTWPL IAADGGYAFK YENGKYDIKD  
 
       190        200        210        220        230        240  
VGVDNAGAKA GLTFLVDLIK NKHMNADTDY SIAEAAFNKG ETAMTINGPW AWSNIDTSKV  
 
       250        260        270        280        290        300  
NYGVTVLPTF KGQPSKPFVG VLSAGINAAS PNKELAKEFL ENYLLTDEGL EAVNKDKPLG  
 
       310        320        330        340        350        360  
AVALKSYEEE LVKDPRIAAT MENAQKGEIM PNIPQMSAFW YAVRTAVINA ASGRQTVDEA  
 
       370        380        390        400        410        420  
LKDAQTNSSS NNNNNNNNNN LGIEGRISHM GSENLYFQGG GDEKTQSHGV KFLDEYQSKV  
 
       430        440  
KRQIFSGYQS DIDTHNRIKD EL  
 
Mouse pumilio-2 puf domain:  
Protein sequence obtained from UniProt code: Q80U58 
       10         20         30         40         50         60  
GTGRSRLLED FRNNRFPNLQ LRDLIGHIVE FSQDQHGSRF IQQKLERATP AERQIVFNEI  
 
        70         80         90        100        110        120  
LQAAYQLMTD VFGNYVIQKF FEFGSLDQKL ALATRIRGHV LPLALQMYGC RVIQKALESI  
 
       130        140        150        160        170        180  
SSDQQSEMVK ELDGHVLKCV KDQNGNHVVQ KCIECVQPQS LQFIIDAFKG QVFVLSTHPY  
 
       190        200        210        220        230        240  
GCRVIQRILE HCTAEQTLPI LEELHQHTEQ LVQDQYGNYV IQHVLEHGRP EDKSKIVSEI  
 
       250        260        270        280        290        300  
RGKVLALSQH KFASNVVEKC VTHASRAERA LLIDEVCCQN DGPHSALYTM MKDQYANYVV  
 
       310        320        330        340        350  
QKMIDMAEPA QRKIIMHKIR PHITTLRKYT YGKHILAKLE KYYLKNSPDL G  
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Human mannose binding lectin (galactose-binding variant): 
Protein sequence obtained from Prof. K. Drickamer (Imperial College London). 
        10         20         30         40         50         60  
GDSSLAASER KALQTEMARI KKWLTFSLGK QVGNKFFLTN GEIMTFEKVK ALCVKFQASV  
 
        70         80         90        100        110        120  
ATPRNAAENG AIQNLIKEEA FLGITDEKTE GQFVDLTGNR LTYTNWNEGQ PDDWYGHGLG  
 
       130        140        150        160        170        180  
GGEDCVLLLK NGQWNDVPCS TSHLAVCEFP IPHITTLRKY TYGKHILAKL EKYYLKNSPD  
 
 
LG  
 
 
Equine heart myoglobin: 
Protein sequence obtained from UniProt code: P68082 
        10         20         30         40         50         60  
GLSDGEWQQV LNVWGKVEAD IAGHGQEVLI RLFTGHPETL EKFDKFKHLK TEAEMKASED  
 
        70         80         90        100        110        120  
LKKHGTVVLT ALGGILKKKG HHEAELKPLA QSHATKHKIP IKYLEFISDA IIHVLHSKHP  
 
       130        140        150  
GDFGADAQGA MTKALELFRN DIAAKYKELG FQG 
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